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Summary
This investigation was undertaken to study the 
effects of adrenergic and ischaemic challenge on the 
activity of lipid metabolising enzymes in the perfused rat 
heart.
Perfusion with adrenaline or the beta agonist 
isoprenaline produced an increase in triglyceride lipase 
(TGL) activity and a fall in glycerol 3-phosphate 
acyltransferase (GPAT) activity. No change was seen in 
carnitine palmitoyl transferase (CPT) activity. These 
changes could be imitated by incubation of heart homogenates 
with cAMP-dependent protein kinase. The non-selective alpha 
agonist phenylephrine, and the alpha^ agonist clonidine 
produced the opposite affect, a fall in TGL activity and a 
rise in GPAT activity. Methoxamine, an alpha^, had no affect 
on TGL activity but reduced GPAT activity. Changes in GPAT 
activity were localized mainly in the microsomal fraction. 
The changes in TGL and GPAT activity are consistant with 
both enzymes being regulated via a cyclic AMP-dependent 
protein kinase system and via alpha adrenergic mechanisms.
Ischaemia was produced by occlusion of the left 
descending coronary artery for 10 minutes. Compared to 
activities measured in tissue from normally perfused hearts, 
GPAT activity measured in tissue from the ischaemic area was 
considerably reduced while TGL activity in the ischaemic 
area was markedly increased. No change was seen in GPAT or 
TGL activity measured in tissue from the non-ischaemic area
or in CPT activity measured in both areas. The changes in 
activities produced by ischaemia were prevented by 
pre-perfusion with the cardio-selective beta antagonist 
Atenolol.
Reperfusion of the ischaemic area resulted in TGL 
activity returning to the value measured in tissue from 
normally perfused hearts. However, GPAT activity, after 1 
minute of reperfusion, fell to a value lower than after 10 
minutes ischaemia. This reperfusion-induced fall in GPAT 
activity was prevented by pre-perfusion with the alpha^ 
antagonist Doxasozin. Pre-perfusion of the alphag antagonist 
Yohimbine resulted in a prolongation of the increased TGL 
activity in the ischaemic area during reperfusion. All 
changes in enzyme activities were prevented when endogenous 
noradrenaline stores were depleted by injection of 6 
OH-dopamine 24 hours before hearts were removed.
These changes in enzyme activities show that during 
ischaemia there is an increased beta-adrenergic drive. On 
reperfusion the beta-adrenergic drive is removed but an 




i. Gross Structure, Blood Supply and Innervation.
The heart is a muscular organ located in the 
thorax. It is composed of four chambers; two upper chambers, 
the left and right atria and two lower chambers, the left 
and right ventricles. The right atrium recieves blood from 
the rest of the body. The blood is delivered to the lungs by 
contraction of the right ventricle. Oxygenated blood returns 
from the lungs to the left atrium. It is pumped around the 
rest of the body by the left ventricle. The atria, which 
recieve blood, are delicate compared to the ventricles which 
drive blood into the circulations. The left ventricle is 
more powerful than the right ventricle (with thicker walls) 
to enable it to develop the high pressure necessary to drive 
blood into the aorta and around the body. Of the total heart 
muscle about two thirds is represented by the left 
ventricular muscle. Fig 1.1 shows the external anatomy and 
the different compartments of the mammalian heart.
Heart tissue, as any other highly active tissue, 
requires an extensive blood supply to deliver substrates and 
remove products. The circulation begins with coronary 
arteries which branch from the aorta just after the position 
of the aortiç valve. The highly oxygenated blood perfuses 
the outer surface of the myocardium, the subepicardial
.. Fig. 1.1 





















region, first. From here the vessels branch into the mid and 
subendocardial regions. Coronary flow is mainly restricted 
to the period between contractions (the diastolic period) 
since, during contractions (the systolic period) the 
increase in myocardial wall tension causes extensive 
occlusion of the coronary vessels. The occlusion is most 
extensive and of longest duration in the subendocardial 
region.
The venous system of the myocardium conveys most of 
the blood to the right atrium via the coronary sinus. A 
small but significant drainage of blood occurs directly into 
the chambers through the thebesian and other small veins.
Section 1.2.
Histology and Physiology of Cardiac Muscle
i. The Cardiac Muscle
The muscular walls of the ventricles consist of 
three layers (fig 1.2). The inner layer called the 
endocardium, a middle layer called the myocardium and an 
outer layer called the epicardium. The layer of tissue 
surrounding the epicardium is called the pericardium.
ii. The Ultrastructure of the Myocardium.
The ultrastructure of the myocardium is shown in 
fig 1.3. The surface membrane of the myocardial cell, the 
sarcolemma, consists of a basement membrane and a plasma
FigureV2
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membrane. The basement membrane is composed of glycoproteins
(Scott, 1968 and Howse et al, 1970) and has the capacity to 
2+bind Ca ions which are important for contraction (Dhalla 
et al, 1977). The enzymes involved in ion pumping are 
located in the plasma membrane in which depolarisation, 
excitation and contraction are initiated.
Invaginations of the sarcolemma form the 
sarcoplasmic reticulum. It consists of the sarcolemmal 
cisternae and the sarcotubular network. The cisternae are 
located under the sarcolemma and alongside the transverse 
tubular system (T-system). The T-system is open to the 
extracellular space and runs alongside the Z-band in cardiac 
muscle.
The sarcoplasmic reticulum has two important
24-functions (Dhalla et al, 1977,78): the release of Ca ions
to the contractile elements following depolarisation of the
2+sarcolemma and the T-system, and the reabsorbtion of Ca 
ions from the contractile elements in order to bring about 
relaxation.
The basic contractile unit in cardiac muscle is 
called the sarcomere. Sarcomeres are joined end to end to 
form myofibrils, the structure of which is shown in fig 1.4. 
Myofibrils have a dark band called the A-band which 
corresponds to myosin and the I-band which corresponds to 
actin. During contraction, the actin molecules slide along 
the myosin molecules.
The cardiac cell contains large numbers of 
mitochondria, illustrating the highly oxidative nature of 
myocardial metabolism. Glycogen granules and lipid droplets 
are also seen and represent internal stores of energy (Stein
Figure 1 4
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Bound to the actin molecules are molecules of
tropomyosin and troponin. The actin-myosin interactions are
2+modulated by Ca , troponin and tropomyosin. There are 3
troponin proteins, troponin-I (Tnl), troponin-C (TnC) and
2+troponin-T (TnT). When Ca binds to TnC, interaction of 
actin and myosin is facilitated. Tnl inhibits the 
actin-myosin interaction, the inhibition is reversed when 
TnC binds Ca^^ (Katz,1977). Fig 1.5 shows that the cycle of 
contraction and relaxation, involving actin and myosin, 
requires energy. This is provided by the breakdown of ATP
through the myosin-bound ATPase. Contraction is believed to
2+ 2+ occur when the intracellular Ca rises and uptake of Ca
by TnC occurs. Relaxation occurs by the active uptake of 
2+Ca ions by the sarcoplasmic reticulum leading to a
2+decrease in the intracellular Ca concentration.
iv. Electrical Properties
In addition to the classical muscular function of 
contraction, the heart exhibits other properties. These 
include automaticity (the ability to contract independently 
of external stimulation) and conductivity (electrical 
impulses passed from one cardiac cell to another without 
intervention of nervous tissue).
Unlike skeletal muscle, the myocardium acts as a 
syncytium allowing the coordination of contraction. This is
Figure 15
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vital to the pumping action of the heart. Electrical 
impulses originate f>n a group of specialised cells» called 
the sinus node, located on the surface of the right atrium 
near its junction with the superior vena cava. The node 
depolarises and repolarises at a constant rate which 
(usually) determines the heart rate. The sinus node provides 
the usual dominant heart rhythm but automaticity is also 
exhibited by the ventricular muscle itself in the absence of 
sinus rhythm.
The impulse from the sinus node spreads across the 
surface of the atria, causing them to contract and then 
passes rapidly to the apex of the ventricles via the 
atrioventricular node and the Purkinje fibres. These are 
muscle cells which, through specialisation, have lost the 
ability to contract but instead conduct electrical impulses 
back up through the bulk of the ventricular muscle mass, 
initiating the rising wave of ventricular contraction.
The electrical wave passes from one muscle cell to 
the next in a way analagous to nervous transmission along 




The Metabolism of the Heart
Several reviews have described the metabolism of 
the heart under normal, ischaemic and hypoxic conditions in 
considerable detail. In partcular, the articles by Bing 
(1965), Wollenberger and Krause (1968), Opie (1968,69), 
Kubler and Spieckerman (1970), Neely, Rovetto and Oram 
(1972a,b), Neely and Morgan (19 74), Gibbs (1978) and two 
articles on ischaemia by Braunwald (1976) and Wildenthal et 
al (19 76) cover the area.
i. Substrates Utilized
The heart is a constantly-acting muscular tissue 
and is therefore a centre of intense metabolic activity. The 
substrates required for combustion, to provide the energy 
needed for mechanical and electrical activity, are supplied 
largely by the blood. The heart normally depends largely 
upon exogenous substrates. Under normal conditions the 
glycogen and lipid stored within the myocardium (endogenous 
substrates) are not extensively utilised. However, under 
certain conditions the balance between utilization of 
endogenous and exogenous fuels can shift markedly. In 




The heart utilizes both glucose and fatty acids as 
sources of energy. However, fatty acids are the preferred 
substrates (Evans, 1934; Cruickshank et al, 1936,41 and 
Opie, 1968). In the human heart 75% of the oxygen 
consumption can be accounted for by oxidation of plasma free 
fatty acids (FFA) (Most et al, 1969 and Lassers et al, 
1971,72). Under most conditions fatty acids are oxidised in 
preference to carbohydrate and their oxidation normally 
accounts for 60-70% of oxidative metabolism (Neely et al, 
1972a,b). When FFA are available, they suppress the 
utilisation of glucose, probably by inhibition of steps 
either in the glycolytic pathway (Shipp et al, 1961 and 
Opie, 1968) or at pyruvate dehydrogenase (PDH), as acetyl 
CoA units formed from the oxidation of FFA would decrease 
PDH activity and thus glucose oxidation (Randle et al, 1970; 
Denton et al, 1972 and Martin et al, 1972).
Mono-unsaturated fatty acids are claimed to be 
utilised more rapidly than saturated or di unsaturated fatty 
acids (Evans, 1964 and Willebrands, 1964). However, these 
studies have been challenged by Stein and Stein (1963) since 
the A-V difference in FFA composition of the blood may be 
altered by exchange reactions catalysed by lipoprotein 
lipase (LPL, see below), with no necessity for net FFA 
uptake. Indeed using isolated perfused rat hearts, no 
selectivity in FFA uptake could be observed (Stein and 
Stein, 1963).
Lipid is also supplied to the heart as 
triglyceride-fatty acids (TGFA). TGFA are present in the 
blood mainly in the form of chylomicra and very low density
13
lipoproteins (VLDL). Both these forms are complexes 
containing approximately similar amounts of triglyceride 
(60%), phospholipid (15%), cholesterol (10%), cholesterol 
esters (5%) and protein (10%) (Fredickson, 1974). The 
chylomicra derive their lipid directly from dietary lipid in 
the intestinal mucosa. VLDL's are synthesised in the liver 
and are discharged into the blood.
The utilization of TGFA proceeds by hydrolysis at 
the cell surface to release FFA which then enter the cell 
(Crass et al, 1965). This hydrolysis is catalysed by LPL.
In addition to the two major substrates, the heart 
can also utilize lactate, pyruvate, ketones and amino acids. 
These under most conditions may not be major substrates 
(Olson, 1962).
iii. Endogenous Substrates
Although exogenous substrates comprise the major
source of energy for the heart, the heart can also utilize a
variety of endogenous substrates as energy sources. The
utilization of endogenous fuel was demonstrated by
substrate-free perfusion of the isolated rat heart (Shipp et
al, 1964 and Olson and Hoeschen, 1967). Glycogen was
depleted within 5 minutes but further contraction was
maintained by endogenous lipid for up to 45 minutes. This
14was confirmed by the production of CO^ from prelabelled 
lipids (Shipp et al, 1964).
The role of phospholipid as an endogenous energy 
source is uncertain (Crass et al, 1969,71).
The rate of endogenous triglyceride utilization can
14
be increased by an increased work-load performed by the 
heart or catecholamine stimulation. The latter appears to be 
mediated by a higher level of cyclic AMP and activation of 
an intracellular lipase by protein kinase (Vavrinkova and 
Mosinger, 1974). This is in contrast to the increased 
lipolysis induced by increased cardiac work, which is 
associated with a lower tissue level of fatty acid (Oram et 
al, 1973). Exogenous glucose has little effect on the degree 
of endogenous triglyceride utilization, but exogenous FFA 
appear to inhibit ne t ^  endogenous lipolysis (Crass et al, 
1975 and Crass and Sterrett, 1975). Elevated levels of 
endogenous fatty acids or long-chain acyl CoA level have 
also been shown to inhibit lipolysis (Neely et al, 1972b).
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Section 1.4
Intracellular Metabolism of the Heart.
Major Pathways
The highly aerobic nature of myocardial metabolism 
exhibited under all but extreme conditions is demonstrated 
by the large number of mitochondria which make up about 30% 
of the cardiac cell volume (Sobel, 1974). Other indices of 
the aerobic nature of the cardiac metabolism are the 
capacity of the heart to utilise lactic acid (Opie, 1968) 
and the high activity of oxidative enzymes, particularly 
cytochromes (Penpargkul and Scheuer, 1970).
The major pathways for generation of energy in the 
myocardium are the normal patways of carbohydrate and lipid 
utilization (Mahler and Cordes, 1966) . These are illustrated 
in figs 1.6 and 1.7, and are briefly outlined here.
i. Glucose Metabolism
Insulin facilitates the transport of glucose across 
the cell membrane into the cytoplasm of the myocardial cell. 
Once inside, the glucose is rapidly phosphorylated by 
hexokinase to glucose-6-phosphate (Morgan et al, 1961;
Morgan and Parmeggiani, 1964; Opie et al, 1973 and Neely and 
Morgan, 1974).
Glucose-6-phosphate may be polymerised and stored 
as glycogen (glycogenesis). Subsequently, glycogen breakdown
16
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Figure 1 7  
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occurs in an energy-yielding process called glycolysis (Opie 
et al, 1963 and Opie, 1968). The Embden-Meyerhof pathway of 
glycolysis is the major pathway of degradation of 
glucose-6-phosphate to yield energy. The end products are, 
under aerobic conditions, pyruvate or, under reduced oxygen 
supply, lactate.
The activity of phosphofructokinase (PFK) provides 
an important control point in the regulation of glycolysis 
in the heart. ATP and citrate reduce the activity of this 
enzyme and thus exert a restriction on the rate of 
glycolysis when these compounds are of a sufficiently high 
concentration i.e. during energy surplus (Mansour, 1963).
ii. Pyruvate Dehydrogenase
Pyruvate dehydrogenase (PDH) carries out the 
oxidative decarboxylation of pyruvate to acetyl CoA. The 
work of Randle et al (1970); Denton et al (1972) and Martin 
et al (19 72) has shown the role of pyruvate dehydrogenase in 
the regulation of energy metabolism in the heart.
The acetyl CoA formed combines with oxaloacetate to 
form citrate and is then oxidised by the reactions 
consituting the tricarboxylic acid (TCA) cycle (fig 1.8). 
This cycle produces reducing equivalents which are oxidised 
by the terminal oxidation chain to yield ATP from ADP and 
phosphate in a process termed oxidative phosphorylation.
Pyruvate dehydrogenase and the enzymes of the TCA 
cycle are found in the mitochondrion. Pyruvate, therefore, 
has to be transported across the inner mitochondrial 
membrane.
19
Figure 1 8  


















iii. Fatty Acid Metabolism
Acetyl CoA is also the major end product of the 
beta-oxidation system for fatty acids, the enzymes of which 
are also located in the mitochondrion.
Fatty acids supplied to the heart from endogenous 
triglycerides or from exogenous sources are activated to 
coenzyme A (CoA) esters and then enter the mitochondrion by 
the carnitine cycle (fig 1.9) under the influence of 
carnitine palmitoyl transferase (CPT). This is located on 
both sides of the inner mitochondrial membrane 
(Bremer,1977). Once inside the mitochondrion the fatty acyl 
ester is oxidised by the beta-oxidation system (fig 1.10) to 
yield acetyl CoA which enters the TCA cycle as before.
Lipid synthesis, from fatty acids, is active in the 
myocardium. Fatty acyl CoA esters react with sn-glycerol 
3-phosphate to produce mono-, di- and mainly triglycerides 
(Denton and Randle, 1965). Phospholipid metabolism is 
believed to occur through classical routes (for review see 
Dawson, 1966) . The production of sn-glycerol 3-phosphate 
from glycerol is not regarded as significant since the 
activity of glycerol kinase in the heart is negligible 
(Scheuer and Olson , 1967; Robinson and Newsholme, 1967).
The major source of glycerol 3-phosphate is from glucose via 
glycolysis.
iv. Minor Pathways
Glucose synthesis from lactate and pyruvate can be
21
FIG 1 - 9
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Figure 1 «10
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observed in heart tissue (Stadie, Haughaard and Pertmultter, 
19 47) but the key enzymes of the Utter-Ochoa pathway (malic 
enzyme, pyruvate decarboxylase and phosphoenolpyruvate 
carboxykinase) are of low activity and the pathway is not of 
great significance (Packer, 1954). The same is true of the 
key enzymes of the hexose monophosphate shunt 
(glucose-6-phosphate dehydrogenase and 6-phosphogluconate 
dehydrogenase) as shown by Clock and McLean (1954).
Protein synthesis and degradation are obviously of 
great significance because of the constant need for 
structural, contractile and enzymic protein. This has 




The Heart in Ischaemia
i. General
Ischaemia is defined as the reduction of the blood 
flow through a tissue (or perfusate in the experimental 
situation). It is distinguished from hypoxia (or the extreme 
case anoxia) which describes a reduction of the oxygen 
content of blood or perfusate. In both cases the prime 
metabolic lesion is reduced oxygen supply but ischaemia is 
complicated by the reduced delivery of substrates and, more 
importantly, the reduced removal from the tissue of 
metabolic products.
Two types of ischaemia exist, chronic and acute 
forms. The onset of chronic ischaemia is usually 
characterised by a progressive narrowing of one or more of 
the larger coronary arteries. This occlusion results from 
degeneration of the arterial wall lining and gradual 
thickening in a process called atherosclerosis (Schettler 
and Boyd, 1969). Lipid and fibrous material are deposited on 
the intimai lining of the artery, resulting in a two-fold 
effect. This is primarily a reduction in blood flow, but 
also the artery loses its elasticity. Competent vessels 
expand during the peak of ventricular ejection (absorbing 
some of the cardiac output) and then contract during 
diastole to sustain diastolic flow. The significance of the 
loss of elasticity in coronary vessels is great since the
26
heart tissue is critically dependent on diastolic flow.
The heart can respond to chronic ischaemia by 
revascularisation and the development of anastomoses 
(Charlier, 1971). No such response is possible with acute 
ischaemia caused by either a coronary thrombosis (blockage 
of a vessel by a fragment of solid material, usually 
sloughed off from atheromatous accumulations) . a $udden 
occlusion of a coronary vessel can also occur due to a spasm 
of the artery. The tissue affected by acute restriction of 
flow is rapidly depressed mechanically (within minutes) and 
can suffer irreversible damage within 30-60 minutes if flow 
is not restored (Oliver, 1972).
The effects of chronic ischaemia have recieved 
little experimental attention mainly due to the time 
required to establish this condition and the uncertainty 
concerning the nature of the causative factor(s). Acute 
ischaemia is, at present, under extensive investigation. A 
number of techniques are being used to study this condition. 
These include acute occlusion in situ of coronary vessels 
in dog hearts (Braunwald, Marokf and Libby, 1974), and 
occlusion of coronary vessels in the isolated perfused rat 
heart (Kannengeiser et al, 1975). Alternatively the 
imposition of whole heart ischaemia by the reduction of 
coronary flow to the whole heart (Brownsey and Brunt, 1977) 
can be used as a model.
ii. Mechanical Responses of the Myocardium to Ischaemia.
The onset of ischaemia is accompanied by a rapid 
and marked decline in the performance of the affected
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tissue. In the perfused rat heart subjected to ischaemia, 
systolic ventricular pressure (and tension) decline, as does 
cardiac output, while end diastolic pressure rises (Opie, 
1965; Neely et al, 1973; Kannengiesser et al, 1975 and 
Fisher et al, 1969).
Despite the depressed mechanical performance of 
ischaemic tissue, the overall performance of the heart, as 
shown by cardiac performance, can be maintained by 
compensatory mechanisms (Feola et al, 1971). These include 
ventricular dilation which provides increased ventricular 
diastolic filling and hence maintenance of cardiac output 
(Lekven et al, 1973).
iii. Metabolic Respones To Ischaemia
a) Carbohydrate Utilisation
One of the major responses to acute ischaemia is 
the shift from aerobic fatty acid oxidation to anaerobic 
glycolysis (Himwich et al, 1934 and Dennis and Moore, 1938). 
Under normal conditions the heart extracts lactate from the 
blood. However, in ischaemia and hypoxia a net^ release of 
lactate is evident (Krasnov et al, 1962).
The response of the heart to ischaemia and hypoxia 
differ markedly. In the case of hypoxia, glucose uptake 
(Scheuer, 1967,72) and lactate release rise sharply. In 
ischaemia, although a transient rise in glucose uptake has 
been shown, it was maintained for only a short period 
(Rovetto et al, 1973). Extensive lactate accumulation occurs 
within the ischaemic tissue, since little capacity for
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release into the perfusate is available. Subsequent 
inhibition of glycolysis occurs at two major sites. The 
decline in cellular pH would be expected to inhibit PFK 
activity (Kubler and Spieckermann, 1970; and Williamson et 
al, 1976). In addition the inability of lactate 
dehydrogenase to reoxidise NADH would cause inhibition of 
the glyceraldehyde 3-phosphate dehydrogenase reaction by 
reducing the availability of NAD (Rovetto et al, 1975).
b) Energy Status
In ischaemia the ATP content of myocardial cells 
declines more rapidly and more extensively than in hypoxia 
(Rovetto et al, 1973). This is likely to be a consequence of 
the inhibition of glycolysis during ischaemia. Not only does 
ATP concentration decline but a nett loss in the total 
adenine pool occurs as increased loss of adenosine through 
the cell walls has been shown (Imai et al, 1964).
Reperfusion of ischaemic hearts results in a rapid 
resynthesis of creatine phosphate but ATP levels remain 
depressed (for review see Hearse, 1977) as the depleted pool 
of adenine nucleotides is not rapidly resynthesised.
Adenosine, arising from adenylate pool degradation, 
is a potent vasodilator and it also markedly decreases 
activated adenyl cyclase activity (Imai et al, 1964; Olsson, 
1970 and Stam and DeJong, 1977)
c) Ionic Disturbances
The loss of certain ions, particularly potassium
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and inorganic phosphate, has been observed from ischaemic 
tissue (Regen et al, 1970 and Opie et al, 1972). These
disturbances are probably a reflection of the disturbed
+ + 24-energy balance in the cell as both Na /K ATPase and Ca
ATPase hydrolyse large quantities of ATP. The elevation of
external potassium may be an important factor contributing
to the high incidence of arrhythmias in severely ischaemic
tissue (Brachfeld, 1973). Inorganic phosphate increases as
ATP is broken down and not resynthesised (Opie et al, 1972).
24-This ion may be a factor in the early failure of the Ca 
ATPase pump due to the formation of calcium phosphate 
(Kubler, 1974).
d) Release of Endogenous Catecholamines
Catecholamines stored in the sympathetic nerve 
endings in the myocardium are released during ischaemia 
(Wollenberger et al, 1967). This is discussed in further 
detail later in the introduction.
iv. Metabolism of Fatty Acids In Ischaemia
Fatty acids and their derivatives accumulate in 
ischaemic tissue due to a number of factors. Both adipose 
tissue (Vaughan and Steinberg, 1963) and cardiac lipolysis 
(Kruger and Leighty, 1967) are stimulated by the presence of 
catecholamines, thus delivering both exogenous and 
endogenous fatty acids to the myocardium. At the same time, 
the capacity for removal of fatty acids by oxidation is 
depressed by oxygen limitation (Opie et al, 1973). Oxidation 
is inhibited at the level of beta-oxidation probably owing
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to increased levels of mitochondrial NADH and FADHg (Whitmer 
et al, 1978). Fatty acyl CoA and fatty acyl carnitine levels 
also increase in ischaemia (Neely and Morgan, 1974 and Neely 
et al , 1972a,b).
The increase in fatty acyl CoA together with an 
increase in NADH (allowing production of sn-glycerol 
3-phosphate from glycolytic dihydroxyacetone phosphate via 
glycerol 3-phosphate dehydrogenase) increases the capacity 
for estérification. (Neely and Morgan, 1974; Opie, 1968 and 
Whitmer et al, 1978). Lipid droplets have been observed in 
ischaemic tissue (Bryant et al, 1958 and Evans, 1964). 
However, Jesmok et al (1977) observed a decrease in 
triglyceride levels in the first 30 minutes after the onset 
of ischaemia followed by increased levels after 60 minutes. 
Whitmer et al (19 78) found a much smaller increase in 
triglyceride synthesis than expected from the marked rise in 
ischaemic hearts of acyl CoA and glycerol 3-phosphate 
levels.
The myocardial content of free fatty acids has been 
variously estimated at between 30 and 10,000 nmole/g of 
tissue depending on the assay procedure employed, storage 
conditions and handling of the tissue samples (for reviews 
see Van der Vusse, 1983 and Victor et al, 1984). There is no 
evidence to suggest that under normal conditions free fatty 
acids are a threat for the heart. The total intracellular 
free fatty acid content is very low (lOpmoles/g) and far 
below the concentration known to inhibit cytosolic and 
mitochondrial processes in vitro (above 50 pmoles/g) (Van der 
Vusse, 1983).
However, myocardial ischaemia leads to a marked
31
increase in tissue levels of free fatty acids up to 3-4 
times the normal level (Wieshaar et al, 1977 and Van der 
Vusse et al, 1982). Also, derivatives of fatty acids such as 
acyl CoA and acyl carnitine may be harmful under ischaemic 
conditions. Tissue levels of acyl CoA and acyl carnitine 
were raised from 14 and 4 nmoles/g in the normal pig heart 
to 24 and 76 nmoles/g respectively in the ischaemic 
myocardium (Liedtke et al, 1978).
High levels of fatty acids and their derivatives 
cause a number of harmful effects to the ischaemic or 
hypoxic heart.
(1) At low concentrations (50pM) FFA labilize 
mitochondria and lysosomes (Acosta and Wenzel, 1974). These 
effects could be explained by the interference with membrane 
integrity. This is consistent with the hydrophobic 
characteristics of FFA and offers a possible general 
explanation for the wide range of toxic effects reported.
(2) FFA, at a concentration of ImM, have been shown 
to depress contractility in the hypoxic-perfused rat heart 
muscle (Henderson et al, 1969 and Williebrands et al, 1973).
(3) FFA have a fairly non-specific "detergent" 
effect which causes enzyme inhibition at high concentrations 
(2pmoles/g of microsomal protein) (Pande and Mead, 1968 and 
Wills, 1961).
(4) At lower concentrations (50pM) FFA have been 
shown to specifically inhibit phosphofructokinase, a key 
enzyme in glycolysis (Ramadoss et al, 1976). Hexokinase, 
another regulatory enzyme in glycolysis, became inactivated 
at concentrations above 0.5mM (Lea and Weber, 1968).
(5) Both FFA and acyl CoA esters, at
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concentrations known to occur in ischaemia tissue (75-100 
nmoles/g dry weight), were found to inhibit mitochondrial 
adenine nucleotide translocase (Shug and Shrago, 1973). This 
would inhibit the transport of ADP into, and ATP out of, the 
mitochondria and further reduce energy production.
(6) In the intact tissue FFA have been argued to 
contrbute to the incidence of ventricular arrhythmias and 
death after acute myocardial infarction (Oliver et al, 1968; 
Julian and Oliver, 1968; Gupta et al, 1972 and Oliver,
1974). The protective effect of an anti-lipolytic agent 
(5-fluoro-3-hydroxymethyl-pyridine) against ventricular 
arrhythmias after myocardial infarction was significant 
provided the control of plasma FFA was good (Rowe et al,
1975). Increased lipolysis, induced by catecholamine 
intervention, has been shown to extend the area of ischaemic 
injury during acute coronary artery ligation in dogs. The 
converse decrease in the area of ischaemic injury by 
antilipolytic therapy has also been reported (Kjekshus and 
Mjos, 1973; Kjekshus, 1974; Lekven et al, 1973,74)f^Leiris 
et al (19 75) has reported that the presence of FFA 
accentuates the release of lactate dehydrogenase (an index 
of ischaemic injury) from the isolated perfused rat heart 
during coronary artery ligation.
A number of reports have appeared which contradict 
the findings reported above. Rutenberg, Pamintuan and Soloff 
(19 69) concluded from studies on human patients that FFA 
levels during the first 24 hours after infarction were not 
related to arrhythmias, late death or cardiogenic shock. 
Similarly, FFA were argued not to be arrhythmogenic in dog 
hearts after coronary artery occlusion in situ (Opie et al.
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1971). In other studies FFA were found not to influence the 
degree of ischaemic injury produced by coronary artery 
occlusion in pigs (Most et al, 1974).
Although a direct link between the concentration of 
fatty acids in ischaemic tissue and the incidence of 
arrhythmias and/or the area of infarct size has not been 
shown, it seems likely that high levels of both tissue and 
plasma FFA do accentuate the deterioration of ischaemic 




Several discrete lipase activities have been 
characterized in mammalian tissues (for review see 
Steinberg, 1978 ; Nilsson-Ehle et al, 1980). The main 
activities include lipoprotein lipase (LPL), neutral 
triglyceride lipase (TGL), monoglyceride lipase and acid 
lipase. (Pancreatic lipase and intestinal lipase will not be 
described here).
i. Lipoprotein Lipase
This enzyme was first described by Hahn (1943) and 
known as clearing-factor lipase or heparin-induced lipase 
(for review see Robinson, 1963,70).
Lipoprotien lipase (LPL) is a glycoprotein (Chung 
and Scanu, 1977; Fielding et al, 1977) with a molecular 
weight, determined by SDS polyacrylamide gel electrophoresis 
of between 60,000 and 70,000 (Twu et al, 1975,76).
The enzyme is known to be present in tissue 
extracts of adipose, heart and skeletal muscle, lactating 
mammary gland, spleen, lung and kidney medulla (Robinson, 
1963,70). It is not present in the brain where free fatty 
acids from triglycerides are not taken up from the blood by 
this organ.
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The enzyme hydrolyses chylomicra or very low 
density lipoprotein (VLDL) triglyceride with the liberation 
of fatty acids. Fatty acids from tissue-bound LPL may be 
absorbed by neighbouring tissues. Alternatively, they are 
able to form water-soluble complexes with plasma albumin 
before their uptake by extra-hepatic tissue (Anderson and 
Fawcett, 1950; Anfinsen et al, 1952; Shore et al, 1953 and 
Gordon et al, 1953).
In the heart, LPL was first reported by Anfinsen et 
al (1952). Since then LPL has been extensively studied in 
both perfused and non-perfused rat heart (Robinson and 
Jennings, 1965; Borensztajn and Robinson, 1970a,b; Robinson, 
1970; Borensztajn et al, 1973; Chohan and Cryer, 1978,79,80 
and Pederson et al, 1981). Ventricular tissue appears to 
contain higher LPL activity (Patelsky et al, 1967). 
Intracellularly LPL has been found in both the microsomal 
(Alousi and Mallov, 1964 and Chohan and Cryer, 1979) and 
100,000g supernatant (Severson, 1979) fractions. However, 
the functional form of the enzyme is bound to the luminal 
surface of capillary endothelial cells and may be released 
from here by heparin perfusion (Borensztajn and Robinson, 
1970b and Borensztajn et al, 1975). The remaining LPL 
activity has been suggested to be an intracellular pool 
which is the precursor of the endothelium-bound LPL 
(Cunningham and Robinson, 1969; Borensztajn and Robinson, 
1970b; Borensztajn et al, 1975; Kompiang et al, 1976; Schotz 
et al, 1977). Palmer and Kane (1983) have suggested that the 
intracellular form is active in hydrolysing intracellular 
triglycerides, thereby providing fatty acids for oxidation 
in the mitochondria.
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The sensitivity of LPL to the dietary status of the 
animal has been reported by Robinson and French (19 60); 
Robinson and Jennings (1965); Borensztajn and Robinson 
(1970a,b) and Borensztajn et al (1972), In contrast to 
adipose tissue LPL, the activity in the heart has been 
reported to increase on starvation. Refeeding animals caused 
a decrease in heart LPL activity while increasing adipose 
LPL activity (Borensztajn et al, 1972).
It has been suggested by Borensztajn and Robinson 
(1970a) and Pederson and Sholtz (19 80) that the 
heparin-releasable (or functional) form of LPL responds 
rapidly to nutritional and hormonal manipulations, and it is 
primarily this fraction that increases in the heart and 
decreases in the adipose tissue during fasting.
Lipoprotein lipase preparations from various 
sources share the general characteristics that the enzyme is 
inhibited by 0.5M NaCl and protamine sulphate, and exhibits 
a pH optimum of 8.5. The activity is critically dependent 
upon the presence of serum protein cofactors, in particular 
apolipoprotein (for reviews see Robinson, 1970; Augustin 
and Greten, 1979; Severson, 1979 and Nilsson-Ehle et al, 
1980) .
ii. Triglyceride Lipase (Triacylglycerol lipase, EC 
3.1.1.3)
Neutral triglyceride lipase (TGL) hydrolyses 
triglyceride to diglyceride and fatty acid (fig 1.11). The 
term "hormone-sensitive" lipase has often been used to refer 
to this enzyme as the activity has been shown to respond to
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Fig.1 1 1 Triglyceride hydrolysis
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a number of different hormones (for review see Steinberg,
1978 and Severson, 1979).
Triglyceride lipase differs from lipoprotein lipase 
in a number of properties. It is not stimulated by heparin 
and has no requirement for serum cofactors. TGL exhibits a 
pH optimum of 6.8 to 7.4 and is inhibited by sodium fluoride 
but not by sodium chloride or protamine sulphate (Severson,
1979 ) .
The structure of TGL is still not clearly 
established (Berglund et al, 1980). A partial purification 
of TGL from rat adipose tissue (Huttunen et al, 1970; 
Schwartz and Jungas, 1971 and Tsai and Vaughan, 1974) and 
from human adipose tissue (Pittman et al, 1972; Khoo et al, 
1974 and Verine et al, 1974) has been reported. Further 
characterization has been limited because the enzyme appears 
to be lipid rich (Huttunen et al, 1970) and may well exist 
in more than one molecular form (Pittman et al, 1972). 
Several reports of the molecular weight of the enzyme have 
been published. As determined by SDS polyacrylamide gel 
electrophoresis, the enzyme from chicken adipose tissue had 
a molecular weight of 65,000 (Berglund et al, 1980). From 
rat adipose tissue it was found to be 84,000 (Khoo et al, 
1980; Belfrage et al, 1980; Nilsson-Ehle et al, 1980 and 
Fredikson et al, 1981).
TGL activity has been localized in the microsomal, 
mitochondrial and lysosomal fraction of heart homogenates 
depending on the cell fractionation procedure or the assay 
conditions used (Shousboe et al, 1973; Jesmok et al, 1976; 
Hulsmanj^and Stam, 1978 and Severson, 1979 ). The high level 
of LPL activity in heart tissue may contribute to the
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conflicting data. Investigators have attempted to minimize 
the possible contamination of TGL activity by LPL by 
including LPL inhibitors (NaCl and Protamine sulphate) in 
the assay system. However, since it is not known if these 
inhibitors are entirely specific for LPL (Severson, 1979), 
there remains doubt about such results.
Severson (1979) has claimed a clear differentiation 
between TGL, LPL and acid lipase activity in rat heart 
fractions.
iii. Diglyceride Lipase (Diacylglycerol lipase EC 
3.1.1.34)
Lipase activity directed towards diacylglycerides 
has been shown to be present in rat adipose (Arnaud and 
Boyer, 1974 and Pittman et al, 1975); chicken adipose tissue 
(Khoo et al, 1976,78 and Berglund et al, 1980) and rat liver 
(Groener and Kanuer, 1981).
Because incubation with cAMP-dependent protein 
kinase has similar effects on the activities of both TGL and 
diglyceride lipase, it has been suggested that these two 
activities reside in the same enzyme (Belfrage et al, 1977 
and Khoo et al, 19 78).
iv. Monoglyceride Lipase (Monoacylglycerol lipase EC 
3.1.1.23)
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This enzyme has been purified from chicken adipose 
tissue and resolved almost completely from TGL and
diglyceride lipase. The purified enzyüme has been shown to/
be a single protein with a molecular weight of 45,000 
(Berglund et al, 1980). In rat adipose tissue the enzyme has 
been purified by Tronquist and Belfrage (1976) and has a 
molecular weight of 40,000.
In the heart both diglyceride and monoglyceride 
lipases are reported to be present (Neely and Morgan, 1974).
V. Acid Lipase(s) (EC 3.1.1.3)
Lipase activity with a pH optimum of 4.0-4.5 has 
been described in rat adipose tissue (Schatz, 1965 and 
Hulsmann and Stam, 1978); and rabbit liver (Mahadevan and 
Tappel, 19 68 and Guder et al, 1969); human liver (Warner et 
al, 1981) and rat heart (Weglicki et al, 1974; Hulsmann and 
Stam, 1978; Severson, 1979 and Severson et al, 1980).
The enzyme is believed to be of lysosomal origin 
since the lysosomal inhibitor chloroquine inhibits the acid 
lipase activity of cardiac and adipose tissue (Hulsmann and 
Stam, 1978; Severson, 1979 and Severson et al, 1980).
The acid lipase has been purified 2,500 fold from 
human liver (Warner et al, 1981) where it was found to have 
a molecular weight of 29,000. In the rat liver however, a 
molecular weight of 59,000 was found (Teng and Kaplan, 1974 
and Brown and Sgoutas, 1980). These differences may reflect 
interspecies differences (Warner et al, 1981).
The substrate specificity of this enzyme has been
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suggested to be triglycerides and diglycerides but not 




This section describes the enzymes of glycerolipid 
synthesis in mammalian tissues. The overall pathway of 
neutral and phospholipid synthesis from glycerol phosphate 
and fatty acid is shown in fig 1.12.
i. Fatty Acyl CoA Synthetase (EC 6.2.1.3.)
Fatty acids are activated to their respective CoA 
thioesters by one of several fatty acyl CoA synthetases, 
depending on their chain length (Groot et al, 1976). As most 
glycerolipids contain predominantly long chain fatty acids, 
long chain fatty acyl CoA synthetase will be discussed here. 
Long chain acyl CoA synthetase will also activate 
unsaturated fatty acids. It requires ATP (Pande and Mead, 
1968) and is inhibited by long chain acyl CoA (Neely and 
Morgan, 1974). This enzyme is also known as palmitoyl CoA 
synthetase. It is present in most tissues (Aas, 1971;
Aas and Daae, 1971; Banis and Tove, 1974; Pederson et al,
19 75 and Brophy and Vance, 1976) and has been shown to be 
present in both the microsomal and mitochondrial fractions 
of liver and adipose tissue (Bloch and Vance, 1977 and Groot 
et al, 1976). It is closely associated with the endoplasmic 
reticulum and with the outer mitochondrial membrane (Garland 
et al, 1970; Pande and Blanchaer, 1970 and Van Toi, 1975).
In the heart the enzyme appears to be located in both the
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Legend for Figure 1.12
1. Fatty acid CoA ligase EC (6.2.1.3)
2. Sn-glycerol-3-P-acyl transferase EC (2.3.1.1.5)
3. Dihydroxy acetone-P-acyltransferase EC (2.3.1.42)
4. Acyl (alkyl) dihydroxyacetone-P-oxidoreductase EC (1.1.1.101)
5. Lysophosphatidic acid acyltransferase EC (2.3.1.-)
6. Phosphatidic acid phosphatase EC (3.1.3.4)
7. Diacylglycerol kinase EC (1)
8. Diacylglycerol acyltransferase EC (2.3.1.20)
9. Choline kinase EC (2.7.1.32)
10. Choiine-P-cytidyltransferase EC (2.7.7.15)
11. Diacylglycerol cholinephosphotransferase EC (2.7.8.2)
12. Ethanolamine kinase EC (2.7.1.CC)
13. Ethanolamine-P-cytidyltrasferase EC (2.7.7.14)
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mitochondrial matrix (Aas and Bremer, 1968) and in the 
cytosol (Barth et al, 1971).
Tanaka (1979) has purified the enzyme from rat 
liver microsomes and mitochondria. They could not 
distinguish them by a large number of characteristics, and 
decided that there is only one form of the enzyme present in 
two or more locations.
ii. Sn-Glycerol 3-Phosphate Acyltransferase (EC 
2.3.1.15)
The activated fatty acid acylates glycerol 
3-phosphate through the acyltransferase enzymes. Two steps 
are involved in the acylation process.
CoA /° P
HO-C-H
acyl-CoA ^  CH.-O-C-R CoA « CH -0-C-R.
------------- ^ I   ̂  ̂  ̂ •
G f-A T h O-CH
i»,-»-©
a-glycerophosphate lysophosphatidic 1*2 Diacylglycerol phosphate
acid (phosphatidate)
The first involves estérification of a long chain 
fatty acyl group into position 1 of glycerol 3-phosphate to 
form 1-acylglycerol 3-phosphate. The second step involves 
the estérification of the 2 position to form diacylglycerol 
3-phosphate (or phosphatidate).
The first step is catalysed by glycerol 3-phosphate
4-6
acyltransferase (GPAT).
GPAT has been found in both mitochondrial and 
microsomal fractions in rat adipose tissue and rat liver 
(Daae and Bremer, 1970; Kako and Liu, 1974; Jamdar and 
Fallon, 1973 and Kelker and Pullman, 1979). Monroy and 
coworkers (1972) first presented evidence suggesting that 
the two subcellular locations contained different 
isoenzymes. This has since been confirmed by others using 
subcellular fractionation techniques (Haidar, 1978; Nimmo, 
1979; Haider et al, 1979; Yamada and Okuyama, 1978; Jamdar 
and Fallon, 1973 and Stern and Pullman, 1978). In adipose 
tissue less than 10% of the total GPAT activity is present 
in the mitochondrial fraction (Schlossman and Bell, 1977).
In the liver and the heart the mitochondrial GPAT activity 
approaches that found in the endoplasmic reticulum (Daae and 
Bremer, 1970; Monroy et al, 1972; Liu and Kako, 1974; 
Zarov-Behrens and Kako, 1976; Kako et al, 1977 and Bremer et 
al, 1976).
In heart, liver and adipose tissue the microsomal 
activity is almost totally inhibited by sulphydryl reagents 
such as N-ethylmaleimide while the mitochondrial activity is 
unaffected (Haidar et al, 1979; Monroy et al, 1972 and Daae 
and Bremer, 1970). The difference in sensitivity to 
N-ethylmaliemide has been used to distinguished between the 
two isoenzymes (Saggerson et al, 1979).
The two isoenzymes have also been shown to differ 
in their Km's for palmitoyl CoA (Yamada and Okuyama, 1978) 
and their pH optimums (Haider, 1978). The mitochondrial 
enzyme has a lower apparent Km for palmitoyl CoA although 
such measurements are tentative when applied to lipid
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substrates since the critical micellar concentration of 
palmitoyl CoA is only an approximation. The Km's for 
glycerol 3-phosphate appear similar and in the region of
0.5mM (Tubbs and Garland, 1964; Denton and Halperin, 1968 
and Evans, 1977).
It has been reported that the mitochondrial enzyme 
is more specific towards the fatty acyl CoA esterified than 
is the microsomal enzyme (Stern and Pullman, 1978). Indeed, 
Monroy et al (1973) found that palmitoyl CoA was esterified 
almost exclusively on position 1 by mitochondial GPAT. This 
acylation was not inhibited by oleyl CoA and linoleyl CoA. 
This specificity is in agreement with the observed 
distribution of fatty acids in naturally-occuring 
glycerolipids. However, it is generally accepted that the 
principal site of glycerolipid synthesis is the endoplasmic
i\reticulm (Bell and Coleman, 1980); here the enzyme is notA
specific utilising palmitoyl CoA and oleyl CoA with equal 
efficiency (Haider, 1978). It appears that either extensive 
transacylation or desaturation must occur or that the 
mitochondrial enzyme iŝ  important for precise specificity 
during estérification. The latter hypothesis has been 
supported by Kelker and Pullman (19 79) who found that a loss 
of mitochondrial GPAT activity paralleled an increase in the 
occurance of oleic acid at position 1 of phospholipids in 
cultured cells.
iii. Dihydroxyacetone Phosphate Pathway
The acylation of dihydroxyacetone phosphate and its 
subsequent reduction to 1 acyl ; glycerol 3-phosphate provides
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an alternative route to phosphatidate (La Belle and Hajra, 
1974 and Hajra, 1977).
u u . C H - O Ha-glycerophosphate i 2
CHT-OH , dehydrogenase g.c
I 2 4---- 7 ---- >
HO-C-H ^  C H ^ - 0 - 0
CH^-0-0 NAD^ NADH + Dihydroxyacetone
a-glycerophosphate 
2 acyl-CoA 








The enzyme which catalyses the acylation of 
dihydroxyacetone phosphate has been shown to occur in both 
the microsomal and mitochondrial fractions (Schlossman and 
Bell, 1977,78). Schlossman and Bell (1977,78) found that the 
microsomal dihydroxyacetone phosphate acyltransferase is 
identical to the microsomal form of glycerol 3-phosphate 
acyltransferase. However, this has recently been disputed by 
Datta and Hajra (1984) who have presented evidence to 
indicate two separate enzymes.
A second enzyme, initially located on the outer 
mitochondrial membrane (Schlossman and Bell, 1977) differs 
from the microsomal form in its resistance to sulphydryl 
inhibitors, trypsin and thermal lability (Schlossman and
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Bell, 1978). Harja and his colleagues however, have located 
a peroxisomal site for this enzyme (Jones and Hajra,
1976,77).
The relative contributions of the glycerol 
3-phosphate and dihydroxyacetone phosphate pathways to 
phospholipid and triglyceride synthesis remain controversial 
(Rognstad et al, 1974; O'Doherty, 1978 and Mason, 1978). In 
the heart the dihydroxyacetone pathway is said to be of 
minor importance (Liu and Kako, 1974).
iv. Phosphatidic acid Phosphatase (EC 3.1.3.4.)
This enzyme, also known as phosphohydrolase, 
catalyses the release of phosphate from 1,2 diacylglycerol 
3-phosphate to form diacylglycerol.
CHg-O-C-R^ phosphat jddrtc. ^  CH^-O-C-Rj^
P I phosphohydrolase ̂  // I
R.-C-O-C-H &-C-0-C-H' I _  /  \  ^ 'CH^-0-(P) H^O T. CHj-OH
1,2 diaclyglycerol 1,2-diacylglycerol
phosphate
The enzyme is widely distributed intracellularly being found 
in mitochondria, lysosomes, microsomes and cytosol in a 
number of tissues (Coleman and Hubscher, 1962; Wilgram and 
Kennedy, 1963 and Hubscher, 1970).
The microsomal and cytosolic but not the
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mitochondrial enzyme has been shown to have an obligatory
2+ 2+ requirement for Mg ions. However, at Mg concentrations
above 5mM the microsomal, cytosolic and mitochondrial forms
are all inhibited (Lloyd-Davies and Brindley, 1975). Thus
there appear to be two phosphatidic acid phosphatases. Mg 2+
independent (appearing mostly in the mitochondrial fraction) 
2+and Mg dependent (localized in the microsomal and 
cytosolic fractions) (Coleman and Hubscher, 1962; Agranoff, 
1962 and Caras and Shapiro, 1975).
V. Diacylglycerol Acyltransferase (EC 2.3.1.20.)
This enzyme is the only enzyme in the glycerolipid 
pathway unique to triglyceride synthesis. It catalyses the 
conversion of 1,2,diacylglycerol to triacylglycerol (Wilgram 








0  ÇH -0-C-R
/ / I
R-C-O-C-H
Diacylglycerol acyltransferase | 0
CH^-O-C-Rg
L CoA CoAAcyl Triaclyglycerol
The investigation of this enzyme has been impeded 
by difficulties inherent in presenting diacylglycerol and 
fatty acyl CoA substrates and the extraction of the reaction 
products from the substrates (Coleman and Bell, 1976 and
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Hosaka et al, 1977). Diacylglycerol acyltransferase from rat 
liver has been found to utilize a broad range of saturated 
and unsaturated acyl CoA thioesters containing fatty acids 
from C ^ 2  t:o C^g (Hosaka et al, 1977).
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Section 1.8.
Oxidation of Fatty Acyl CoA
It is generally agreed that fatty acyl CoA 
thioesters within the cytosol can take essentially only two 
metabolic courses; either estérification to form 
glycerolipids or oxidation within the mitochondrion (McGarry 
and Foster, 1980).
It has been known for some time that the rates of 
estérification and oxidation in the liver vary in opposite 
directions under different hormonal and nutritional states 
(Borrebaek et al, 1976; McGarry and Foster, 1971a,b and 
Lossow et al, 1956). Borrebaek et al (1974) reported that, 
in the liver, the activity of the first enzyme in each 
pathway, glycerol 3-phosphate acyltransferase (GPAT) 
(estérification) and carnitine palmitoyl transferase (CPT) 
(oxidation), had a reciprocal relationship. During 
starvation GPAT activity rose and CPT activity fell, the 
reverse occurred on refeeding (Borrebaek et al, 1974). They 
suggested that in the liver the competing activities of the 
two enzymes decided the distribution of fatty acids between 
estérification and oxidation. However, in the heart the 
activities of GPAT and CPT were found not to alter with the 
nutritional state of the animal (Borrebaek et al, 1974). The 
importance of the oxidation/esterification branch point in 
determining the fate of fatty acids has been emphasised by a 
number of researchers (Fritz, 1961; Mayes and Felts, 1967; 
Wieland and Matschinsky, 1962; Tzur et al, 1964; McGarry and 
Foster, 1971a,b; Ontko, 1972,73 and Woodside and Heimberg,
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i. Carnitine Palmitoyl Transferase (EC 2.3.1.21)
Carnitine palmitoyl transferase catalyses the 
transfer of fatty acyl CoA thioesters from the cytosol into 
the mitochondrion (fig 1.9.). It exists in two forms located 
on the outside (CPT^) and the inside (CPTjj.) of the inner 
mitochondrial membrane (Chase et al, 1965, Kopec and Fritz, 
1973 and Bremer, 1977). Both enzymes have been reported to 
have a molecular weight of 150,000, and on treatment with 
sodium dodecyl sulphate dissociate into two subunits of 
75,000 with a concomitant loss of activity (Kopec and Fritz, 
1973). CPTj catalyses the reaction;
palmitoyl CoA + carnitine <----- > CoA + palmitoyl-carnitine
The palmitoyl carnitine is then transferred to the inside of 
the inner mitochondria membrane where CPT^^ catalyses the 
reverse reaction to release acyl CoA into the mitochondrial 
matrix (fig 1.9). The acyl CoA so formed then undergoes 
beta-oxidation to form acetyl CoA. It is not clear whether 
CPTj and CPT^^ activities are due to different proteins or 
whether their different properties (such as immunogenic 
differences) are due to their different presentation and 
position in the mitochondrial membrane (Clarke and Bieber, 
1980) .
The role of carnitine palmitoyl transferase (CPT) 
activity in determining the rate of fatty acid oxidation has
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been shown in a number of studies (Fritz, 1961; Aas and 
Daae, 1971; Harano et al, 1972 and Norum, 1965). McGarry and 
Foster (1971a,b) showed that octanoic acid, a medium-chain 
fatty acid, which by passes the carnitine-dependent 
transport mechanism, was oxidised to acetyl CoA at similar 
rates in livers from fed, fasted and diabetic rats whose in 
vivo fatty acid oxidation rates were markedly different.
The view that carnitine palmitoyl transferase was 
the rate-limitting step for fatty acid oxidation was 
challenged by Van Toi and Hulsmann (1969) and Pande (1971) 
who found that the measurable CPT activity in rat liver 
mitochondria greatly exceeded that of the beta-oxidation 
enzymes. Subsequently it was found that malonyl CoA (an 
intermediate in fatty acid synthesis) was a potent inhibitor 
of both fatty acid oxidation (McGarry et al, 1977) and CPT 
activity (McGarry et al, 1978a,b) in rat liver homogenates.
It was also found that malonyl CoA only inhibits CPT^ and 
not CPTjj (McGarry et al, 1978a,b). This is probably due to 
either the orientation of CPT^^ in the membrane or the 
inability of malonyl CoA (formed by the enzyme acetyl CoA 
carboxylase in the cytoplasm) to enter the mitochondrial 
matrix (McGarry et al, 1978a,b).
Although the Ki for malonyl CoA toward CPT^ in rat 
liver mitochondria has been shown to be extremely low (l-2pM) 
the precise mechanism of ihibition has not been established. 
Available evidence indicates a competitive type of 
inhibition against long chain acyl CoA substrates (McGarry 
et al, 1978a,b).
The concentration of malonyl CoA in the liver is 
known to fluctuate with the nutritional state of the animal
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(McGarry et al, 1977), and the rate of fatty acid synthesis. 
Thus, during starvation, fatty acid synthesis and malonyl 
CoA concentration are low while CPT activity and fatty acid 
oxidation are elevated; the reverse occurs on refeeding (for 
reveiw see McGarry and Foster, 1980). These changes of the 
rate of oxidation and estérification caused by the 
nutritional status appear to be mediated by the 
glucagon/insulin ratio (McGarry et al, 1978b). In the liver 
glucagon inhibits fatty acid synthesis, and thus decreases 
malonyl CoA concentration (Witters et al, 1979). During 
starvation glucagon levels are high (Borrebaek et al, 1974). 
On refeeding, as glucagon levels fall and insulin levels 
rise, malonyl CoA concentration rises as fatty acid 
synthesis is stimulated and CPT activity and oxidation is 
depressed (McGarry and Foster, 1980).
The sensitivity of CPT^ to malonyl CoA has been 
shown to increase with a rise in the concentration of 
malonyl CoA (Robinson and Zammit, 1982) and to a fall in the 
pH (Stephens et al, 1983).
In the heart CPT activity has been shown to be more 
sensitive to the concentration of malonyl CoA than the liver 
enzyme (McGarry et al, 1978c,83; Saggerson and Carpenter, 
1981 and Saggerson, 1982). Although heart tissue does not 
contain a highly active cytosolic pathway for fatty acid 
synthesis, malonyl CoA has been found in heart tissue and 
its concentration is sensitive to the nutritional state of 
the animal (McGarry et al, 1983). Thus, a similar, mechanism 
of CPTj control as that in the liver but at a lower malonyl 
CoA concentration may apply in the heart.
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There have been no reports as to the effect of 
acute hormonal intervention on the activity of this enzyme, 
either in the heart or any other tissue.
Chronic myocardial ischaemia has been shown to 
markedly reduce the actvity of CPT in dog hearts after 1 day 
of ischaemia (Wood et al, 1973). However, the effects of 
acute ischaemia have not been reported.
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Section 1.9.
Catecholamines and the Heart
Naturally occurring catecholamines, noradrenaline 
and adrenaline, mediate a variety of cellular functions.
They are hormonal messengers produced in response to either 
external or internal physiological stress and they cause 
changes in both the physiology and biochemistry of the 
animal.
In the heart, catecholamines, either from 
sympathetic nerve stimulation (noradrenaline) or from 
circulating adrenaline from the adrenal glands, cause an 
increase in cardiac output. This involves an increase in 
heart rate (chronotropy) and the force of contraction 
(inotropy). To meet the increased energy demands, 
catecholamines also increase energy production by myocardial 
metabolism.
Such externally acting hormones involve regulation 
via membrane-bound receptors. These, upon stimulation, 
elicit intracellular signals which mediate the cellular 
response of the hormone. The occurance of receptor subtypes 
which specifically recognise hormones has been known for 
some time (Ahlquist, 1948).
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i. Adrenergic Receptors
It was Ahlquist (1948) who first assigned the 
prefixes az and p to the adrenergic receptor subtypes, based 
on the order of potency of a number of synthetic adrenergic 
agonists (stimulators) in different tissues. He concluded 
that there must be two kinds of adrenergic receptor. Later 
Lands et al (19 67) using the same method as Ahlquist, showed 
that the p-adrenergic receptors were not homogenous but 
could be divided into p^ and p ^ . Noradrenaline was 
slightly more potent than adrenaline for the p^ receptor 
while adrenaline was more potent than noradrenaline for the p 
2  receptor (Lands et al, 1967).
More recently cc-adrenergic receptors were found to 
contain two different populations (Langer, 1974).
Originally, cc-adrenergic receptors were found on the 
post-synaptic and pre-synaptic membranes of sympathetic 
nerve terminals and these were termed o:^ and cc 2  receptors 
respectively (Langer, 1977,81; Starke, 1977,81 and Westfall,
19 77). However, it was soon found that the preferences for 
appropriate and selective agonists and antagonists 
(blockers) upon which (Creceptors had been classified, did 
not agree with the post- and pre- synaptic location. It has 
since been agreed that the terms cx̂  and oc^ indicate the 
preference of the receptors for different agonists and 
antagonists and not their anatomical location (Berthelson 
and Pettinger, 1977; Wikberg, 1979; Starke and Langer, 1979 
and Timmermans and Van Zwieten, 1981,82).
The structures of different ozand preceptor
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agonists and antagonists are shown in figs 1.13 and 1.14.
ii. Distribution of Adrenergic Receptors
The padrenergic receptor subtypes were, according 
to Lands et al (1967), characterised by absolute organ 
specificity. However, experiments with selective P 
-adrenergic antagonists both in vivo and in vitro gave 
indication of the coexistence of p̂  ̂ and p^ in the same 
organ (Carlsson et al, 1972). Recently the use of direct 
binding studies has led to rapid progress in the 
identification of adrenergic receptor subtypes (Aurbach et 
al, 1974; Lefkowitz et al, 1974 and Levitzki et al, 1974). 
Using this technique Hedberg et al (19 80) found that cat and 
guinea pig atria contained 80% p ̂  and 20% p ̂  receptors 
while the ventricle contained almost 100% p^ receptors. 
Supporting this work was the finding that noradrenaline 
stimulated the heart rate mainly via p^ receptors and 
adrenaline stimulated the heart, at least partly, through p 
2 receptors. However, the increase in the force of 
contraction was only evident via p̂  ̂ receptor mediated 
mechanisms in the ventricle of a number of mammalian species 
(Minneman et al, 1981 and Nahorski, 1981).
The location of the oc^ adrenergic receptor is 
confined mainly to the post synaptic membrane of almost all 
tissues innervated by sympathetic nerves (for reveiw see 
McGrath, 1983). All presynaptic oz-adrenergic receptors 
appear to be of the oc^ subtype with the possible exception 
of the heart where both cc^ and 2 receptors are found on
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Presynaptic cc^ adrenergic receptors have been 
demonstrated at almost all sympathetic nerve terminals (for 
review see Van Zwieten and Timmermans, 19 83) including the 
rat heart (Drew, 1979 and Fichier and Koblinger, 1978). 
Post-synaptic o: adrenergic receptors having the 
pharmacological characteristics of q̂ 2 receptors have been 
demonstrated in vascular smooth muscle (Berthelsen and 
Pettinger, 1977 and Timmermans and Van Zwieten, 1982); 
platelets, pancreatic islets, adipocytes (Starke, 1977); 
central nervous system (Schmitt, 1971; Kobinger, 1978) and 
in the kidney (Jarrott et al, 1979 and Summers, 1980). There 
has been an unconfirmed report of post synaptic (C g
adrenergic receptors in the heart (Cavero and Roach, 1980).
Drew and Whiting (1979) first reported the 
existence of both and receptors occurring
post-syhaptically in the same tissue. This has since been 
confirmed by other workers (Docherty and Starke, 1981; 
Docherty and Reichenbacher, 19 81 and Timmermans et al,
1979 ) .
Langer et al (19 80) presented evidence suggesting 
that post-synaptic oc^ receptors are located closer to the 
sympathetic nerve terminal that the oc^ receptor. Adrenaline 
is known to be slightly more potent at ocg than at o: ^
receptors whilst noradrenaline is more potent at than ct
2  receptors. Thus, it has been proposed that sympathetic
nerve activity releasing noradrenaline acts mainly on 
receptors while o= 2 mediated effects are more dependent oj 
circulating adrenaline (Langer and Shepperson, 1982).
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FIG 1-15
Distribution of Adrenergic Receptors at the Cardiac Sympathetic 
Nerve Terminal,
Cardiac
cellN e rv e  term ina
Co
N A
c A M P
NA= noradrenaline 
AC= adenyl cyclase
from Carlsson et al, 1981,
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iii. Modulation of Noradrenaline Release by Presynaptic 
Adrenergic Receptors
Alpha adrenergic antagonists have been found to 
increase the overflow of noradrenaline elicited by 
sympathetic nerve stimulation in guinea pig and rabbit heart 
(Starke et al, 1972a,b). This could not be explained by 
decreased retention or degradation of noradrenaline within 
the tissue and, hence, was due to a facilitation of 
noradrenaline release from the sympathetic nerve terminals 
(Starke et al, 1971a,b). Conversely, oc-adrenergic 
agonists, such as clonidine, phenylephrine and noradrenaline 
itself, inhibited the nerve stimulation-evoked release of 
noradrenaline (Starke, 1972a,b and Werner et al, 1970).
Thus, it was proposed that the sympathetic nerve endings in 
the heart (and subsequently in other tissues) possess oc 
-adrenergic receptors, the activation of which by either 
exogenous agonists or endogenous noradrenaline results in 
depression of noradrenaline release (Starke, 1971).
The release of noradrenaline is also effected by 
drugs with affinity for p-adrenergic receptors. In 
guinea-pig isolated atria, isoprenaline, a p agonist, 
increased, while propranolol, a p antagonist, decreased, the 
nerve stimulation-evoked noradrenaline release 
(Adler-Graschinsky and Langer, 1975). Thus, it appears that 
sympathetic nerve terminals also possess P-adrenergic 
receptors, the stimulation of which facilitates 
noradrenaline release (Adler-Graschinsky and Langer, 1975).
The presynaptic (c receptors were shown to be of the
CC 2 subtype (Starke, 1981) while the presynaptic P
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receptors appear to be P 2 (Westfall et al, 1970).
Presynaptic cc and g receptors have been shown to 
occur in the hearts of a number of animals including the rat 
(Yamaguchi et al, 1977; Starke, 1981 and Westfall et al, 
1970) .
The results led to the hypothesis that the 
presynaptic receptors are links in local, release-controlled 
feedback circuits. When activated by previously released 
noradrenaline, they may facilitate ( p 2  receptors) or 
depress ( receptors) noradrenaline release by subsequent 
action potentials. This hypothesis is widely accepted for 
presynaptic € = 2  receptors (Bacq, 1976; Starke, 1977;
Stjarne, 1975; Vizi, 1979 and Westfall, 1977). However, for 
the presynaptic preceptors the hypothesis has not been 
proven (Stjarne and Brundin, 1975 and Westfall, 1977). 
Adrenaline is a far more potent p 2  agonist than 
noradrenaline and it has been proposed that the presynaptic 
P^ receptors are one of the physiological targets for 
adrenaline (Starke et al, 1972b).
iV . Intracellular Signals Mediated by Adrenergic 
Receptors
After the adrenergic agonists have become bound to 
the receptor an intracellular signal is induced which 
mediates the cellular response to the extracellular 
stimulus. The binding of different agonists to different 
subtypes of adrenergic receptor has been shown to lead to 
the generation of different intracellular signals (for 
reveiw see Jakobs and Schultz, 1980).
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a) Beta-adrenergic Receptors
Stimulation of either p-adrenergic receptor, ie.p 
^ occuring predominantly in the heart, or p 2  occurring 
predominantly in vascular, bronchial and uterine smooth 
muscle, causes an increase in the intracellular 
concentration of cAMP (Cassel and Slinger, 1978; Hoffman and 
Lefkowitz, 1980; Lefkowitz and Hoffman, 1980; Levitzki,
1981; Levitzki and Helmreich, 1979 and Rodbell, 1980). These 
studies have revealed that the p-adrenergic 
receptor/adenylate cyclase system is composed of at least 
three membrane proteins: the p-adrenergic receptor, the 
catalytic subunit of adenylate cyclase and a guanyl 
nucleotide-binding protein.
The sequence of events from binding of the P 
adrenergic agonist (H), to activation of the catalytic 
subunit of adenylate cyclase (C) by the guanylate 
triphosphate-activated binding protein (N) is shown in fig 
1.16.
b) Alpha 2  Adrenergic Receptors
Binding of oc2  agonists to their respective 
adrenergic receptors has been shown to reduce the 
intracellular concentration of cAMP levels by inhibiting 
adenylate cyclase (Jakobs, 1979; Jakobs and Schultz, 19 80 
and Jakobs et al, 1980,81). Inhibition occurred almost 
immediatly and was reversed by appropriate antagonists
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FIG 1-16
Activation of the Beta Adrenergic Receptor and the Coupling to 
Adenyl Cyclase Activation,
H









H= beta agonist 
Rss beta adrenergic receptor 
N= nucleotide binding protein 
C= adenyl cyclase
from Schultz and Jakobs, 1981,
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without any lag phase (Jakobs and Schultz, 1980). Basal and 
hormonally-stimulated rates of cAMP formation were inhibited 
by between 50 and 80% (Jakobs et al, 1980,81).
The molecular mechanism by which oc^ adrenergic 
agonists inhibit adenylate cyclase is less clear than the 
mechanism of p-adrenergic stimulation of the enzyme. It 
appears that stimulation of adrenergic receptors
increases the deactivation of adenylate cyclase by the 
hydrolysis of N-GTP-C to N-GDP in fig 1.16 (Arktories and 
Jakobs, 19 81 and Jakobs et al, 19 81).
Although it is known that stimulation of p 
-adrenergic receptors stimulate and oc 2  adrenergic 
receptors inhibit adenylate cyclase, the basis of the 
different coupling of p and oc^ receptors to the enzyme is 
not understood. It is possible that there are different 
stimulatory and inhibitory guanyl nucleotide-binding 
proteins involved (Jakobs, 1979 and Rodbell, 1980).
c) Alpha^ Adrenergic Receptors
Based on studies in a variety of tissues it is now
generally accepted that the main intracellular signal
generated by the occupancy of Oc^ receptors is an increase
2+in cytosolic free Ca concentration (Berridge, 1975,80; 
Exton, 1981 and Michell and Kirk, 1981) . Several calcium 
pools may contribute to this increase depending on the 
tissue. Besides the extracellular space, intracellular 
storage sites such as the mitochondria, endoplasmic 
reticulum and membrane phospholipids, are possible sources
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of the hormone-induced increase in cytosolic Ca^^ in the 1 j:/
(for review see Reinhart et al, 1984).
The molecular mechanisms involved in signal
transformation by adrenergic receptors are far from
clear. receptors are not coupled to the regulatory guanyl
nucleotide-binding protein and adenylate cyclase as are
and receptors (Hoffman and Lefkowitz, 1980).
Occupancy of receptors does lead to a rapid
breakdown and subsequent resynthesis of membrane
phosphatidylinositol (Michell and Kirk, 1981 and for review
see Fain, 1984). The production of inositol triphosphate
from phosphatidylinositol 4,5-bisphosphate has been shown to
2+increase cytosolic Ca concentration in pancreatic acinar
cells (Streb et al, 1983) and hepatocytes (see fig 1.17)
(Joseph et al, 1984 and Burgess et al, 1984). Inositol
triphosphate is rapidly resynthesised to
phosphatidylinositol-phosphate (Litosch et al, 1983).
Diacylglycerol, also formed from the breakdown of
phosphatidylinositol 4,5-bisphosphate, activates protein
kinase C (Kishimoto et al, 1980 and Takai et al, 1984) which
phosphorylates a number of proteins (Garrison, 1983).
However, there are still large gaps in the
hypothesis, eg. how inositol triphosphate increases 
2+cytosolic Ca concentration or how membrane
phosphatidylinositol turnover occurs in parallel to the 
2+increase in Ca or even secondary to and not a causal factor 
(Michell and Kirk, 1981).
Other signals have been proposed for the mediation 
of adrenergic responses. Cyclic guanylate monophosphate
(cGMP) levels have been shown to increase after
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adrenergic stimulation in the rat ductus deferens (Schultz
et al, 1975). The Œ^-induced rise in cGMP levels are
2+reduced or even abolished in the absence of Ca (Schultz et 
al, 1973). It has been proposed that Œ ^ induced stimulation 
of cGMP formation involves a calcium-induced release of 
arachidonic acid and, possibly, other unsaturated fatty 
acids (Spies et al, 1980).
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FIG 1:18














H= adrenergic agonist 
N= nucleotide binding protein 
AC= adenyl cyclase .
from Schultz and Jakobs, 1981
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Section 1.10.
Adrenergic Control of Lipid Metabolism
i. Adrenergic Control of Triglyceride Lipase Activity in 
Adipose Tissue.
Lipolysis in adipose tissue is an important part of 
energy metabolism in the whole animal. By regulating this 
process, various hormones influence the supply of free fatty 
acids to muscles and other tissues of the body.
Activation of lipolysis by fat-mobilizing hormones, 
such as adrenaline, has been explained by activation of TGL 
via adenyl cyclase (EC 4.6 .1.1.) and cyclic 3*5' adenosine 
monophosphate dependent protein kinase (Butcher et al, 19 65; 
Corbin et al, 1970 and Huttunen and Steinberg, 1971). Since 
the lipase is the rate-limitting step in the hydrolysis of 
triglyceride its activation leads to an increase in 
lipolysis (Vaughan and Steinberg, 1963 and Vaughan et al, 
1964) .
Adrenaline has been shown to increase the activity 
of TGL in rat epididymal adipose tissue (Rizack, 1961; 
Vaughan and Steinberg, 1963; Vaughan et al, 1964; Ho et al, 
1967 and Huttunen et al, 1970). in 1964, Rizack showed that 
the TGL in fat cell homogenates could be activated under 
phosphorylating conditions in a reaction that was stimulated 
by cAMP. Since then it has been established that the general 
mechanism of action of cyclic AMP involved the stimulation 
of a protein kinase and phosphorylation of various proteins
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(Walsh et al, 1968). It was proposed that a cyclic 
AMP-dependent protein kinase catalysed the phosphorylation 
of TGL and so mediated the activation of lipolysis by 
fat-mobilising hormones. Subsequently, TGL was found to be 
activated by incubation with cAMP-dependent protein kinase 
in rat (Huttunen et al, 1970; Corbin et al, 1970; Khoo et 
al, 1972 and Belfrage et al, 1977), human (Khoo et al, 
1972,74) and chicken (Khoo and Steinberg, 1974) adipose 
tissue.
Recently direct phosphorylation of purified TGL 
from rat adipose tissue, by the catalytic subunit of 
cAMP-dependent protein kinase has been demonstrated 
(Belfrage et al, 1980). The extent of phosphorylation was 
closely correlated with the rate of lipolysis in cells 
stimulated with noradrenaline (Belfrage, et al, 1980).
Removal of the lipolytic hormone or addition of an 
antilipolytic agent reverses the activation of lipolysis 
(Mangeniello et al, 1971 and Allen et al, 1973). This 
reversibility suggests the presence of an endogenous 
reversible deactivator of TGL. This has been suggested to be 
a phosphoprotein phosphatase. Khoo and Steinberg (19 74) 
found that a partially purified TGL from chicken adipose 
tissue can be activated by incubation with cAMP and muscle 
cAMP-dependent protein kinase, deactivated by dialysis and 
subsequently reactivated by addition of cAMP and ATP. This 
reversible activation/deactivation cycle can be repeated 
several times and is presumed to reflect the presence of a 
lipase phosphatase. Recently, direct dephosphorylation by a 
partially purified phosphatase has been shown to reduce 
activated TGL activity (Berglund et al, 1980). The
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"lipolytic activation cascade" is shown in fig 1.19.
The beta-adrenergic agonist isoprenaline has been 
shown to increase TGL activity in rat adipose tissue and 
this activation was blocked by the beta-adrenergic 
antagonist isopropylnitrophenyl ethanolamine (Christian et 
al, 1969). Thus the activation of TGL by adrenaline appeared 
to be associated with the beta-adrenergic receptor.
Diglyceride lipase and monoglyceride lipase in 
adipose tissue have also been shown to be activated by 
cAMP-dependent protein kinase, the activation being blocked 
by the addition of protein kinase inhibitor (Belfrage et al, 
1977; Khoo et al, 1977,78).
In contrast to the above proposed mechanisms, a 
novel system of lipolytic activation by adrenaline has been 
proposed by Okuda et al (1970) and Wise and Jungas (1978). 
These authors suggest adrenaline activation is achieved by 
facilitation of the substrate-enzyme interaction rather than 
by activation of the enzyme itself.
ii. Alpha Adrenergic Effects on Lipolysis,
It has been found that isoprenaline was over 5 fold 
more potent than adrenaline in activating adipose lipolysis 
(Fain, 1973). Subsequently, it was found that alpha 
adrenergic agonists inhibited lipolysis in human adipocytes 
(Burns et al, 19 81) . It has been demonsfrated that alpha 
adrenergic stimulation reduces cAMP levels by deactivating 
adenyl cyclase in human and hamster, but not rat, adipose 
tissue (Arktories et al, 1979; Burns et al,1981). Also, 
lipolysis in rat brown adipose tissue has been shown to be 




























1983). These effects of alpha adrenergic stimulation are 
confined to alpha 2  mechanisms, stimulation of alpha^ 
receptors appear to have little if any effect (for review 
Fain and Garcia-Sainz, 1983).
It is reasonably clear, therefore, that alphag and 
beta adrenergic mechanisms mediate opposing effects on 
lipolysis in hamster and human adipose and rat brown adipose 
tissue. The balance between these mechanisms could be a 
point of regulation that determines the final effect of the 
natural catecholamines on adipose tissue in vivo.
iii. Adrenergic Control of Lipolysis in the Heart.
Perfusion of the heart with catecholamines 
increases the rate of cardiac lipolysis. This has been 
demonstrated by the finding of decreased tissue levels of 
total triglyceride (Crass et al, 1975); Gartner and Vahouny, 
1973; Hron et al, 1977 and Jesmok et al, 1977) and increased 
rates of glycerol output (Williamson, 1964; Kriesberg, 1966; 
Chrisitian et al, 1969; Hron et al, 1977; Jesmok et al, 1977 
and Severson et al, 1980). Cardiac lipolysis has also been 
shown to be increased by both adrenaline and noradrenaline 
when studied by the disappearance of label from isotopically 
pre-labelled triglyceride (Crass et al, 1975).
Adrenaline was found to increase lipase activity in 
heart homogenates (Bjorntorp and Furman, 1962). Similar 
activation of lipase activity by adrenaline was not seen by 
Severson (19 79).
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Cyclic AMP levels (Robinson and Newsholme, 1968 and 
Mayer et al, 1970) and the protein kinase activity ratio 
(Keely et al,1977; Keely and Corbin, 1975 and Hron et al,
1977) are both increased in the isolated perfused rat heart 
following adrenaline perfusion. As in adipose tissue this 
effect appears mediated by beta adrenergic mechanisms 
(Mayer, 19 74). This would suggest that cardiac TGL could be 
activated by cAMP-dependent protein kinase in a way 
analogous to that described for adipose tissue (Shipp et al, 
1973 and Hron et al, 1977). In the isolated working rat 
heart, the cAMP analogue dibutyryl cAMP, increased lipolysis 
(Crass, 1973). It also increased triglyceride mobilization 
in the Langendorff perfused heart (Gartner and Vahouny, 
1973). However, attempts to activate cardiac TGL activity 
directly by incubation with cAMP-dependent protein kinase 
have proved unsuccessful (Severson, 1979 and Rosen et al, 
1981) .
Apart from hormonal control, metabolic control may 
also be important in regulating cardiac lipolysis. Exogenous 
free fatty acids are known to inhibit both basal and 
catecholamine-stimulated rates of lipolysis (Crass, 1973 and 
Crass et al, 1975). It may be that increased rates of 
adipose tissue lipolysis would inhibit endogenous 
triglyceride mobilization in the heart (Severson, 1979). 
Indeed, it has been shown that triglyceride levels are 
increased when the supply of exogenous fatty acid is 
elevated (Crass et al, 1971; Hron et al, 1978 and Neely et 
al, 1969). Severson and Hurley (19 82) have shown how cardiac 
neutral TGL activity is inhibited by fatty acids and fatty 
acyl CoA compounds. Thus, the balance between synthesis and
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lipolysis can be influenced not only by hormones but also by 
exogenous substrates.
iv. Alpha Adrenergic control of Lipolysis in the Heart.
Keely et al (19 77) reported that alpha adrenergic 
stimulation results in a small but significant fall in cAMP 
levels in the perfused rat heart. This was confirmed by 
Watanbe et al (19 77) using cardiac myocytes. However, no 
effect of alpha adrenergic stimulation on cardiac lipolysis 




The estérification pathway has been reported to be 
under hormonal control (Denton and Halperin, 1968 and 
Sooranna and Saggerson, 1975).
The identification of rate-limitting steps and 
regulatory points in the estérification pathway is, at best, 
tentative. Enzyme activities measured in vitro can be quite 
different from the in vivo situation due to the problems 
inherent in presenting lipid-soluble substrates to the 
enzymes and their intramembrane location.
Recent work by Declercq et al (19 82) and 
Pikkukangas et al (19 82) together with earlier work by 
Denton and Halperin (1968) have suggested that, in the 
liver, hormones may exert their control over the 
estérification pathway by altering the substrate supply. 
However, a large number of studies have reported direct 
hormonal effects on some of the enzyme activities in this 
pathway.
Since it is generally recognised that the 
endoplasmic reticulum is the major site of triglyceride 
synthesis, research has been concentrated on the activities 
of the microsomal enzymes (Numa and Yamashita, 1974 and 
O'Doherty, 1978).
Coleman et al (19 78) have observed large increases 
in the microsomal forms of fatty acyl CoA synthetase, 
glycerol 3-phosphate acyltransferase, 1 acylrglycerol 
3-phosphate acyltransferase and diacylglycerol 
acyltransferase in mice fibroblasts as they differentiate
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into adipocytes. These enzyme changes accompany the large 
increase in the capacity of these cells to synthesise 
triglycerides.
i. Fatty acyl CoA Synthetase
Most workers agree that fatty acyl CoA synthetase 
is not rate-limitting for estérification, Lloyd-Davies and 
Brindley (1975), using two assay methods for long-chain acyl 
CoA synthetase in liver found that the activity was much 
higher than that required to maintain maximal rates of 
glycerol 3-phosphate estérification.
In addition examination of enzyme activities after 
fasting have shown that carnitine palmitoyl transferase 
activity increases while glycerol 3-phosphate 
acyltransferase activity decreases in the liver (Borrebaek 
et al, 1974). Since carnitine palmitoyl transferase (McGarry 
and Foster, 1980) and glycerol 3-phosphate aclytransferase 
(Lloyd-Davies and Brindley, 1975) have been cited as 
regulatory points for oxidation and estérification 
respectively, it seems unlikely that fatty acyl CoA 
synthetase, the preceeding enzyme for both pathways, can be 
a rate-limiting step for either pathway (Bell and Coleman, 
1980).
However, in adipose tissue, where estérification 
plays a far more dominant role, the situation may be 
different. Indeed insulin has been shown to increase (Jason 
et al, 19 76) and adrenaline to decrease (Sooranna and 




It has long been thought that the activity of this 
enzyme could be the major regulatory point for the 
estérification pathway (Denton and Halperin, 1968), A number 
of direct hormonal effects on the activity of this enzyme 
have been shown and these will be discussed later,
iii, Phosphatidic acid Phosphatase
This enzyme has also been cited as a major 
regulatory point in triglyceride synthesis (Lamb and Fallon, 
1974 and Lawson et al, 1981). Lamb and Fallon (1974), Fallon 
et al (19 77) and Brindley et al (19 79) report evidence 
suggesting that nutritional and hormonal alterations in the 
rate of estérification are paralleled by changes in the 
activity of this enzyme.
Acute hormonal effects on the activity of 
phosphatidic acid phosphatase have also been reported (Cheng 
and Saggerson, 1978) and evidence for a
phosphorylation/dephosphorylation system of control has been 
presented (Berglund et al, 1980), However, since the enzyme 
is not the first unique step in the biosynthetic pathway it 
is unlikely to be the sole rate-limit;ting step for 
glycerolipid synthesis. The variations reported with diet 
and hormones has been disputed by Murthy and Shipp (1980).
iv. Diacylglycerol acyltransferase
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This enzyme is the only one exclusively concerned 
with the synthesis of triglycerides and thus, may be 
considered as a potential regulatory point (Bell and 
Coleman, 19 80).
Diet-induced changes in triglyceride synthesis in 
adipose tissue were paralleled by marked changes in the 
activity of this enzyme (Fallon et al, 1975). Sooranna and 
Saggerson (19 78) have reported a stable decrease in 
diacylglycerol acyltransferase activity after fat cells were 
exposed to adrenaline. Recently, Haagsman et al (19 81) have 
shown that the activity of this enzyme can be inactivated by 
cAMP-independent phosphorylation and can be reactivated 
under dephosphorylation conditions.
Diacylglycerol acyltransferase activity has been 
claimed to have the lowest activity of all the enzymes in 
triglyceride synthesis in both the rat and rabbit heart 
(Kako and Patterson, 19 75 and Murthy and Shipp, 19 80) and 
thus, it may be rate-limiting in triglyceride synthesis in 
the heart.
V. Adrenergic Control of Glycerol 3-phosphate 
Acyltransferase Activity (GPAT).
This enzyme is the first, and probably major, 
regulatory point in the regulation of glycerolipid synthesis 
(Bell and Coleman, 1980). Acute hormonal effects on the 
activity of this enzyme have been observed by a number of 
workers.
Sooranna and Saggerson (19 76,78) have shown that
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exposure of either adipose tissue or isolated fat cells to 
adrenaline or noradrenaline results in a marked decrease in 
GPAT activity. This effect was prevented by inclusion of the 
beta blocker propranolol or insulin (Sooranna and Saggerson, 
1978). The effect of noradrenaline was seen on both GPAT 
activity from the mitochondrial (N-ethylmaleimide 
insensitive) and from microsomal (NEM sensitive) fractions 
(Rider and Saggerson, 1983a).
Soler-Argilaga et al (19 78) reported a decrease in 
estérification after livers were perfused with the cAMP 
analogue, dibutyryl cAMP, and suggested the involvement of 
glycerol 3-phosphate acyltransferase. Nimmo and Houston 
(1978) presented evidence to indicate that the activity of 
GPAT in liver microsomes was inactivated by a 
cAMP-dependent phosphorylation mechanism and could be 
reactivated by a phosphatase. Recently, however. Rider and 
Saggerson (1983a,b) were unable to confirm these reports. 
They suggested that the inactivation, by noradrenaline, of 
the mitochondrial and microsomal forms of the enzyme seen in 
rat adipocytes was due to a protein present in the 
post-microsomal supernatant, and similar to an acyl CoA 
binding protein.
There have been no reports on the role of alpha 
adrenergic mechanisms in the control of estérification or 
GPAT activity.
Very little is known about the regulation of 
estérification in the heart. It has been demonstrated that 
the concentration of triglycerides in the heart is reduced 
as a result of adrenaline perfusion (Gartner and Vahouny,
1973). This could be a result, not only of increased
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lipolysis, but also of decreased estérification.
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Section 1.12.
Catecholamines in the Ischaemic Heart
i. Release of Endogenous Catecholamines During Ischaemia.
Several investigations have indicated that 
increased adrenergic activity occurs in the acutely 
ischaemic myocardium (Shahab and Wollenberger, 1967; Shahab 
et al, 1969; Abrahamsson et al, 1981; Corr et al, 1978; 
Holmgren et al, 1981 and Podzuwiet et al, 1978). This could 
be due to an increase in nerve impulse flow in the heart, 
either by activation of sympathetic nerves (Karlsberg et al, 
1979 and Staszewska-Barczak, 1971) or by local cardiac 
reflexes (Brown and Malliani, 1971 and Bosnjak et al, 1979). 
In addition, direct effects on adrenergic neurones 
(independent of nerve impulses) could all play a part in 
increasing noradrenaline release or decreasing re-uptake 
(Langer, 1980). Certain prostaglandins, for example, prevent 
excessive stimulation of adrenergic receptors by inhibiting 
noradrenaline release (Langer, 1980 and Malik, 1978), while 
a high extracellular concentration seen during ischaemia 
can increase noradrenaline release (Lorenz and Vanhoutte, 
1975). The fall in pH in the ischaemic myocardium soon after 
coronary occlusion would be expected to inhibit 
noradrenaline release (Puig and Kirpekar, 1971) and 
re-uptake (Karapati et al, 1974). Hypoxia (Shahab and 
Wollenberger, 1967) and energy deficiency within the neurone 
itself (Wakade and Furchgott, 1968) could both play a part
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in increasing noradrenaline release.
Although a large volume of evidence indicates an 
increased release of noradrenaline in the ischaemic heart, a 
number of reports have contradicted this (Marshall and 
Parratt, 1976; McGrath et al, 1981 and Riemersma and Forfar, 
19 82). These workers have suggested that the increase in 
noradrenaline overflow from the ischaemic area seen in 
earlier reports (Shahab et al, 1972) occured during 
reperfusion and not during occlusion. However, absence of 
noradrenaline overflow during ischaemia should not be 
interpreted as absence of noradrenaline release from nerve 
terminals as the major fate of released noradrenaline is 
normally re-uptake into the neurones (Iverson, 1977).
In acute ischaemia cAMP levels are known to rise 
markedly (Dobson and Mayer, 1973; Krause et al, 1978; 
Podzuweit et al, 1978; Wollenberger et al, 1969 and Opie et 
al, 1979). Occlusion of the left coronary artery in the 
isolated rat heart model for 2 minutes resulted in a marked 
increase in cAMP levels in both the non-ischaemic and 
ischaemic areas (Krause and Wollenberger, 1967). After 20 
minutes of occlusion cAMP levels had returned to normal in 
the non-ischaemic area but remained elevated in the 
ischaemic area. Concurrent with the rise in cAMP levels 
Krause and Wollenberger (19 67) found an increase in the 
activities of cAMP-dependent protein kinase, phosphorylase 
kinase and phosphorylase in ischaemic tissue. Pre-perfusion 
before occlusion by the beta adrenergic antagonist 
propranolol completely prevented the rise in cAMP levels and 
the activity of cAMP-dependent protein kinase but only 
partly prevented the rise in phosphorylase kinase and
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phosphorylase activity in ischaemic tissue (Krause and 
Wollenberger, 1967).
ii. Arrhythmias Associated with Ischaemia and Reperfusion
Abnormalities of the heart beat which occur during 
ischaemia or subsequent reperfusion account for at least 
half of the deaths due to acute myocardial infarction 
(Armstrong et al, 1972). These abnormalities, incuding 
ventricular arrhythmias, ventricular fibrillation, ectopic 
beats and supra-ventricular arrhythmias, are often 
associated with an increase in plasma catecholamine levels 
(Gazes et al, 1959; Valori et al, 1967; Siggers et al, 1971; 
Webb et al, 1972 and Videbaek et al, 1972).
There is impressive evidence incriminating 
myocardial noradrenaline in the development of ventricular 
arrhythmias during acute myocardial ischaemia and 
reperfusion. Surgical denervation of the heart significantly 
reduces the incidence of ventricular fibrillation following 
coronary occlusion providing that it is carried out long 
enough prior to the occlusion to allow depletion of 
myocardial catecholamines to occur (Ebert et al, 1968). 
Chemical denervation by 6 OH-dopamine almost completely 
abolished the occurance of ventricular fibrillation during 
both coronary occlusion and reperfusion in the cat (Sethi et 
al, 1973 and Sheridan et al, 1980) and guinea pig (Culling 
et al, 1984) heart.
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iii. Pre-perfusion with Beta Adrenergic Antagonists
There are numerous reports concerning the effects 
of p-adrenergic antagonists on the functional, 
electrophysiological and morphological changes in the heart 
following acute myocardial ischaemia (Fitzgerald, 1972). In 
the dog model alone there are 27 reports concerning the 
effects of six different pantagonists on cardiac 
arrhthymias and survival after acute ischaemia. The 
conclusion from such studies is that p-adrenergic 
antagonism will;
(1) increase the time before ventricular arrhthymias 
occur (Rosenfeld et al, 1978);
(2) reduce the incidence of arrhythmias (Khan et al,
1972) and
(3) improve survival (Evans et al, 1976).
However, there have been 3 reports where p 
antagonism with propranolol has not reduced the incidence of 
arrhthmias or the survival rate (Pearle et al, 1978; 
Pentecost and Austen, 1966 and Khan et al, 1972).
In the isolated perfused rat heart model, Lubbe et 
al (1978) showed that adrenaline increased tissue cAMP 
levels and lowered the electrophysiological threshold for 
ventricular fibrillation. These changes were prevented by 
adding atenolol, a cardio-selective P^-adrenergic 
antagonist, to the perfusate. Following ligation of the left 
coronary artery in the same preparation, there was a fall in 
ventricular fibrillation threshold and a rise in cAMP 
levels. This was not blocked by atenolol but was blocked by
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the non-selective p antagonist propranolol (Lubbe et al,
1978).
Acute ligation of the left coronary artery in rats 
causes a predictable pattern of ventricular arrhythmias in 
about 60% of animals (Kenedi and Losonci, 1973). The effects 
of various p adrenergic antagonists in this model have been 
assessed by a number of studies (Kane et al, 1979; Campell 
and Parratt, 1981; Szekeres, 1978 and Siegmund et al, 1979). 
The various studies clearly indicate that p -adrenergic 
antagonism has a beneficial effect on the consequences of 
occlusion of the left coronary artery in rats.
iv.Pre-perfusion with Alpha-adenergic antagonists.
The <T-adrenergic antagonist phentolamine has been 
shown to reduce the incidence of ventricular arrhythmias 
caused by nicotine or adrenaline (Leimdorfer, 1953); 
acontine or chloroform inhalation (Vargaftig and Coignet, 
1969); digitalis-induced arrhythmias (Ettinger et al, 1969) 
and also in man following acute myocardial infarction (Gould 
et al, 1971+75).
In a recent study a chloralose-anaesthetised cat 
model of coronary occlusion and reperfusion was used to 
study the relative importance of Œ  and P adrenergic 
receptor blockade (Sheridan et al, 1980). These workers 
found that either Œ  blockade with phentolamine or depletion 
of endogenous noradrenaline with 6 OH-dopamine significantly 
reduced the incidence of ventricular arrhythmias during both
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coronary occlusion and reperfusion. In contrast, the p 
antagonist propranolol only reduced the incidence of 
arrhthmias during occlusion and not during reperfusion. It 
was also found that prasozin, a specfic Œ ^ adrenergic 
antagonist gave the same results as phentolamine, thus 
conferring Œ  ^ specificity to the beneficial effects of 
antagonists (Sheridan et al, 1980).
Preliminary evidence has suggested that œ  receptor 
responiveness may be altered during myocardial ischaemia 
(Moore and Parratt, 1973). Shayman et al (1980) have 
suggested that the number of CC receptors is increased in 
the early phase of reperfusion while Sheridan et al (1980) 
give evidence of an enhanced Œ  -adrenergic responsiveness 
soon after reperfusion of the ischaemic area has begun.
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V. Ischaemia, Catecholamines and Lipid Metabolism
The increased release of noradrenaline may play a 
significant role in the development of tissue damage during 
ischaemia. It is believed to contribute, not only to the 
incidence of ventricular arrhythmias, but, by increasing 
metabolic disturbances, it causes myocardial cell damage 
(Corr and Gillis, 1978; Hjalmarso, 1980 and Maroko et al,
19 71). Several workers have shown that depletion of 
catecholamines from the heart (Gaudal et al, 1979; Gercken 
and Doring, 1973 and Sakai and Spieckermann, 1975) or p 
-adrenergic antagonism (Sakai and Spieckermann, 1975;
Manning et al, 1980; NaylOr et al, 1980 and Pieper et al, 
1980) have been beneficial in protecting against hypoxic or 
ischaemically induced myocardial injury.
One of the possible causes of cell damage and 
consequent myocardial dysfunction is the cellular 
accumulation of long chain fatty acids and their metabolites 
resulting from catecholamine-stimulated lipolysis of 
endogenous triglyceride (Opie, 1976). High levels of fatty 
acids and their metabolites have been implicated in the 
genesis of arrhythmias in the infarcting myocardium (Oliver,
1974) while antilipolytic agents have been shown to reduce 
infarct size and protect against ventricular arrhythmias 
(Ilebekk and Mjos, 1973; Ilebekk and Lekven, 1974 and Rowe 
et al, 1975). Thus, the regulation of lipid metabolism in 
the ischaemic heart is re^vent to the occurance of 





Perfusion of Hearts 
(For source see Materials), 
i. Perfusion apparatus.
Hearts were perfused by a non-recirculating 
Langerdorff system. The apparatus is shown in fig 2.1. The 
perfusion system consists of water-jacketed glassware 
connected by polythene tubing (internal diameter 0.86 mm, 
external diameter 4.8 mm). The perfusate was puirped by a 
variable speed peristaltic pump (Watson Marlow MHRE 22, 
Falmouth, Cornwall). The silicon tubing at the peristaltic 
pump measured 3.2 mm (i.d.) and 6.4 mm (o.d.).
Air bubbles were removed from the system by the
bubble trap. A thermostated-recirculating pump supplied 
heated water from a reservoir to the water-jacketed
glassware. The perfusate also passed through^a heat
exchanger shortly before entering the heart. The temperature 
of the perfusate emerging from the cannula was 37°C. The 
perfusate was filtered before entering the heart by a 25 mm
diameter prefilter and filter (0.45^m pore size) and aerated
by flowing downwards through a jacketed reflux column 
against a flow of humidified 95% / 5% COg.
To calibrate the flow rate the perfusate leaving
the cannula was collected in a measuring cylinder over a 2
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Components of the perfusion apparatus
A heart perfusion vessel
C variable speed peristaltic flow inducer 
D bubble trap
E temperature equilibration coil 
F membrane filter and housing
G cannula
H perfusate aerator column
I  Strain gauge 






minute period. For all perfusions a flow rate of 
approximately 10 ml per minute was used. The total volume of 
the perfusion apparatus was 15 ml.
ii. Preparation of Perfusate
The perfusate was glucose bicarbonate buffer (Krebs 
and Hensleit, 19 32) pH 7.4. The final composition of the 
Krebs/Hensleit solution was: sodium chloride (118.4 mM) , 
potassium choride (4.6 m M ) , sodium hydrogen carbonate (24.9 
m M ) , magnesium sulphate (1.1 mM), sodium dihydrogen 
orthophosphate (1 mM) and calcium chloride dihydrate (2.54 
m M ) . To prevent the precipitation of calcium phosphate, all 
the salts except calcium chloride were dissolved in double 
distilled water and the solution gassed for 2 0  minutes with 
9 5 % O^/ COg" The calcium chloride, dissolved in distilled 
water, was then added to the buffer. Immediately before use, 
glucose was added to a final concentration of 11 mM.
iii. Perfusion procedure.
Male albino rats, Wistar strain, weighing 200g and 
fed ad libitum on laboratory chow (Oxoid 41B) were used. The 
rats were anaesthetised by intraperitoneal injection of a 
mixture of sodium pentobarbitone ("Sagatal", May and Baker, 
Dagenham, Essex) 80 mg/kg, and heparin (sodium salt, Evans 
Medical, Speke, Liverpool), 24,000 U/kg. To prepare the 
anaesthetic, 58 mg of heparin was dissolved in a mixture of 
5.2 ml of Krebs/Hensleit buffer and 0.6 ml of Sagatal. 0.8
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ml of this preparation was introduced into the rats by 
intraperitoneal injection.
The heart was quickly excised and placed in 
ice-cold Krebs/Hensleit buffer. This cold buffer arrested 
the heart beat. Blood was rinsed free of the heart while 
extraneous (mainly adipose tissue) material was removed. The 
aorta was attached to a vinyl cannula with an artery clip. 
(The cannula was made from an intravenous cannula, o.d. 1.65 
mm, cut obliquely 3.5 mm from the head). The heart was then 
mounted on the perfusion apparatus and immediately perfused 
with Krebs/Hensleit buffer and glucose at 37^C. The aorta 
was tied to the cannula with a silk suture ("Abra Silk", 
black braided, no. 2 ).
A thread was attached to the apex of the heart by a 
small hook. The thread was attached to a ÜF2 dynamometer 
strain gauge by way of a pulley wheel. The physiological 
recorder (Devices Instruments Ltd., Welwyn Garden City, 
Herts) recorded total and developed tension of the heart 
after resting tension had been set at 2 grammes. Heart rate 
was measured manually using a stop watch.
After 20 minutes of perfusion, hearts were removed 
from the cannula, placed in ice-cold Krebs/Hensleit buffer 
and the atria and aorta transected from the ventricles. The 
ventricular muscle was then homogenized in 5 ml of ice-cold 
STE buffer (0.25 M sucrose, 10 mM Tris, 1 mM EDTA, pH 7.6) 
for 10 seconds by a polytron homogeniser (Northern Media 
Supply Ltd., North Cave, North Humberside) at a power 
setting of 3.5.
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iv. Perfusion Procedure for the study of the Affects of 
Adrenergic Agonists and Antagonists.
For the investigations of the affects of adrenergic 
agonists the perfusion was continued for 2 0  minutes before 
the agonist was introduced in to the system, via the reflux 
column, to a final concentration of 10 ^M. The peak effect 
of any change in inotropy or chronotropy was noted 1 - 2  
minutes after the addition. At this time the hearts were 
removed and homogenised as before.
When investigating the affects of adrenergic 
antagonists, hearts were perfused normally for 1 0  minutes 
and thereafter with perfusate containing the antagonist 
(10 ^M) for a further 10 minutes. At this time the hearts 
were removed and homogenized as before.
V. Perfusion Procedure for the study of the Affects of 
Coronary Occlusion and Reperfusion.
Hearts were perfused normally for 10 minutes, after 
which a silk suture was inserted behind the left descending 
coronary artery using a small surgical needle. The artery 
was occluded by ligation of the silk suture. The ischaemic 
area of the left ventricle was clearly visible after 1 0  
minutes occlusion. At this time hearts were removed and 
placed in ice-cold Krebs/Hensleit buffer. Tissue samples 
(approximately lOOmg) were quickly dissected from the 
ischaemic area of the left ventricle and the non-ischaemic 
area of the right ventricle. These were homogenised
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separately in 3 ml of ice-cold STE buffer.
For reperfusion studies a polythene tube (id 0.86 
mm, od 1.52, length 4 mm) was inserted between the artery 
and the suture just before ligation. This was removed after 
1 0  minutes occlusion, allowing reperfusion of the artery. 
Tissue samples were taken from previously ischaemic and 
non-ischaemic areas, as before, at 1 minute and 5 minutes 
after reperfusion had begun.
When using the adrenergic antagonists the procedure 
for coronary occlusion and reperfusion was followed. The 
antagonist was introduced into the perfusate 1 0  minutes 
before occlusion and remained present throughout the rest of 
the perfusion at a concentration of 1 0  ^M.
To study the affects of 6 -hydroxydopamine rats were 
injected intravenously 24 hours before use. 50 mg of 6  
OH-dopamine was dissolved in 1 ml of Krebs/Hensleit buffer.
This was injected into the rats to give a concentration of
h'l50 mg/ml'. The following day the procedure to study the 
affects of ischaemia or of reperfusion were followed.
vi. Sterilization and Washing of the Perfusion Apparatus.
To avoid and bacterial contamination the apparatus 
was filled with an antibiotic mixture of penicillin (300 
U/ml), streptomycin (Img/ml) and neomycin (Img/ml). This 
solution remained in the apparatus overnight. After 
approximately 2 0  perfusions the apparatus was disconnected 
and the components washed first in chromic acid then in 
Decon 700 detergent. (Decon Ltd., Hove). This was followed
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by a wash with distilled water. At the same time all the 
vinyl tubing and three way taps were replaced.
Section 2.2.
i. Extraction of Enzyme.
Fresh tissue was immediately homogenised in the 
polytron homogenizer (SM20 generator, power setting 3.5) for 
10 seconds in STE buffer. The tube was maintained cold by 
immersing it in an ice bath. The homogenate was then either 
used directly as a crude glycerol 3-phosphate 
acyltransferase (GPAT) preparation or it was centrifuged at 
2,000g in a bench centrifuge at 4^C for 5 minutes. This 
supernatant was either used directly as a crude triglyceride 
lipase (TGL) preparation or it was centrifuged at 10,000g in 
an Eppendorf microfuge at 4°C for 8  minutes. The pellet so 
formed was resuspended in STEB buffer (0.25 M sucrose, 10 mM 
Tris, 1 mM EDTA, and 0.1% fatty-acid poor bovine serum 
albumin, pH 7.6) to give a final protein concentration of 
approximately 2 mg/ml. This was used as a mitochondrial 
preparation for the assay of carnitine palmitoyl transferase 
(CPT) and the mitochondrial form of GPAT. The 10,000g 
supernatant was used as a crude preparation of the 
microsomal form of GPAT.
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ii. Incubation with N-ethylmaleimide (NEM) .
2 0 0 ^ 1  of homogenate was incubated in the presence or 
absence of 15 mM NEM for 5 minutes at 30^C. This was then 
assayed for GPAT activity. NEM-sensitive activity was 
calculated as that due to the microsomal form of the enzyme. 
NEM-insensitive (mitochondrial) activity was calculated as 
the difference in activity between that measured in the 
absence and presence of NEM.
iii. Sonication of Mitochondrial Pellet.
400^1 of mitochondrial suspension (2 mg/ml of 
protein) was sonicated for two periods of 15 seconds at a 
power setting of 40 watts using a sonicator (Model 180, 
Ultrasonics Ltd.) The mitochondrial suspension was kept cool 
throughout by immersion in an ice bath. Sonicated 
suspensions were measured for total carnitine palmitoyl 





i. Glycerol 3-phosphate acyltransferase (GPAT).
This method is derived from the work of Evans 
(1977). The principle of the method is:
a) Long chain acyl CoA + glycerol 3-p monoacyl glycerol 3-P + CoA
b) Long chain acyl CoA + monoacyl glycerol 3-P diacyl glycerol 3-P
+ CoA.
MGPAT = monoacyl glcerol 3-P acyltransferase and is not rate-limitting.
This assay was performed at 30°C in a final volume
of lOOpl containing 0.25 mM sucrose, 10 mM Tris, 1 mM EDTA,
1450 mM potassium chloride, pH 7.4 with 5 mM [Ü- C] glycerol 
3-phosphate (aunmonium salt) (O.lpCi), 100 pM palmitoyl CoA and
0.2 mg of fatty-acid poor bovine serum albumin. The reaction 
was initiated by the addition of 1 0  pi of homogenate 
(approximately) 50pg of protein). After 5 minutes the 
reaction was stopped by the addition of 300pl of 
TCA-saturated butanol. After vortexing the layers were 
separated by centrifugation (1 0 ,0 0 0 g) in an eppendorf 
microfuge for 2 minutes. The aqueous layer was removed while
1©3
the butanol layer was washed with 750pl of butanol-saturated 
trichloroacetic acid (TCA). After a further centrifugation a 
lOOpl sample of the butanol layer was dissolved in 
scintillation fluid (600 ml Triton, lOg 2,5- diphenyloxazole 
(PPO), 1400 ml toluene). Each time point was done in 
triplicate. A zero time point was also measured and 
subtracted from the measurement at 5 minutes. Radioactivity 
was counted in a Tricarb liquid scintillation counter 
(Packard Instruments Ltd., Caversham, Berks). GPAT activity 
is expressed as nmole of glycerol 3-phosphate esterified per 
minute per mg of protein.
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ii. Carnitine Palmitoyl Transferase (CPT) (2.3.1.2.1.)
This method is a modified version of the method 
employed by Saggerson (19 82). The princple of the method is 
as follows:
C P TPalmitoyl CoA + L(-) Carnitine------ > Palmitoylcarnitine +
CoA.
The assay was carried out at 30°C in a final volume
of lOOpl containing 0.25M sucrose, lOmM Tris, 50mM potassium
chloride, ImM EDTA, pH 7.4; with 0.5mM 
14DL-[methyl- C]-carnitine hydrochloride (O.OSpCi), 50pM 
palmitoyl CoA and 0.02mg of fatty-acid poor bovine serum 
albumin. The reaction was initiated by the addition of 20pl 
of mitochondrial suspension (approximately 40pg of protein). 
After 3 minutes the reaction was stopped by the addition of 
50pl of ice-cold 6 M HCl. 300pl of water-saturated butanol was 
then added. After vortexing, the layers were separated by 
centrifugation in an Eppendorf microfuge for 2 minutes. The 
aqueous layer was removed while the butanol layer was washed 
with 750|il of butanol-saturated water. After vortexing and 
recentrifuging a lOOpl sample of the butanol layer was 
dissolved in scintillation fluid. This was done in 
triplicate and a zero time-point was subtracted from the 
average. Radioactivity was counted in a Tricarb Liquid 
scintillation counter.
105
iii. Triglyceride Lipase Assay
The activity of triglyceride lipase was determined 
by a modified version of the method of Severson (1979).
The Glycerol tri [1-^^C] oleate (triolein) 
substrate, 9.2mM in hexane (specific activity 1.6pCi/pM) was 
dried under nitrogen and resuspended in an equal volume 
(3.125 ml) of absolute ethanol. A solution of 264mg of 
triolein in 1 ml hexane was prepared and then 0 .1 ml of this 
was added to 3.025ml of absolute ethanol. This was used to 
increase the concentration of triolein in the radioactive 
aliquots. lOpl of "hot" triolein and 20|il of "cold" triolein 
were mixed together just before use.
The incubation was carried out in a total volume of 
80|il. Final concentrations were 0.4mM triolein (0.15pCi),
50mM sodium phosphate and 0.08mg of fatty-acid poor albumin 
pH 7.5. This suspension was sonicated for 30 seconds 
immediately before use. The reaction was initiated by the 
addition of lOpl of supernatant (approximately 40pg of 
protein) and incubations proceeded for 30 minutes at 30^C.
The assay blank contained lOpl of water or buffer in place of 
the supernatant. All incubations were performed in 
triplicate. The assay was stopped by the addition of 300pl of 
an extraction solution containing
methanol: chloroform:heptane (1.41: 1.25: 1) and O.lmM 
carrier oleic acid (Belfrage and Vaughan, 1969). 10|il of IM 
sodium hydroxide was then added. The mixture was vortexed 
vigorously and then centrifuged in an Eppendorf microfuge
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for 3 minutes. An aliquot (50pl) of the upper aqueous phase 
was dissolved in 4ml of scintillation fluid containing 5pl of 
IM HCl and counted in a Tricarb liquid scintillation 
counter.
iv. Removal of Fatty Acid From Bovine Serum Albumin
Bovine serum albumin fraction V (Sigma Chemical 
Co., Poole Dorset), was defatted according to the method of 
Chen (1967). 50g of albumin was dissolved in 500ml of water 
at 4°C . 25g of activated charcoal was added, the pH 
adjusted to 3 with IM HCl and the mixture stirred at 4°C for 
1 hour. The charcoal was removed by centrifugation at 
20,000g for 20 minutes at 4°C. The charcoal pellet was 
washed with 100ml of acidified water (pH 3, 4°C), 
recentrifuged and the supernatant fractions pooled. The 
supernatant was filtered through a 50mm diameter 0.45pm pore 
size membrane filter (to remove the remaining charcoal), the 
pH readjusted to 7 with 2M sodium hydroxide and the solution 
was freeze-dried. The fatty-acid poor albumin was stored at 
-20°C.
Section 2.4
i. Purification of cAMP-Dependent Protein Kinase.
Cyclic-AMP-dependent protein kinase was prepared
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from rabbit skeletal muscle by the method of Walsh et al, 
(1968).
1 .1 kg of rabbit skeletal muscle was homogenised in 
a Waring Blender at low speed at 4°C for 45 seconds with 
2.5 1 of 4mM EDTA. All the following steps were also 
performed at 4°C. The suspension was centrifuged at 6,000g 
for 45 minutes and the supernatant decanted through glass 
wool. The supernatant was adjusted to pH 6.1 with IM acetic 
acid and the precipitate formed was collected by 
centrifugation at 6000g for 45 minutes and discarded.
The supernatant was adjusted to pH 6 . 8  using IM 
dipotassium hydrogen phosphate (pH 7.2). Fractionation was 
performed by the addition of 32.5g of ammonium sulphate per 
100ml of supernatant. The precipitate, collected by 
centrifugation (20,000g for 45 minutes) was dissolved in 
150ml of 5mM dipotassium hydrogen phosphate, 2mM EDTA, pH 7 
and dialysed against 3 changes of 51 of the same buffer. The 
protein solution was then centrifuged at 80,000g for 1  hour 
and the precipitate discarded.
Whatman DE52 anion exchange (Whatman Ltd., 
Springfield, Maidstone, Kent) was equilibrated with 5mM 
dipotassium hydrogen phosphate, 2mM EDTA, pH 7 and poured 
into a column (24cm x 4.5cm). The protein solution was run 
onto the column followed by 300ml of 5mM, 20mM, 50mM, and 
finally lOOmM dipotassium hydrogen phosphate, pH 7 all 
containing 2mM EDTA. The eluate was collected in 10ml 
fractions and assayed for protein spectrophotometrically at 
À280. Fractions from the same peak containing 0.4mg/ml of 
protein or higher were pooled. Ammonium sulphate was added 
to the pooled samples at 0.4mg/ml and the precipitate so
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formed was collected by centrifugation (20,000g for 45 
minutes) and redissolved in 3 mis of 5mM dihydrogen sodium 
phosphate, 2mM EDTA pH 7, The samples were then assayed for 
the activity of cAMP-dependent protein kinase.
Two peaks of protein kinase activity were found.
The first eluted with 20mM phosphate, the second with lOOmM 
phosphate. The former activity was used in subsequent 
incubations to study the effect of cAMP-dependent protein 
kinase on the activity of glycerol 3 -phosphate 
acyltransferase and triglyceride lipase.
These were stored in lOOpl aliquots of the phosphate 
buffer at -25°C.
ii. Preparation of the Catalytic Subunit.
Whatman DE 52 anion exchange was equilibrated with 
50mM dipotassium hydrogen phosphate, 2mM EDTA, pH 7 and 
poured into a 5ml column. The cAMP-dependent protein kinase 
holoenzyme was equilibrated with the same buffer. 1 ml of the 
enzyme solution was run on to the column. lOmls of 50mM 
KgHPO^, 2mM EDTA, ph 7 and lOpM cAMP was then run through the 
column and the fractions containing the catalytic subunit 
were pooled. This was concentrated by dialysis against 70% 
w/v sucrose and dialysed further against 50mM K^HPO^, lOmM 
mercaptoethanol and 3% glycerol. This was kept in the fridge 
(4°C) for up to one month.
iii. Cyclic AMP-dependent Protein Kinase Assay
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A final volume of lOOpl contained 60mM sodium 
dihydrogen phosphate, 20mM sodium fluoride, 2mM magnesium 
chloride, ImM EGTA, pH 7.5, with 300pM Adenosine 5*-/[^^P] 
triphosphate, triethylammonium salt (approximately 
50cpm/pmol), 30|iM cyclic AMP and 0.5mg of histone (Sigma, 
type IIIS). The reaction was initiated by the addition of 
approximately 50pg of enzyme protein (25pl). At intervals from 
30 seconds up to 5 minutes duplicate samples of lOpl from the 
reaction mixture were spotted on to Whatman filter paper 
(No.l) squares and placed in 10% trichloroacetic acid (TCA).
30 minutes after the last addition the TCA was replaced by a 
fresh volume of TCA. After a further 30 minutes the filter 
paper squares were washed with ethanol, dried and placed in 
scintillation vials with 3ml of water. These were counted by 
Cherenkov counting in a Tricarb liquid scintillation counter 
(Packard Ltd.) with an open channel. A zero time point was 
spotted on to a filter paper square before the addition of 
enzyme protein. The reaction was linear up to 5 minutes.
iv. Incubation with cAMP-dependent Protien Kinase.
Freshly perfused rat heart homogenate, supernatant, 
or mitochondrial preparation (approximately 0.5mg) was 
incubated at 30°C for 15 minutes in buffer (0.25M sucrose, 
lOmM Tris, lOmM magnesium chloride, ImM EDTA pH 7.6) with, 
when included, 5mM ATP, 5pM cAMP, and O.lmg cAMP-dependent 
protein kinase (prepared as described previously) in a final 
volume of 200^1. Samples were then assayed immediately after 
incubation for their activity of GPAT (homogenate),or TGL
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(supernatant).
V. Incubation with Dephosphorylation Conditions.
The method used here is based on the method of
2+Severson et al (1977). It depends on the activation by Ca 
2+and Mg of endogenous phosphoprotein phosphatase. To SOOpl 
of whole homogenate or supernatant enzyme preparation, 50pl 
of lOOmM MgClg, 50^1 of 120mM EGTA, 50^1 of 120mM CaClg, lOOpl 
of lOOmM MOPS (pH 7) were added. The mixtures were vortexed 
and incubated at 30°C for 30 minutes. This was then assayed 
for TGL and GPAT activity.
Control mixtures contained the same reagents except 
MgClg and CaClg (200pl of water was added instead). This 
preparation was then assayed for TGL and GPAT activity after 
incubation at 30°C for 30 minutes.
Section 2.5
i. Determination of Protein Content
This was based on the method of Bradford (1976) 
using bovine serum albumin as standard. 50mg of Coomassie 
blue G 250 was dissolved in 25ml of ethanol (95%) . To this 
was added 50ml of orthophosphoric acid and made up to a 
final volume of 500ml with double-distilled water. The
Ill
solution was filtered twice through Whatman filter paper 
(No.l) before use. 2ml of this solution was added to lOOjjl of 
the test protein and the absorbance determined at 595 nm.
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Section 2.6 
Numerical Analysis of Results
Statistical analysis was performed according to the usual 
formula for Student's t-test. Differences between groups 
were tested for significance with an unpaired t-test. All 
values are presented as mean + standard error of the mean 
(SEM).
Calculation of Results
i. Activity of Glycerol 3-phosphate acyltransferase (GPAT) 
GPAT activity was expressed as nmole/min/mg protein.
1 1000sample count  ̂  ̂ . v  T— :---:--- — ----- ̂  300
t— r— 3— T----- — X  nmoles in standard X  -----  protein in aliquot ̂standard count time ^ 100
The Standard count was measured by taking lOpl from the assay 
mixture (prepared as described) added to 2 ml of 
scintillation fluid, vortexed and counted.
ii. Activity of Triglyceride Lipase (TGL)
TGL activity was expressed as nmole/min/mg protein. To 
calculate the standard count, lOpl from the assay mixture 
(prepared as described earlier) was added to 4ml of 
scintillation fluid, vortexed and counted.
113
stândarl^ u nt " in standard x p r o t e ! % "  a R ^ t
210
5o
iii. Activity of Carnitine Palmitoyl Transferase (CPT)
CPT activity was expressed as nmole/min/mg protein. To 
calculate the standard count lOpl of the assay mixture was 
added to 2 ml of scintillation fluid, vortexed and counted.
s_an,ple count ^ mmoles in s t a n d a r d x ^  X  :------------------ ^ ^





0.45pm membrane filters were obtained from Sartorius 
GmbH, Gottingen, West Germany (cat. no. 1130 6 ) or from 
Millipore, London (cat. no. HAWPOY7000). The 25mm diameter 
prefilters were obtained from Millipore (cat. no.
AP25025000). The membrane filter housing was a Millipore 
Swinnex 25.
Silicone tubing for the pump and glass to polythene 
tubing connections were from Watson Marlow, Falmouth, 
Cornwall. The dimensions were id 3.2mm, od 6.4mm.
Polythene transmission tubing was supplied by 
Portex Ltd. (Hythe, Kent) (cat. no.800/100/280).
Perfusion glassware was obtained from Jencons Ltd. 
(Hemel Hempstead, Herts).
Physiological recorders (M19) were from Devices 
Instruments Ltd. (Welwyn Garden City, Herts).
Tricarb liquid scintillation counter was from 
Packard Instruments Ltd. (Caversham, Berks).
ii. Chemicals
Laboratory chemicals were Analar grade from BDH 
Ltd. Poole Dorset.
Sigma Chemical Co. supplied; glycerol 3-phosphate 
(ammonium salt), palmitoyl CoA, bovine serum albumin
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(fraction V powder), streptomycin sulphate, pencillin, 
neomycin, adrenaline, clonidine, yohimbine, isoprenaline, 
atenolol, DL-carnitine hydrochloride, 6 -hydroxydopamine.
Radiochemicals were from The Radiochemical Centre, 
Amersham, Bucks.
Methoxamine was a gift from Welcome Research, 
Beckenham, Kent.





Characteristics of Enzyme Assays
i. Triglyceride Lipase (TGL) Activity.
The TGL activity of the isolated perfused rat heart 
was measured by the method of Severson (19 79) (see methods 
section) . The differentiation between TGL and lipoprotein 
lipase activity has been extensively characterised in 
previous work in this laboratory (Al-Muhtaseb, 19 82) . The 
experiments described in this section and in previous work 
(Al-Muhtseb, 1982) provide the basis for the incubation 
conditions adopted for subsequent routine assays.
a) Effect of Incubation Time
The effect of incubation time (0,20,30 and 40 
minutes) on the activity of TGL measured in rat heart 
supernatant was studied. The incubation medium and 
homogenisation procedure were as descibed in the methods 
section. It can be seen from fig 3.1 that the rate of free 
fatty acid (FFA) release was linear over the 40 minutes. A 
similar result was observed by Severson (1979) for rat heart 
fractions and Vaughan et al (1964) for rat adipose tissue.
An incubation time of 30 minutes was adopted as routine.
117
Figure 3*1
Effect of Incubation Time Against TGL Activity.
No. of Measurements » 6 














b) Effect of Enzyme Concentration
The relationship of TGL activity to the 
concentration of supernatant added to the assay is shown in 
fig 3.2.
The assay conditions were identical to that 
detailed in the methods section except that different 
concentrations of supernatant protein were added to the 
assay. TGL activity is linear with increasing amounts of 
protein up to at least lOOpg of protein added per 80pl of 
assay. Consequently, all subsequent determinations were 
performed using between 20 and 40pg of protein per 80 pi of 
assay.
c) Other Characteristics
The effects of triolein concentration, 
homogenisation time and pH on TGL activity are reported in a 
previous work from this laboratory (Al-Muhtaseb, 1982).
ii. Glycerol 3-phosphate Acyltransferase (GPAT) Activity
GPAT activity was measured by a direct method using 
glycerol 3-phosphate and palmitoyl CoA (Brands et al, 19 63 
and Bates and Saggerson, 1977). Other workers have used 
different methods. One using palmitate, CoA and ATP to
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Figure 3 2
Effect of Enzyme Concentration Against TGL Activity
No. of Observations ■ 6


















generate palmitoyl CoA assumes that palmitoyl CoA synthetase 
is not rate-limitting (Angel and Roncari, 1967; Lamb and 
Fallon, 1970; Breach and Oils, 1975 and Jamdar et al, 1978). 
Alternatively, some groups have used palmitoyl carnitine,
CoA and added the enzyme carnitine palmitoyl transferase to 
obtain palmitoyl CoA. This gave comparable rates of 
estérification to that seen with palmitate or palmitoyl CoA 
(Daae and Bremer, 1970 and Nimmo, 1979).
In this study the direct method was used based on 
the method described by Evans (1977). This assay method has 
the advantage of not relying on another enzyme system which 
could, under abnormal conditions, be rate-limiting.
a) The Effect of Incubation Time
The effect of incubation time on GPAT activity can 
be seen in fig 3.3. It can be seen that estérification of 
glycerol 3-phosphate was linear up to 5 minutes. Beyond 
this time linearity was never achieved in agreement with 
Evans (1977) and Jamdar and Fallon (1973) using adipose 
tissue homogenates. Possible reasons for the decrease in the 
rate are exhaustion of one or more of the substrates, or 
inactivation of the enzyme by a factor produced during 
incubation (end product inhibition). However, no 
satisfactory explanation for this phenomenon has been 
reported. Therefore, the standard assay is incubated for 5 
minutes and linearity checked by measurements at 2.5 
minutes.
b) The Effect of Enzyme Concentration
The relationship of activity to the concentration
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Figure 3 3
if—Incubation Time Against GPAT Activity.
No. Oi Observations » 6 



















of homogenate assayed is shown in fig 3.4. The assay 
conditions were identical with those detailed in the methods 
section except that different homogenate concentrations were 
added to the assay.
It can be seen that GPAT activity is linear with 
increasing amounts of protein up to at least 130 pig of 
protein per lOOpil of assay. All subsequent determinations 
were performed with homogenate additions of between 50 and 
70 pig of protein.
c) Other Characteristics
Previous work in this laboratory has detailed the 
effects of different concentrations of palmitoyl CoA, 
glycerol 3-phosphate and albumin. The final assay system is 
detailed in the methods section using 100pm palmitoyl CoA,
O.SmM glycerol 3-phosphate and albumin (2 mg/ml).
d) Identification of Lipid End Products of Glycerol 
3-Phosphate Acylation
Previous studies have suggested that the major end 
products of the glycerol 3-phosphate estérification system 
in vitro were mainly phosphatidate and to a lesser extent 
lysophosphatidate (Lands and Hart, 1965 and Evans, 1977).
In previous work in this laboratory the 
end-products of acylation by perfused rat heart homogenate 
was examined by thin-layer chromatography. It was found that 
the majority (79%) of the end-product was phosphatidate.
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Figure 3»4
Effect of Enyyme Concentration Against GPAT
ActivityNo, of Observations » 6 



















Thus, the acylation system appears similar to that reported 
for other tissues and there is little or no accumulation of 
triglyceride or monoacyl glycerol 3-phosphate.
iii. Carnitine Palmitoyl Transferase (CPT) Activity
This assay was based on the method of Saggerson (19 82). The 
effects of changing the assay parameters are described by 
Saggerson (1982) and McGarry et al (1983).
a) The Effect of Incubation Time
The results of measuring the formation of palmitoyl 
carnitine against time can be seen in fig 3.5. CPT activity 
is linear up to 3.5 minutes under the assay conditions 
described in the methods section. Subsequently CPT activity 
was measured over a period of 3 minutes.
b) The Effect of Different Concentrations of Mitochondrial 
Protein
\CPT activity measured after the addtion of 
different amounts of mitochondrial protein is shown in fig 
3.6. It can be seen that the assay is linear at least up to 
the addition of 40 pg of mitochondrial protein. In subsequent 
determinations 10 to 20 pg of mitochondrial protein was
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FIG 3-5
CPT Activity Against Time
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assayed for the activity of CPT.
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Section 3.2
The Effect of Catecholamines on Lipid Metabolising 
Enzymes in the Normal Rat Heart.
Introduction
It has been shown that perfusion of the heart with 
catecholamines increases the rate of cardiac lipolysis 
(Gartner and Vahouny, 1973; Crass et al, 1975; Hron et al,
19 77; Jesmok et al, 19 77; Hulsmann and Stam, 19 78 and 
Severson et al, 19 80). This stimulation can be blocked by  ̂
-adrenergic antagonists (Christian, 19 69 and Jesmok et al, 
1977). The p-adrenergic effects of catecholamines on 
cardiac metabolism are generally considered to be mediated 
through increased tissue levels of cAMP and subsequent 
phosphorylation of key rate-limiting enzymes by 
cAMP-dependent protein kinase (for review see Mayer, 1974).
Bjorntorp and Furman (19 62) first reported direct 
evidence of a stimulation of cardiac triglyceride lipase 
(TGL) activity by adrenaline in rat heart homogenates. 
However, Severson (19 79) was unable to confirm this possibly 
due to his use of previously frozen tissue.
The inhibition of triglyceride synthesis could also 
lead to increased net triglyceride mobilization. Although no 
effects of catecholamines on the activities of 
triglyceride-synthesising enzymes in the heart have been 
reported, there is evidence to show that glycerol
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3-phosphate acyltransferase (GPAT) is inhibited by 
catecholamines in adipose tissue (Sooranna and Saggerson, 
1976,78). It has been suggested that this could be mediated 
by a cAMP-dependent phosphorylation system (Nimmo and 
Houston, 19 78).
The activity of carnitine palmitoyl transferase 
(CPT) has been shown to regulate the activity of the g 
-oxidation pathway (McGarry and Foster, 19 80). CPT activity 
has not been shown to respond to catecholamines in any 
mammalian tissue.
The purpose of the present study was to investigate 
the action of catecholamines on the activities of TGL, GPAT 
and CPT in the isolated-perfused rat heart. The activities 
of all three enzymes were measured at the same time and in 
the same heart. Details of the perfusion protocol and enzyme 
assays are given in the methods section.
i. The Effect of Adrenaline Perfusion
Adrenaline was introduced into the perfusion
-6apparatus to reach a final concentration of 10 M. The 
expected increase in both the heart rate and the developed 
tension was seen. An average increase in heart rate was from 
250 to 350 beats per minute whilst developed tension 
increased approximately 50% from 4g to 6g. The increased 
mechanical performance of the heart reached a maximum at 1.5 
minutes after adrenaline addition whereupon the hearts were 
dismounted, homogenised and the activities of TGL, GPAT and
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CPT were measured as detailed in the methods section.
Table 3.1 shows the activities of TGL, GPAT and CPT 
at the time of the peak adrenaline effect. It can be seen 
that TGL activity was increased by 50% above its control 
value while GPAT activity was decreased by 48% below its 
control value. No change was seen in CPT activity.
Ten minutes after adrenaline infusion the 
mechanical performance of the heart had returned to normal. 
Table 3.1 also shows that the activities of TGL and GPAT had 
returned to normal 10 minutes after adrenaline infusion.
ii. The Effect of Adrenaline on Mitochondrial and 
Microsomal GPAT Activity
The isoenzymes of GPAT are found in the 
mitochondrial and microsomal fractions of most mammalian 
tissues (for review see Bell and Coleman, 19 80). Rider and 
Saggerson (19 83a) found that both the mitochondrial and
microsomal forms of the enzyme in rat adipocytes respond to
noradrenaline. No information is available about such 
effects in the heart and it was decided to examine this. It 
is possible to distinguish between the two types by 
inhibiting the microsomal form with N-ethylmaleimide (NEM) 
(Bates and Saggerson, 19 77; Monroy et al, 19 72 and Haidar et
al, 19 79). Table 3.2 shows the effect of incubating
homogenates from control or adrenaline-treated hearts with 
15mM NEM for 5 minutes at 30°C.
It can be seen that, in the control heart, the
132
Table 3.1
The effect of adrenaline, at 10 ^M, on the activities of 
triglyceride lipase (TGL), glycerol 3 -phosphate acyltransferase 
(GPAT) and carnitine palmitoyl transferase (CPT^) in rat heart 
supernatant, homogenate and whole mitochondria.















Values are expressed as (no. of observations) means +S.E.M. 




The response of NEM-sensitive (microsomal) and
NEM-insensitive (mitochondrial) glycerol 3-phosphate acyltransferase
-6(GPAT) activity to adrenaline (10 M ) .
GPAT Activity (nmole/min/mg protein)
NEM-sens(microsomal) NEM-insens(mitochondrial)
Control (8) 0.35+0.04 (8) 0.23+0.03
Adrenaline (9) 0.16+0.05** (6) 0.14+0.02*
Values are (no. of observations) mean+S.E.M.
Statistical significance v control, *= P,0.05, **= P<0.01.
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NEM-sensitive (microsomal) GPAT activity accounts for 
approximately 60% of the total activity. Mitochondrial 
(NEM-insensitive) activity accounts for 40%. Thus the 
proportion of GPAT activity in heart due to the 
mitochondrial fraction is similar to the liver but 
considerably greater than adipose tissue (Bates and 
Saggerson, 19 77; Monroy et al, 1972 and Haidar et al, 1979) 
Adrenaline reduced the microsomal activity by 54% 
and the mitochondrial activity by 39%. Thus, adrenaline 
appears to decrease both forms of the enzyme but 
particularly the microsomal form.
iii. The Effect of Adrenaline on CPT^ and CPT^^ Activities.
Carnitine palmitoyl transferase is located on the 
outer (CPTj) and inner (CPT^^) surfaces of the inner 
mitochondrial membrane (McGarry and Foster, 1980). CPT^ 
activity was measured with whole mitochondria. Disruption of 
the mitochondria by sonication revealed the total CPT 
activity, the difference being the latent activity or CPT^^ 
activity (see Methods).
Table 3.3 shows the activities of CPT^ and CPT^^ 
both before and after adrenaline infusion. No change was 
seen in the activity CPT^ , CPT^^ or the total CPT activity.
iv . The Effect of Adrenaline on the Sensitivity of CPT^
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Table 3.3
The effect of adrenaline (10 ^M) on total CPT, CPT^ and CPT^^ 
activities in rat heart mitochondria.
Control
Adrenaline







Number of observtion = 6 
Values are means+S.E.M.
Table 3.4.
The effect of adrenaline on the inhibition of CPT^ by malonyl CoA.













Number of observations = 6 
Values are means+S.E.M.
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Activity to Malonyl CoA.
Malonyl CoA is a potent inhibitor of CPT^ but not
CPTii activity (McGarry and Foster, 1978). It is a
physiological regulator of CPT activity and hence 
beta-oxidation of fatty acid in the heart where the 
concentration of malonyl CoA has been shown to decrease on 
starvation (McGarry and Foster, 1978). The sensitivity of
CPT activity to malonyl CoA has been shown to vary with the
nutritional (Saggerson and Carpenter, 19 81) and thyroidal 
(Stakkestad and Bremer, 19 83) state of the animal.
Table 3.4 shows the effect of two concentration of 
malonyl CoA on the activity of CPT^ measured in whole 
mitochondria prepared from control and adrenaline-treated 
hearts. The concentration of 3pM was chosen because it has 
been reported to give approximately 50% inhibition 
(Saggerson, 1982). If a change in the sensitivity of CPT^ to 
malonyl CoA were to occur it would probably be most clearly 
evident around this concentration. 15pM is reported to give a 
very high degree of inhibtion (80%) (Saggerson, 1982).
It can be seen from table 3.4 that 3 pM malonyl CoA 
caused 30% inhibition and 15|iM caused 48% inhibition in 
mitochondria from control hearts. These values were not 
significantly altered in whole mitochondria from 
adrenaline-treated hearts. Thus, adrenaline did not alter 
the sensitivity of CPT^ to malonyl CoA.
These % inhibition values are rather low compared 
to the results of Saggerson (1982). This would suggest that 
some of the mitochondria were in a broken state and that 
CPTjj was also assayed. As CPT^^ is not inhibited by malonyl
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CoA (McGarry et al, 1978b), this fraction will remain active 




The Effect on enzyme activités of Incubation with 
cAMP-dependent Protein Kinase and Phosphatase Conditions.
In rat adipose tissue, adrenaline has been shown to 
activate TGL via a cAMP-mediated, reversible phosphorylation 
system ("the lipolytic activation cascade") (Steinberg and 
Huttunen, 1970 and Stralfors and Belfrage, 1983). GPAT 
activity is reduced when adipocytes are exposed to 
adrenaline (Sooranna and Saggerson, 1976), possibly by a 
similar cAMP-mediated phosphorylation mechanism (Nimmo and 
Houston, 19 78). If the adrenaline effects reported in the 
previous section are similar to those seen in adipose tissue 
it might be expected that cAMP-dependent protein kinase 
would have an effect on these enzymes.
Homogenates and 2,000g supernatants from hearts 
perfused in the absence of adrenaline for 20 minutes were 
incubated for 15 minutes with cAMP-dependent protein kinase, 
together with cAMP and ATP (see Methods section). The 
activities of TGL (supernatant) and GPAT (homogenate) were 
then measured. The results are shown in Table 3.5.
With cAMP-dependent protein kinase, cAMP and ATP 
present TGL activity increased to 0.22+0.04 above a control 
value of 0.17+0.03. GPAT activity was reduced under the same 
conditions from 0.58+0.03 to 0.28+0.03. No changes were seen 




The effect of cAMP-dependent Protein Kinase on the activity of 
Triglyceride lipase (TGL) and Glycerol 3-phosphate acyltransferase 
(GPAT) in rat heart supernatant or homogenate.
INCUBATION
Buffer alone





Buffer + ATP 0.17+0.04 0.59+0.05
Buffer + cAMP 
+ ATP 0.15+0.01 0.58+0.03
Buffer + cAMP + 
cAMP-depend. 
Protein Kinase 0.16+0.02 0.58+0.03
CAMP + ATP + 
cAMP-depend. 
Protein Kinase 0.22+0.04 0.28+0.03 * *
Number of experiments = 3 (separate perfused hearts).
Values are means+S.E.M.
; Statistical significance v Control, * = P< 0.05, ** = P< 0.01.II Incubations for 15 minutes at 30°C as detailed in the methodsI; section.
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The catalytic subunit of cAMP-dependent protein 
kinase was prepared as detailed in the methods section. This 
was used to study the effect of cAMP-dependent 
phosphorylation on mitochondrial and microsomal forms of 
GPAT. Fractionation of the homogenate into mitochondrial and 
microsomal (10,000g supernatant) samples was by 
centrifugation as described in the methods section.
As can be seen in fig 3.7 that the catalytic 
subunit decreased microsomal GPAT activity in a 
time-dependent manner but did not alter mitochondrial 
activity. Thus, the mitochondrial activity must respond to 
adrenaline by a different mechanism, possibly by a 
cAMP-independent phosphorylation system.
Similarly, incubation of the 2,000g supernatant 
with the catalytic subunit resulted in a slight increase in 
TGL activity over 20 minutes whereas the control value fell 
(fig 3.8).
When using tissue from hearts perfused with 
adrenaline (Table 3.6) no activation of TGL activity by 
cAMP-dependent protein kinase above the already activated 
level was seen. Similarly, GPAT activity was not changed 
from the low level seen in tissue from adrenaline-treated 
hearts by incubation under phosphorylation conditions.
Table 3.6 also shows the results of incubation of
tissue from adrenaline-treated hearts with the
dephosphorylation conditions detailed in the methods
section. This method relies on the activation of endogenous
2+ 2+phosphatase by Ca and Mg ions (Severson et al, 1977). 
After 30 minutes incubation under dephosphorylation 
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FIG 3 8
Incubation -with the C ata ly t ic  Subunit of
cAMPdependent  Protein Kinase
TGL A c t i v i t y
VALUES ARE MEANS ± S.E.M
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The effect of cAMP-dependent Protein Kinase and Dephosphorylation 
Conditions on the Activity of Glycerol 3-phosphate acyltransferase 
(GPAT) and Triglyceride lipase (TGL) in Rat Hearts Perfused with 
Adrenaline.
INCUBATION ENZYME ACTIVITY (nmole/min/mg protein)
TGL GPAT
Phosphorylation
controls (Table ^ ) 0.35+0.04 0.30+0.02
cAMP + ATP +
cAMP-depend.
Protein Kinase 0 .37+0.03 0.29+0.02
Dephosphorylation
control
(without Ca^^fMg^^) 0.31+0.04 0.32+0.04
Dephosphorylation
Conditions
(with Ca2+,Mg2+) 0.19+0.03* 0.55+0.07*
Number of experiments = 3 (separate adrenaline perfused hearts) 
Values are means+S.E.M.
Statistical significance v Control, * = P< 0.05.
Incubations for 15 minutes (phosphorylation) or 30 minutes 
(dephosphorylation) at 30^C as detailed in the methods section.
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activity measured in control hearts. Similarly, the 
inactivated GPAT activity had risen to control values. Thus 
the activation of TGL and inactivation of GPAT can be 
reversed under dephosphorylation conditions.
These results are consistant with those found for 
the same enzyme activities in adipose tissue and suggest 
that at least some of the effects produced by adrenaline 




The Effect on the Enzyme Activities of Perfusion with 
Adrenergic Agonists and Antagonists
i. Perfusion with Alpha and Beta Adrenergic Agonists 
Introduction
Adrenaline has been shown to activate both <r and p 
adrenergic mechanisms (Lands et al, 19 67 and Berthelson and 
Pettinger, 1977). Both these systems are present in the rat 
myocardium (Benfey, 1973; Alexander et al, 1975; Hancock et 
al, 19 79 and Williams and Lefkowitz, 19 78). Table 3.7 shows 
the effect on TGL, GPAT and CPT^ activities of perfusing the 
isolated rat heart with either the Œ  adrenergic agonist 
phenylephrine or the p adrenergic agonist isoprenaline at a 
concentration of 10 ^M.
It can be seen that phenylephrine induced a fall in 
TGL activity and a rise in GPAT activity. This is in accord 
with the fall in cAMP levels produced by phenylephrine in 
the isolated rat heart (Keely et al, 19 77) and in rat 
myocytes (Watanabe et al, 1977).
No change was seen in the activity of CPT.
The changes in enzyme activity produced by the fè̂ 
adrenergic agonist isoprenaline were in the same direction 
as those produced by adrenaline infusion but of a greater 
magnitude. This is consistant with the greater increase in 
cAMP levels produced by isoprenaline than by adrenaline in 
rat adipose tissue (Fain, 1973).
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TABLE 3.7
The effect of perfusing the heart with phenylephrine (alpha-adrenergic
-6agonist) and isoprenaline (beta-adrenergic agonist) at 10 M on the 
activities of TGL, GPAT and CPT^.
Enzyme Activities (nmoles/min/mg protein)
TGL GPAT CPT.
Control (8) 0.22+0.05









Values are (number of observations) means + S.E.M. 
Statistical siginificance v control;
*= P< 0.05, **= P< 0.01, ***= P< 0.001.
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Table 3.8.
The effect of infusion of the alpha-adrenergic agonist Phenylephrine 
(10 ^M) and the beta-adrenergic agonist Isoprenaline (10 ^M) on the 





Enzyme Activity (nmole/min/mg protein)





(6) 0.20+0.0 5 
(5) 0.19+0.03
Values are (number of observations) means + S.E.M. 
Statistical significance v control; *= P< 0.01.
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Thus, the changes in enzyme activities produced by 
Œ  and p adrenergic stimulation appear to be in opposite 
directions.
Table 3.8 shows the effect of phenylephrine and 
isoprenaline infusion on the activities of mitochondrial and 
microsomal GPAT. It appears that the changes in GPAT 
activity seen with both the Œ and p adrenergic agonists are 
localised mainly in the microsomal fraction.
ii. Perfusion with Alpha ^ and Alpha g Adrenergic 
Agonists.
Introduction
The CE-adrenergic system has been divided into (C ^ 
and Œ g  on the basis of the ability of different agonists 
and antagonists to stimulate or inhibit the Œ  receptor 
(Wikberg, 1979). It has been shown that stimulation of Œ   ̂
and Œ 2  receptors results in different intracellular signals 
(Wikberg, 1979). Œ 2  -adrenergic stimulation involves a 
reduction of cAMP levels (Wright and Simpson, 19 81 and Burns 
et al, 1981), while the main intracellular signal generated 
by stimulation of <E ̂  receptors appears to be the increase 
of cytosolic free Ca^^ (Michell and Kirk, 1981).
Stimulation of receptors has also been shown
to reduce endogenous noradrenaline release via pre-synaptic 
Œ 2  receptors (Dart et al, 1984a; Langer, 1974 and Starke et 
al, 19 71a,b).
Both and receptors have been shown to
exist in the rat heart (Benfey, 1973 and Williams and
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Lefkowitz, 19 78). The effects of perfusing the isolated rat 
heart with the Œ  agonists clonidine (Œ g ) and methoxamine 
( ) on the activities of TGL and GPAT are shown in Table
3.9.
It can be seen that clonidine infusion at a 
concentration of 10 resulted in a fall in TGL activity 
and a rise in GPAT activity. This result is similar to the Œ  
2  adrenergic inhibition of lipolysis observed in other 
mammalian tissues (Lafontan and Berlan, 19 80) and is 
consistant with a fall in cAMP levels.
The concentration of 10 was used as this 
appeared maximal. At 10 the changes in TGL and GPAT
activities were similar to those reported but not as great.
Infusion of the Œ ^ adrenergic agonist, 
methoxamine, at a concentration of 10 ^M, did not change 
TGL activity (Table 3.9). However, a marked reduction was 
seen in GPAT activity. Thus, it appears that adrenergic
mechanisms could mediate a reduction in GPAT activity.
Table 3.10 shows the effects of clonidine and 
methoxamine infusion on the mitochondrial and microsomal 
GPAT activities. It can be seen that the changes seen in 
total GPAT activity are localised mainly in the microsomal 
or NEM-sensitive fraction. A tendency for the mitochondrial 
activities to be stimulated by methoxamine does not reach a 
statistically significant level.
iii. Perfusion With Adrenergic Antagonists
Table 3.11 shows the results of continuous 
perfusion (10 minutes) with the cardioselective p ^
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Table 3.9
The effect of infusion of the alpha^ agonist Methoxamine (10 ^M) and 





Enzyme Activity (nmole/min/mg protein).
TGL GPAT
(8) 0.22+0.02 (8) 0.63+0.04
(6) 0.20+0.03
(6) 0.18+0.01
* *(8) 0.49+0.04 
(6) 0.79+0.05**
Values are (number of observations) mean+S.E.M.
Statistical significance v controls; *= P= 0.05, **= P< 0.01.
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Table 3.10
The effect of infusion of the alpha^ agonist Methoxamine (10 ^M) and 
the alphag agonist Clonidine (10 ^M) on the activity of microsomal 




Enzyme Activity (nmole/min/mg protein)
Microsomal (NEM-sens) Mitochondrial (NEM-insens)
(8) 0.35+0.04
(5) 0.27+0.03




Values are (number of observations) mean + S.E.M.





The effect of continuous perfusion with atenolol (a beta-adrenergic 
antagonist), yohimbine (an alphUg-adrenergic antagonist) and doxazosin 
( an alpha^-adrenergic antagonist) on the activities of TGL and GPAT.
Enzyme Activity (nmole/min/mg protein)
TGL GPAT




Number of observations = 6.
Values are means + S.E.M.
Statistical significance v controls; *= P< 0.05, **= P< 0.01,
***= P< 0.001.
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adrenergic antagonist atenolol, the CE^ adrenergic 
antagonist doxazosin and the d  ̂  adrenergic antagonist 
yohimbine.
It can be seen that continuous perfusion with 
doxazosin and yohimbine did not result in any changes in the 
activities of TGL or GPAT.
However, perfusion with the p ̂  antagonist atenolol 
resulted in a fall in both TGL and GPAT activities.lt 
appears that control hearts were still showing a degree of p 
-adrenergic stimulation and that perfusion with the P 
antagonist blocked this small adrenergic drive and reduced 
TGL activity. Comparison of the activity of TGL in Table 
3.11 with the activity shown in Table 3.7 shows an increase 
of almost 4 fold from a level of 0.13+0.01 under p antagonism 
to 0.42+0.07 with p -adrenergic stimulation.
However, the fall in GPAT activity can not be
explained by this mechanism as a reduced adrenergic drive
would be expected to increase GPAT activity. Thus the change
in GPAT activity caused by perfusion with atenolol suggests
that the reduction in the activity of this enzyme seen with
adrenaline may not be solely due to cAMP-dependent protein
"“T'kinase effects mediated by the B-adrenergic system. ...
Table 3.12 shows that the reduction in GPAT 0 *
activity associated with continuous perfusion of atenolol is 
localised mainly in the microsomal fraction although a 
statistically insignificant decrease was seen in the 
mitochondrial fraction.
No change was seen in GPAT activity in either the 
microsomal or mitochondrial fractions, when yohimbine or 
doxazosin was present (Table 3.12).
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Table 3.12.
The effect of continuous perfusion with atenolol (a p -adrenergic 
antagonist), yohimbine (an cC2 "&drenergic antagonist) and doxazosin 
(an Œ ^-adrenergic antagonist) on the activity of the microsomal 





GPAT Activity (nmole/min/mg protein)
Microsomal (NEM-sens.) Mitochondrial (NEM-insens.)
(8) 0.35+0.04 







Values are (number of observations) means + S.E.M. 
Statistical significance v control; *= P< 0.05.
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Section 3.5
The Effect of Acute Ischaemia and Reperfusion on the 
Activities of TGL, GPAT and CPT.
Introduction
Several investigations have indicated that an 
increased adrenergic drive occurs in the acutely ischaemic 
myocardium (Abrahamsson et al, 19 81; Corr et al, 1978; 
Holmgren et al, 1981; Podzuwiet et al, 1978; Shahab et al,
19 69 and Shahab and Wollenberger, 19 67 ). This increase in 
adrenergic activity may play a significant role in the 
development of tissue damage in ischaemia. It is believed to
/tcontribute to the occurance of ventricular arrhythmias and, 
by increasing metabolic disturbances, it causes myocardial 
cell damage (Corr and Gillis, 1978; Hjalmarso, 1980 and 
Maroko et al, 19 71). Indeed, several authors have shown that 
depletion of myocardial catecholamines (Gaudel et al, 1979; 
Gercken and Doring, 19 73 and Sakai and Spieckermann, 1975) 
or P -adrenergic antagonism (Sakai and Speickermann, 1975; 
Peiper et al, 1980; Manning et al, 1980 and Nay1er et al,
19 80) have been beneficial in protecting against hypoxic or 
ischaemically-induced injury.
One of the possible causes of cell damage and 
consequent myocardial dysfunction under these circumstances 
is the cellular accumulation of long chain fatty acids and 
their metabolites resulting from catecholamine-stimulated
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Table 3.13.
The effect of 10 minutes ischaemia and subsequent reperfusion for 1 
and 5 minutes on the activity of Triglyceride Lipase (TGL) measured in 
tissue from the non-ischaemic (NI) and ischaemic (I) areas of the 
heart.
After 20 min. 
normal perfusion
After 10 min. 
ischaemia 
After isch.+ 1 
min. reperfusion 
After isch.+ 5 
min. reperfusion








Number of observations = 6 
Values are means + S.E.M.
Statistical significance v non-ischaemic area; *= P< 0.05, **= P<
0.01, ***= P< 0.001.
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lipolysis of endogenous triglyceride (Opie, 1976).
In this section, the effect of acute ischaemia and 
subsequent reperfusion on the activities of TGL, GPAT and 
CPT is reported. Acute ischaemia is produced by ligation of 
the left coronary artery for 10 minutes as detailed in the 
methods section. Reperfusion of the ischaemic area, for 1 or 
5 minutes, is brought about by release of the occlusion. The 
enzyme activities are measured in both the non-ischaemic and 
the ischaemic areas of the heart.
In preliminary experiments the activities of TGL, 
GPAT and CPT were measured in right and left ventriclular 
tissue (non-ischaemic and ischaemic tissue in subsequent 
experiments) from hearts that had undergone sham operations. 
It can be seen from Tables 3.13, 3.14 and 3.16 that all 
three enzymes showed similar activities in the two areas.
i. The Effect of Acute Ischaemia and Reperfusion on TGL 
Activity.
Table 3.13 shows the activity of TGL in tissue from 
the non-ischaemic and ischaemic areas of the heart after 10 
minutes occlusion, and after 1 and 5 minutes reperfusion. In 
the non-ischaemic area TGL activity remained unchanged 
throughout occlusion and reperfusion. However, in the 
ischaemic area TGL activity increased by 72% after 10 
minutes ischaemia. During reperfusion this high value fell 
to control values.
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ii. The Effect of Acute Ischaemia and Reperfusion on GPAT 
Activity.
Table 3.14 shows the activity of GPAT in tissue 
from the non-ischaemic and ischaemic areas after 10 minutes 
occlusion and after 1 and 5 minutes reperfusion. GPAT 
activity remained unchanged in the non-ischaemic area 
throughout the occlusion and reperfusion. In the ischaemic 
area, GPAT activity was reduced by 28% compared to control 
values after 10 minutes ischaemia. After 1 minute 
reperfusion the activity measured in the previously 
ischaemic area was found to be significantly lower than the 
activity found after 10 minutes ischaemia (p<0.05). Even 
after 5 minutes reperfusion GPAT activity was still 
significantly lower than the activity seen in the 
non-ischaemic area or the control value. Thus, it appears 
that reperfusion of the ischaemic area caused a further fall 
in GPAT activity, below the fall seen during ischaemia.
iii. The effect of ischaemia and reperfusion on the 
activity of GPAT in the mitochondrial (NEM-insensitive) and 
microsomal (NEM-sensitive) fractions.
It can be seen from Table 3.15 that GPAT activity 
in both fractions remained unaltered in the non-ischaemic 
area throughout occlusion and reperfusion. In the ischaemic 
area after 10 minutes occlusion both fractions showed a 
lower activity than the non-ischaemic area. This change was 
more pronounced in the mitochondrial fraction.
After 1 minute reperfusion, microsomal activity in
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Table 3.14.
The effect of 10 minutes ischaemia and subsequent reperfusion for 1 
and 5 minutes on the activity of Glycerol 3-phosphate acyltransferase 
(GPAT) measured in tissue from the non-ischaemic (NX) and ischaemic 
(I) areas of the heart.
After 20 min. 
normal perfusion
After 10 min. 
ischaemia 
After isch.+ 1 
min. reperfusion 
After isch.+ 5 
min. reperfusion













Number of observations = 6 
Values are means + S.E.M.
Statistical significance v non-ischaemic area; *= P< 0.05, **= P< 
0.01, ***= P< 0.001.
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Table 3.15.
The effect of 10 minutes ischaemia and subsequent reperfusion for 1 
and 5 minutes on the activity of microsomal (NEM-sensitive) and 
mitochondrial (NEM-insensitive) Glycerol 3-phosphate acyltransferase 
(GPAT) measured in tissue from the non-ischaemic (NX) and ischaemic 
(I) areas of the heart.
GPAT Activity (nmole/min/mg protein)
Microsomal (NEM-sens) Mitochondrial (NEM-insens)
After 20 min.
normal perfusion 0.40+0.06 0.41+0.06 0.22+0.05 0.22+0.03
NI I NX I
After 10 min.
ischaemia 0.43+0.04 0.35+0.03* 0.20+0.03 0.11+0.02**
After isch.+ 1
min. reperfusion 0.45+0.05 0.17+0.03 0.21+0.03 0.16+0.03
After isch.+ 5
min. reperfusion 0.43+0.02 0.23+0.03 0.20+0.02 0.21+0.02
Number of observations = 6 
Values are means + S.E.M.
Statistical significance v non-ischaemic area; *= P< 0.05, **= P<
O.Cl, ***= P< 0.001.
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the previously ischaemic area was considerably reduced 
compared to the activity seen after 10 minutes ischaemia in 
the same area. This reperfusion-induced fall in microsomal 
GPAT activity was not seen in the mitochondrial fraction.
After 5 minutes reperfusion mitochondrial activity 
had returned to control values. At this time microsomal 
activity was still depressed.
Thus, it appears that ischaemia induces a fall in 
both the mitochondrial and microsomal GPAT activities 
whereas the reperfusion-induced fall in GPAT activity is 
evident only in the microsomal fraction.
iv. The Effect of Acute Ischaemia on the Activity of CPT.
Tables 3.16 and 3.17 show the effect of ischaemia 
on the activities of total CPT, CPT^ and CPT^^ in 
mitochondria from non-ischaemic and ischaemic areas of the 
heart after 10 minutes occlusion. It can be seen that there 
is no change of either CPT^ , CPT^^ or total CPT activity in 
the non-ischaemic or the ischaemic areas.
Thus, ischaemia does not change the activity of CPT 
in the rat heart.
162
Table 3.16.
The effect of 10 minutes ischaemia on the activity of total CPT 
measured in sonicated mitochondria from the non-ischaemic (NX) and 
ischaemic (I) areas of the heart.
CPT Activity (nmole/min/mg protein)
After 20 min. 
normal perfusion
After 10 min. 
ischaemia
Number of observations = 6 








The effect of 10 minutes ischaemia on the activities of CPT^ and CPT^^ 
measured in mitochondria from non-ischaemic (NI) and ischaemic (I) 
areas of the heart.
CPT Activity (nmole/min/mg protein)
CPT. CPT II
After 20 min.
normal perfusion 5.17+0.91 5.43+1.36 2.18+1.25 2.26+1.03
NI NI
After 10 min.
ischaemia 5.48+1.18 5.44+1.45 1.75+0.96 1.14+0.39
Number of observations = 6 
Values are means + S.E.M.
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Section 3.6
The Effect of 6 OH-Dopamine on the Changes in TGL and GPAT 
Activity Induced by Acute Ischaemia and Reperfusion
Depletion of endogenous noradrenaline by injection 
of 6 OH-dopamine 24 hours before acute ischaemia was induced 
has been shown to almost completely abolish the occurance of 
ventricular arrhythmias during both coronary occlusion and 
subsequent reperfusion (Sethi et al, 1973 and Sheridan et 
al, 1980). Table 3.18 shows TGL and GPAT activities in 
hearts from animals pre-injected with 6 OH-dopamine after 10 
minutes ischaemia and then 1 and 5 minutes reperfusion.
In hearts from 6 OH-dopamine-treated animals, the 
changes in TGL and GPAT activities produced by ischaemia and 
reperfusion seen previously did not occur. It can be assumed 
from this that the changes induced in TGL and GPAT 
activities by ischaemia and reperfusion in hearts not 




The effect of 10 minutes ischaemia and subsequent reperfusion for 1 
minute on the activity of Triglyceride Lipase (TGL) and Glycerol 
3-phosphate acyltransferase (GPAT) measured in tissue from the 
non-ischaemic (NX) and ischaemic (I) areas of the heart.Hearts were 
taken from rats which had been pre-injected with 6 OH-dopamine 24 
hours previously.
After 20 min. 
normal perfusion 
After 10 min. 
ischaemia 
After isch.+ 1 
min. reperfusion
Enzyme Activity (nmole/min/mg protein)
TGL GPAT
0.17+0.03 0.17+0.02 0.56+0.08 0.56+0.07
NI I NI
0.19+0.03 0.19+0.04 0.56+0.08 0.56+0.08
0.17+0.03 0.17+0.04 0.59+0.06 0.62+0.04
Number of observations = 6 
Values are means +S.E.M.
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Section 3.7
The Effect of Perfusion of Adrenergic Antagonists on the 
Changes in Enzyme Activities produced by Ischaemia and 
Reperfusion.
i. Pre-perfusion with the Beta Antagonist Atenolol.
The presence of a p adrenergic antagonist has been 
shown to reduce the cellular damage caused by ischaemia 
(Sakai and Speickermann, 1975; Pieper et al, 1980 and 
Manning et al, 1980), possibly by inhibiting 
catecholamine-stimulated cardiac lipolysis (Opie, 1976).
Perfusion with the cardioselective P ̂  adrenergic 
antagonist atenolol was begun 10 minutes before occlusion of 
the left coronary artery occurred and thereafter for the 
rest of the experiment. The activities of TGL and GPAT 
after ischaemia and reperfusion from hearts perfused 
continuously in the presence of atenolol are shown in Table 
3.19.
The small changes seen in the activities of TGL and 
GPAT in the non-ischaemic area compared to control values 
did not reach statistical significance.
In the ischaemic area TGL activity did not increase 
after 10 minutes ischaemia as seen in the absence of 
atenolol (Table 3.13). Similarly, there was no change in 
GPAT activity in the ischaemic area after 10 minutes 
ischaemia. This is in contrast to the decrease in GPAT 
activity seen in the absence of atenolol. Thus, it appears
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TABLE 3.19..
The effect of continuous perfusion with the p antagonist Atenolol on 
the activities of Triglyceride lipase (TGL) and Glycerol 3-phosphate 
acyltransferase (GPAT) produced by 10 minutes ischaemia and 
subsequent reperfusion. Measurements were made in tissue from both the 
non-ischaemic (NX) and ischaemic (I) areas of the heart.
Atenolol perfusion was begun 10 mins before occlusion.
ENZYME ACTVITY (nmole/min mg)
TGL GPAT
NI I NI I
After 10 min. 
ischaemia 






After isch. + 5 
min. reperfusion 0.56+0.04 0.46+0.03
Number of observation = 6 
Values are means + S.E.
Statistical significance v non-ischaemic value; *= p<0.05; **= p<0.01.
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clear that the changes in enzyme activities brought about by 
ischaemia are mediated by p-adrenergic mecheinisms.
Since the ischaemically-induced change in TGL 
activity is completely prevented by atenolol perfusion, 
changes in the activity of this enzyme were not studied 
during reperfusion.
During reperfusion, GPAT activity measured in the 
previously ischaemic area was significantly decreased 
compared to the activity measured after 10 minutes 
ischaemia. Thus, the reperfusion-induced fall in GPAT 
activity was not prevented by preperfusion with atenolol. 
Either an additional adrenergic drive occurs on reperfusion 
which is not blocked by atenolol (unlikely as no additional 
increase in TGL activity was seen on reperfusion in Table 
3.13) or a component of the reperfusion-induced response 
which is not blocked by atenolol was responsible.
ii. Preperfusion with the Alphag Adrenergic Antagonist 
Yohimbine.
Perfusion with the Cg adrenergic antagonist 
yohimbine has been shown to increase noradrenaline release 
in response to sympathetic nerve stimulation (Langer, 1976) . 
The effects of perfusion with the CC g antagonist for 10 
minutes before occlusion and thereafter throughout the 
experiment are shown in Table 3.20.
It can be seen that the non-ischaemic area showed a 
slightly elevated TGL activity after 10 minutes ischaemia 
and a slightly lowered GPAT activity after 1 and 5 minutes
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TABLE 3.20.
The effect of continuous perfusion with the Œ 2  antagonist Yohimbine 
on the activities of Glycerol 3-phosphate acyltransferase (GPAT) and 
Triglyceride lipase (TGL) produced by 10 minutes ischaemia and 
subsequent reperfusion. Activities were measured in tissue from both 
the non-ischaemic (NX) and ischaemic (I) areas of the heart.




After 10 min. 
ischaemia 0.24+0.04 0.30+0.03 0.60+0.04 0.43+0.07
After isch. + 1 
min reperfusion 0.20+0.03 0.23+0.03 0.51+0.04 0.42+0.03
After isch. + 5
mins. reperfusion 0.21+0.02 0.27+0.03 0.55+0.07 0.42+0.0
Number of observations = 6 
Values are means + S.E.
Statistical significance v non-ischaemic value; *= p<0.05.
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reperfusion compared to control values. These changes did 
not reach statistical significance but do suggest the 
possibility that a small increase in adrenergic activity 
occurs in the non-ischaemic area during occlusion and 
reperfusion.
In the ischaemic area, after 10 minutes ischaemia, 
TGL and GPAT activities were similar to the activities seen 
in the absence of the & 2  antagonist, ie. high TGL activity 
and low GPAT activity.
During reperfusion, however, the presence of 
yohimbine prevented TGL activity returning to normal in the 
previously ischaemic area. It appears that yohimbine has 
prolonged the ischaemic effect during reperfusion and kept 
TGL activity, in the previously ischaemic area, elevated.
GPAT activity remained low in the ischaemic area 
throughout the reperfusion period. This appears similar to 
the result seen in the absence of yohimbine. This could be 
due either to a continuation of the p,-adrenergic drive (as 
TGL activity remained elevated) or to the
reperfusion-induced fall in GPAT activity previously noted 
and which is not mediated by <r adrenergic mechanisms.
iii. Pre-perfusion with the Alpha^ Adrenergic Antagonist 
Doxazosin.
Doxazosin is a water-soluble derivative of the 
widely used adrenergic antagonist prasozin (Pfizer
Central Research). Prasozin has been shown to be very 
effective in preventing the occurance of ventricular
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arrhythmias due to coronary occlusion and subsequent 
reperfusion (Sheridan et al, 1980). The effect of continuous 
perfusion with doxazosin before, during and after ligation 
is shown in Table 3.21.
In the presence of doxazosin the change in TGL
activity measured in tissue from both the non-ischaemic and
ischaemic areas during occlusion and reperfusion shows a 
similar pattern to that seen in the absence of any 
adrenergic antagonist (Table 3.13). Similarly the fall in 
GPAT activity induced by ischaemia in the ischaemic area was
similar in the presence or absence of doxazosin.
On reperfusion, as in the absence of doxazosin,
GPAT activity in the previously ischaemic area was reduced 
compared to the activity measured in the non-ischaemic area. 
However, this value was not reduced when compared to the 
activity seen in control hearts and higher than the activity 
seen after 10 minutes ischaemia (Table 3.21). Indeed, after 
5 minutes of reperfusion with doxazosin present, GPAT 
activity in the previously ischaemic area was comparable to 
that seen in the non-ischaemic area. This return to normal 
values was not seen with perfusion of Krebs/Hensleit buffer 
alone or in the presence of atenolol or yohimbine. Thus, it 
appears that the reperfusion-induced fall in GPAT activity 
was prevented by preperfusion with the Œ adrenergic 
antagonist doxazosin. This provides strong evidence that the 
fall in GPAT activity seen on reperfusion of the ischaemic 
area is mediated by Œ adrenergic mechanisms.
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TABLE 3.21.
The effect of continuous perfusion with the ([^antagonist Doxazosin on 
the activities of Glycerol 3-phosphate acyltransferase (GPAT) and 
Triglyceride lipase (TGL) produced by 10 minutes ischaemia and 
subsequent reperfusion. Activities are measured in tissue from both 
the non-ischaemic (NI) and ischaemic (I) areas of the heart.
ENZYME ACTIVITY (nmole/min/mg)
TGL GPAT
NI I NI I
After 10 min. 
ischaemia 0.23+0.03 0.31+0.02 0.66+0.04 0.48+0.04
After isch. + 1 
min reperfusion 0 .21+0.02 0.28+0.01 * * 0.68+0.05 0.51+0.03
After isch. + 5
min. reperfusion 0.21+0.02 0.24+0.02 0.64+0.03 0.64+0.03
Number of observations = 6 
Values are means + S.E.




The effect of adrenaline on the activities of triglyceride 
lipase, glycerol 3-phosphate acyltransferase and carnitine 
palmitoyl transferase.
The triglyceride content of the heart muscle 
appears to be in a dynamic state where the level of tissue 
triglyceride depends on the relative rates of estérification 
and lipolysis (Neely and Morgan, 1974). A considerable 
amount of evidence has accumulated to show the existence, in 
the heart, of lipases necessary for the hydrolysis of 
endogenous triglyceride stored at intracellular sites 
(Bjorntorp and Furman, 19 62; Hamid et al, 19 73 and 
Kriesberg, 19 66).
The heart also contains a substantial activity of 
lipoprotein lipase which will, under appropriate 
physiological conditions, hydrolyze circulating triglyceride 
prior to entry into the cardiac cell (Robinson, 1970). The 
contribution of lipoprotein lipase to the activity measured 
as triglyceride lipase was reduced to a minimum by using a 
phospate buffer (pH 7.5) and avoiding any conditions known 
to stimulate lipoprotein lipase (such as the presence of 
serum cofactors) (Severson, 1979 and Al-Muhtaseb, 1982). 
Also, it might be expected that by administering heparin in 
the intraperitonial injection before the heart was excised, 
a large proportion of the extracellular lipoprotein lipase 
would have been removed (Borensztajn and Robinson, 1970a,b).
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Numerous reports have described the hormonal 
control of intracellular triglyceride mobilization in heart 
tissue. Catecholamines have been shown to increase the rate 
of triglyceride mobilization in the perfused rat heart as 
demonstrated by increased rates of glycerol output 
(Williamson, 19 64; Challoner and Steinberg, 19 65; Kriesberg, 
19 66; Christian et al, 19 69; Jesmok et al, 1977 and Severson 
et al, 19 80) and decreased tissue levels of total 
triglyceride (Gartner and Vahouny, 1973; Crass et al, 1975 
and Palmer et al, 1981).
The results reported in this study show that 
adrenaline perfusion can stimulate triglyceride lipase 
activity in the isolated rat heart. Bjorntorp and Furman 
(19 62) have reported that a lipase was stimulated in the 
homogenate of rat hearts treated with adrenaline.
Stimulation of TGL activity by adrenaline has also been 
observed in fat cell homogenates (Rizack, 19 64; Huttunen et 
al, 1970; Corbin et al, 1970 and Steinberg, 1978).
In the same adrenaline-perfused hearts which showed 
a stimulated TGL activity, a concurrent fall in the activity 
of glycerol 3-phosphate acyltransferase was also seen. A 
similar inactivation of GPAT activity by adrenaline has been 
reported for fat cells (Sooranna and Saggerson, 19 7 6,78), 
but not previously for the heart.
Adrenaline perfusion did not alter the activity of 
carnitine palimtoyl transferase in the perfused rat heart.
No acute hormonal effects, arising from covalent 
modifications, have yet been.shown on the activity of this 
enzyme in any tissue.
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Section 4.2.
Mode of Adrenaline Action
Previous studies in the heart (Mayer, 1972; Kaumann 
and Birnbaumer, 1974 and Picken and Jarrett, 1975) have 
established that catecholamine-receptor interaction leads to 
increased adenyl cyclase activity and the generation of 
higher levels of cAMP. The mechanism by which cAMP has been 
shown to carry out its function as a second messenger in the 
transmission of hormonal signals is through the regulation 
of protein kinases found in various tissues (for review see 
Mayer, 1974).
It has been shown here that when homogenates or 
supernatants from perfused heart tissue were incubated in 
the presence of cAMP, ATP and cAMP-dependent protein kinase, 
the activity of TGL increased while the activity of GPAT 
decreased. The results suggest that TGL can be activated 
whilst GPAT can be inactivated by a phosphorylation reaction 
catalysed by cAMP-dependent protein kinase.
Activation of protein kinase by cAMP is thought to 
occur according to the following equation: (Brostorm et al, 
1970)
[y
2RC (inactive) + ^ b A M P  > 2R-CAMR + 2C (active)
The enzyme exists as a tetramer with two regulatory (R)
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and two catalytic (C) subunits. Binding of cAMP to the 
regulatory subunit of the inactive protein kinase (RC) 
causes a dissociation of the enzyme into the regulatory 
(R-cAMP complex) and an active catalytic (C) subunit. In the 
heart the protein kinase activity ratio (active 
enzyme/total enzyme), has been shown to correlate very well 
with the tissue cAMP levels under a variety of conditions 
(Corbin et al, 1970; Soderling et al, 1973 and Keely and 
Corbin, 1975). In work reported here, it has been shown that 
incubation of heart homogentate with the catalytic subunit 
(prepared from the holoenzyme by affinity chromotography and 
eluting with cAMP) results in activation of TGL and 
inactivation of GPAT by a time-dependent mechanism.
In adipose tissue it is well established that TGL 
can be activated by cAMP-dependent phosphorylation (Corbin 
and Krebs, 19 69) and that this leads to an activation of 
lipolysis (Huttunen et al, 1970; Corbin et al, 1970; Khoo et 
al, 1976 and Belfrage et al, 1977). In rat heart however, 
Severson (1979) failed to detect any change in TGL activity 
in the presence of cAMP-dependent protein kinase. This was 
possibly due to his use of quick frozen tissue. In our 
hands, TGL activity measured in supernatants from frozen 
tissue was no longer activated by cAMP-dependent protein 
kinase.
With respect to GPAT activity there has been little 
previous evidence of adrenergic control. Only in rat adipose 
tissue has there been any reports of hormonal control. Nimmo 
and Houston (19 78) reported that GPAT activity can be 
inactivated by cAMP-dependent protein kinase. However, Rider 
and Saggerson (1983a,b) failed to confirm this.
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This present study shows that in perfused rat heart 
tissue GPAT activity can be inactivated by cAMP-dependent 
phosphorylation. Also in agreement with the results 
reported by Nimmo and Houston (19 78) in adipose tissue, it 
was found that the microsomal but not the mitochondrial form 
of GPAT was inhibited by cAMP-dependent protein kinase 
phosphorylation. The fall in mitochondrial GPAT activity 
seen with adrenaline perfusion could not be explained by 
direct cAMP-dependent phosphorylation mechanisms.
If the activation of TGL and the inactivation of 
GPAT by cAMP-dependent protein kinase reflects the 
physiological process of adrenaline action, then TGL and 
GPAT in homogenates prepared from tissue previously perfused 
with adrenaline should already be largely in the activated 
(TGL) or inactivated (GPAT) form. This would mean that the 
activities should undergo little or no change when incubated 
with cAMP-dependent protein kinase. The results presented in 
Table 3.18 show this to be the case.
Attempts were made to dephosphorylate the enzymes
from adrenaline-treated hearts by incubation under
dephosphorylation conditions. Thus, homogenates or
supernatants from hearts perfused with adrenaline were
2+ 2+incubated with high Ca and Mg ion concentrations. Such 
conditions are known to favour phosphoprotein phosphatase 
activity (Severson et al, 1977). Under these conditions 
adrenaline-activated TGL activity was deactivated while 
adrenaline-deactivated GPAT activity was reactivated, ie.
the effects of adrenaline were reversed. These results
2+ 2+ suggest the presence of a Ca and/or Mg dependent
phosphoprotein phosphatase in heart tissue capable of
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reversing the effects of adrenaline stimulation.
Thus, it is attractive to consider that adrenaline 
stimulates lipolysis through activation of TGL activity and 
decreases estérification through inactivation of GPAT 
activity. Both processes would be regulated by 
cAMP-dependent protein kinase and an integrated regulation 
of triglyceride mobilization and synthesis could occur.
Section 4.3.
The Role of Different Types of Adrenergic Receptor in the 
Regulation of Triglyceride Mobilization.
Naturally occuring catecholamines, namely 
noradrenaline and adrenaline, can interact with 4 different 
receptors on the cardiac cell surface; ([ ̂ , Œ  2  ̂ and
adrenergic receptors (Lands et al, 19 67; Berthelson and 
Pettinger, 1977 and Wikberg, 1979).
i. Beta Adrenergic Receptor
Beta agonists, such as isoprenaline, increase 
intracellular cAMP levels by activating membrane-bound 
adenyl cyclase, resulting in increased lipolysis after 
phosphorylation of triglyceride lipase in adipose tissue 
(Burns et al, 19 71 and Fain, 19 80). The increased 
mobilization of triglyceride in heart tissue as a result of 
catecholamine simulation is mediated via p -adrenergic
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receptors (Shipp et al, 1973; Mayer, 1974; Hron et al, 1977 
and Jesmok et al, 1977).
Perfusion of isoprenaline in our work resulted in a 
greater stimulation of TGL activity than was seen in the 
presence of adrenaline. Isoprenaline has been found to be 
more potent than adrenaline in increasing both intracellular 
cAMP levels and lipolysis in adipose tissue (Fain, 1973).
Similarly, perfusion of isoprenaline produced a 
greater fall in GPAT activity than was seen with adrenaline.
Thus, it appears that the changes in TGL and GPAT 
activities brought about by adrenaline perfusion are likely 
to result from the stimulation of p-adrenergic receptors. 
However, isoprenaline was more potent than adrenaline in 
producing an activation of TGL and an inactivation of GPAT.
ii. Alpha Adrenergic Receptor
Adrenaline and noradrenaline can also activate both 
and Œ  ̂  adrenergic receptors in the heart (Koblinger 
and Pichler, 1980,82; Drew, 1979 and Pichler and Koblinger, 
1978) .
Perfusion of the non-selective Œ  agonist 
phenylephrine resulted in a fall in TGL activity and a rise 
in GPAT activity. This is consistant with the fall in cAMP 
levels measured by Keely et al (19 77) when phenylephrine was 
perfused through the isolated rat heart.
In human and hamster adipose tissue a reduction in 
cAMP levels and a consequent reduction in the rate of 
lipolysis is mediated by Œ  2  adrenergic receptors
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(Arktories et al, 1979,81 and Burns et al, 1981). Perfusion 
of the Œ  2  agonist clonidine in this work caused a fall in 
TGL activity and a rise in GPAT activity. This, again, is 
consistant with stimulation of the  ̂ receptor causing a
fall in cAMP levels. This would be produced by a decreased 
activity of adenyl cyclase (Jakobs, 1979; Jakobs and 
Schultz, 1980 and Jakobs et al, 1980,81) and would result in 
a reduced cAMP-dependent protein kinase activity.
A rather high concentration of clonidine was needed 
to achieve the maximum change in activities. This suggests 
that Œ  2  receptors are present at a low concentration and 
may not have a physiological role in the normal rat heart. 
However, their role might become more important under 
abnormal conditions such as in ischaemia where a fall in pH 
is known to favour the stimulation of Œ  2  receptors 
(McGrath, 1982).
Apart from post-synaptic Œ 2  receptors, which 
directly decrease adenyl cyclase activity, the rat heart 
also contains pre-synaptic Q[ 2  receptors. Stimulation of 
these reduces noradrenaline release from sympathetic nerve 
terminals (Langer, 1974; Starke et al, 1975 and Dart et al, 
19 84a). Thus, perfusion of clonidine could also reduce 
intracellular cAMP levels indirectly by reducing the release 
of noradrenaline from the sympathetic nerve endings in the 
heart.
In the rat heart GC  ̂ adrenergic receptors are 
found on both pre- and post- synaptic membranes (Koblinger 
and Pichler, 1980,82). The physiological significance of 
pre-synaptic Œ  ̂ receptors remains unclear but recent
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evidence suggests that stimulation of this receptor can also
reduce noradrenaline release (Ledda and Mantelli, 1984).
Post-synaptic receptors have been shown to cause an increase
in inotropy (Wagner and Brodde, 1978) possibly mediated by
2+an increase in intracellular free Ca concentration in the
cardiac cell (Miura et al, 1978). This appears to be the
2+result of an influx of Ca from extra-cellular and/or
intra-cellular storage sites (Berridge, 1975,80). It has
been proposed (Michell and Kirk, 1981) that stimulation of
phosphatidylinositol degradation is a primary and causal
2+change involved in Ca mobilization by agonists.
Perfusion of the isolated rat heart with the Œ
^agonist methoxamine has been reported to increase glucose
uptake, the phosphofructokinase activity ratio and lactate
release (Clark and Pattern, 1981 and Clark et al, 1982)
suggesting enhanced glycolysis. The effect of adrenergic
stimulation on triglyceride mobilization has not been
reported before.
The present work has shown that perfusion of the
isolated rat heart with the gc^ agonist methoxamine had no
effect on TGL activity but produced a persistant fall in
GPAT activity. This affect has not been reported before and
2+suggests that GPAT is sensitive to Ca or some other œ   ̂
mediated signal. In support of this hypothesis, 
Soler-Argilaga et al (1978) have reported that phosphatidate
24-synthesis in the liver is reduced by an infux of Ca ions.
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iii. Mitochondrial and Microsomal GPAT Activity.
The changes in GPAT activity produced by perfusion 
with the p agonist isoprenaline and the <e agonists 
phenylephrine, clonidine and methoxamine are localised in 
the microsomal (NEM-sensitive) fraction. The mitochondrial 
(or NEM-insensitive) fraction appears relatively 
unresponsive to these adrenergic agonists. This is 
consistant with the generally held belief that the 
endoplasmic reticulum is the prinicpal site of glycerolipid 
synthesis (Bell and Coleman, 1980).
iv. Carnitine Palmitoyl Transferase Activity.
Perfusion of the p agonist isoprenaline and the (E 
agonist phenylephrine has no effect on CPT activity measured 
in the outer surface of the inner mitochondrial membrane. 
This agrees with the lack of any change in CPT^ activity 
produced by adrenaline perfusion and further supports the 
hypothesis that the activity of this enzyme is not regulated 
by acute hormonal effects in the rat heart.
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Section 4.4.
Perfusion of Adrenergic Antagonists.
i. Beta Adrenergic Antagonist
Continuous perfusion of the cardioselective 
adrenergic antagonist atenolol results in a marked reduction 
in TGL activity (almost half that found in hearts perfused 
in the absence of atenolol). This suggests that control 
hearts were exhibiting some degree of adrenergic 
stimulation, even after 15 minutes perfusion. This could 
arise by local release of endogenous noradrenaline from
sympathetic nerve endings during the perfusion. Overall the
activity of TGL was seen to increase almost 4 fold from a
level of 0.13+0.01 under P -adrenergic antagonism to
0.42+0.07 with p-adrenergic stimulation.
However, the fall in GPAT activity measured with 
continuous perfusion of atenolol cannot be explained by this 
method as a reduced adrenergic drive would be expected to 
increase GPAT activity. Thus, the fall in GPAT activity 
caused by perfusion with atenolol suggests that the 
reduction in activity caused by adrenaline may not be solely 
due to cAMP-dependent protein kinase effects mediated by the 
p-adrenergic system. It is possible that the 
adrenergic system is involved.
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ii. Alpha Adrenergic Antagonism
Continuous perfusion of the Œ ^-adrenergic
./
antagonist doxazosin and the <E 2 antagonist Yohimbine did 
not result in any change in the activities of TGL or GPAT. 
This suggest that in the normal heart no appreciable CC^ or
Œ 2  adrenergic drive exists
Section 4.5.
The Effect of Ischaemia on the Activities of TGL, GPAT and 
CPT.
In the rat, ligation of the left descending 
coronary artery leads to ischaemia and infarction in a large 
area of the left ventricluar wall (Fishbein et al, 1980).
During acute ischaemia, increased release of 
noradrenaline from the sympathetic nerve terminals occurs 
(Shahab et al, 1972; Abrahamsson et al, 1983 and Schomig et 
al, 1984). This could be due to increased extracellular 
potassium (Hirche et al, 1980), acidosis (Eular and 
Lishajoko, 19 61), hypoxia (Shahab and Wollenberger, 19 67) 
and/or energy defficiency within the neurone itself (Wakade 
and Furchgott, 1968). Local release of noradrenaline from 
sympathetic nerve terminals is probably more important than
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nerve-stimulated noradrenaline release during ischaemia, 
particularly during the early stages (Dart et al, 1984b and 
Schomig et al, 19 84).
Exogenous catecholamines have been shown to 
stimulate myocardial lipolysis (Christian et al, 19 69; Crass 
et al, 1975; Gartner and Vahouny, 1973; Hron et al, 1977 and 
Jesmok et al, 1977). It has been reported in the present 
work that both adrenaline and isoprenaline can increase 
lipolysis and decrease estérification by changes in the 
activities of the initial rate-limiting enzymes TGL and 
GPAT. During acute ischaemia and hypoxia increased lipolysis 
occurs (Opie, 19 7 6 and Karwatowska-Kryna and Beresewicz,
19 83) probably as a direct effect of increased noradrenaline 
release.
Catecholamine-stimulated lipolysis in the 
normally-perfused rat heart is probably mediated by 
increased cAMP levels via p-adrenergic stimulation 
(Christian et al, 19 69 and Crass et al, 1975). In acute 
ischaemia, cAMP levels are known to rise markedly 
(Wollenberger et al, 19 69 and Dobson and Mayer, 1973). After 
2 minutes of ischaemia an increase in cAMP levels was seen 
in both the non-ischaemic and ischaemic areas of the rat 
heart (Krause and Wollenberger, 19 67 and Krause et al,
1978). However, after 20 minutes, cAMP levels remained 
elevated in the ischaemic area but had returned to normal in 
the non-ischaemic area (Krause and Wollenberger, 19 67 and 
Krause et al, 1978). By contrast, Podzuwiet et al (1978) 
found that cAMP levels were elevated only in the ischaemic 
area. This difference could be explained if the rise in cAMP 
levels in the non-ischaemic area is transitory.
185 .
Concurrent with the increased cAMP levels was an 
increase in the cAMP-dependent protein kinase activity ratio 
and the activities of phosphorylase kinase and phosphorylase 
(Krause and Wollenberger, 19 67 and Dobson and Mayer, 1973). 
Pre-perfusion with the p adrenergic antagonist propranolol 
completely prevented the rise in cAMP levels and protein 
kinase activity ratio but only partly prevented the rise in 
phosphorylase kinase and phosphorylase activity (Krause and 
Wollenberger, 19 67).
i. The Effect of Ischaemia on TGL, GPAT and CPT 
Activities.
The results reported here are in accord with the 
theory of an ischaemia-induced rise in cAMP levels and 
protein kinase activity. After 10 minutes occlusion TGL 
activity, measured in the ischaemic area, was increased by 
50% compared to activity measured in normally-perfused 
hearts. A fall in GPAT activity (30%) occured in the 
ischaemic area. No change was seen in TGL or GPAT activity 
in the non-ischaemic area.
No change was seen in the activities of CPT  ̂ or 
CPTjj or the total CPT activity in the ischaemic area after 
10 minutes occlusion. Thus, both acute adrenergic challenge 
and acute ischaemic challenge do not appear to alter the 
activity of CPT.
Injection of 6 OH-dopamine at least one day 
previously has been shown to markedly reduce both the level 
of endogenous noradrenaline and the incidence of arrhythmias
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during ischaemia and reperfusion in the cat (Sheridan et al, 
1980) and guinea pig (Culling et al, 1984) heart. In the 
work reported here depletion of noradrenaline by injection 
of 6 OH-dopamine 24 hours before the hearts were excised 
prevented the rise in TGL activity and the fall in GPAT 
activity in the ischaemic area. This suggests that the 
changes in TGL and GPAT activities measured after 10 minutes 
ischaemia are caused by release of endogenous noradrenaline 
during ischaemia.
ii. Preperfusion with Adrenergic Antagonists
Preperfusion with the p antagonist atenoloL, but 
not the antagonist doxazosin or the Œ 2  antagonist
yohimbine, also prevented the ischaemia-induced changes in 
TGL and GPAT activities. Thus, it appears that these changes 
are mediated by the p -adrenergic receptor.
iii. Ischaemia-induced rise in Free Fatty Acids.
The accumulation of fatty acids and their acyl CoA 
derivatives in the ischaemic myocardium has been well 
documented (for review see Victor et al, 1984). Severson and 
Hurley (19 82) have found that rat heart triglyceride lipase 
is inhibited by high concentrations of free fatty acids and 
fatty acyl CoA. These observations are in accord with 
previous work in our laboratory (Al-Muhtaseb, 1982). Thus, 
it may be expected that high levels of free fatty acids, 
produced during ischaemia, could inhibit TGL activity, 
overriding the activation produced by phosphorylation. This
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would explain the results of Crass and Pieper (1975) who 
were unable to find any increase in triglyceride 
mobilization in the hypoxic heart.
Section 4.6.
Reperfusion of the Ischaemic Area.
It was Jennings et al (19 60) who first noted that 
reperfusion of the ischaemic myocardium may not nescessarily 
be beneficial. They reported electrophysiological and 
structural damage associated with reperfusion. Since this 
observation our knowledge of the mechanisms eind consquences 
of ischaemia and reperfusion have expanded enormously (for 
review see Hearse, 19 77; Manning and Hearse, 1984 and Corr 
and Nitkowski, 1984). However, whilst it is obvious that the 
ischaemic myocardium cannot recover without the restoration 
of adequate coronary flow, there is now a convincing body of 
evidence to suggest that reperfusion can induce a 
paradoxical extension of ischaemic damage.
There is considerable evidence of an increase in <r 
-adrenergic activity during reperfusion of a previously i 
ischaemic area (Sheridan et al, 1980). Using an 
anaesthetised cat model of coronary occlusion and 
reperfusion, Sheridan et al (19 80) were able to show that 
whilst both p-adrenergic antagonism with propranolol and(C 
-adrenergic antagonism with phentolamine reduced the 
incidence of ventricular arrhythmias during occlusion, only 
phentolamine was effective in reducing reperfusion-induced 
arrhythmias. Similar results were found with the specific
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antagonist prasozin (Sheridan et al, 1980), thus 
indicating specificity to the antiarrhythmic effect of
phentolamine.
i. The Effect of Reperfusion on the Activities of TGL and 
GPAT.
In this study, ischaemically-activated TGL activity 
returned to control values during reperfusion of the 
ischaemic area. However, GPAT activity measured during 
reperfusion was significantly lower than the activity 
measured after 10 minutes of ischaemia.
This reperfusion-induced fall in GPAT activity did
not occur in hearts from rats preinjected with 6 OH-dopamine
24 hours previously. Thus, this change in GPAT activity »•
Voccured as a result of endogenous noradrenaline release.
ii. Preperfusion with Adrenergic Antagonists.
Unlike the ischaemically-induced fall in GPAT 
activity, the reperfusion-induced fall was not prevented by 
preperfusion with the p antagonist atenolol. However, 
preperfusion with the Œ  ̂ antagonist doxazosin did prevent 
it.
It has been shown earlier that perfusion of control 
hearts with the Œ  ̂ -adrenergic agonist methoxamine resulted 
in a fall in GPAT activity but did not alter TGL activity. 
Thus, there is good evidence to suggest that, on 
reperfusion, an increased œ   ̂ adrenergic stimulus results 
in a fall in the activity of GPAT and, therefore, reduces
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the capacity of the tissue to re-esterify endogenous fatty
acids. This can be prevented by removal of endogenous
noradrenaline (by 6 OH-dopamine injection) or by Œ
antagonism (with doxazosin).
Recent work has suggested that ce ^ adrenergic
antagonism may not be a specfic aspect of the benefits of
prasozin in reducing the occurance of ventricular
arrhythmias (Thandroyen et al, 19 83 and Dukes and
Vaughan-Williams, 1984). They suggest that these agents may
have a local membrane-stablising effect. However, the fact
that hearts from 6 OH-dopamine treated animals did not show
a reperfusion-induced fall in GPAT activity does suggest
that this change is mediated by adrenergic receptor
mechanisms and that the evidence is in favour of doxazosin
acting via its adrenergic antagonist properties.
It is known that ce ̂  adrenergic agonists increase 
2+cytosolic Ca in the heart (Muira et al, 1978). Recently,
it has been shown that reperfusion of the ischaemic
2+myocardium is accompanied by an increased Ca influx
mediated by CE^ adrenergic mechanism(s) (Sharma et al,
2+19 83). An increase in Ca concentration has also been
implicated in the reduction of phosphatidate synthesis by
glucagon in hepatocytes (Soler-Argilaga et al, 1978).
Therefore, it would appear possible that a
2+reperfusion-induced rise in Ca influx into the cardiac 
cytoplasm, mediated by Œ ^ adrenergic mechanism(s), causes 
a fall in GPAT activity and hence in estérification.
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iii. Preperfusion with an Alphag Adrenergic Antagonist.
Presynaptic CT2  adrenergic receptors are powerful 
modulators of noradrenaline release (Langer, 1976) .
Yamaguchi et al (1977) have shown increased noradrenaline 
overflow from the heart with CEadrenergic antagonism. The 
Œ 2  antagonist, yohimbine (Tanaka and Starke, 1980), has been 
shown to potentiate noradrenaline release from the ischaemic 
area of an anaesthetised dog when intermittent left ganglion 
stimulation was applied (Forfar et al, 1983).
In our isolated system, the presence of yohimbine 
did not increase the changes in TGL or GPAT activities seen 
after 10 minutes ischaemia. However, on reperfusion, the <E 
2  antagonist did appear to postpone the return of TGL 
activity to control values, possibly by inhibiting neuronal 
reuptake (Forfar et al, 1983).
GPAT activity remained low during reperfusion with 
yohimbine present and did not recover to control values.
This could be due to either a prolonged P adrenergic drive 
or the reperfusion-induced fall in GPAT activity seen in the 
absence of yohimbine.
Although no statistically significant changes in 
enzyme activities were seen in the non-ischaemic area, there 
was some evidence of a rise in TGL activity and a fall in 
GPAT activity in this area when yohimbine was present. Also, 
perfusion of the p antagonist atenolol, which has been shown 
to reduce TGL activity in control hearts did not reduce the
191
activity in the non-ischaemic area. These results would be 
consistant with a small, transient, rise in cAMP levels in 
the non-ischaemic area after coronary artery ligation, as 




The work reported in this thesis has shown how 
catecholamine and ischaemic challenge can effect 
triglyceride mobilization in the heart via the activities of 
triglyceride lipase and glycerol 3-phosphate 
acyltransferase. Adrenaline has been shown to activate TGL 
activity and inactivate GPAT activity thus facilitating 
triglyceride mobilization. This effect is probably mediated 
by activition of the p adrenergic system, causing an increse 
in CAMP levels and an increase in the activity of 
cAMP-dependent protein kinase.
Stimulation of adrenergic receptors produces a
fall in TGL activity and a rise in GPAT activity. This is 
probably mediated by a fall in cAMP levels. Stimulation of Œ  
 ̂ adrenergic receptors does not alter the activity of TGL 
but does produce a fall in GPAT activity.
After 10 minutes ischaemia TGL activity in the 
ischaemic area is higher than control values whilst GPAT 
activity is lower. This is probably caused by 
ischaemically-induced release of endogenous noradrenaline 
from sympathetic nerve terminals. These changes in TGL and 
GPAT activities can be prevented either by depletion of
f
endogenous noradrenaline by preinjection with 6 OH-dopamne 
or by preperfusion with the p adrenergic antagonist 
atenolol.
During reperfusion of the ischaemic area, TGL
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activity returns to control values. GPAT activity, though, 
is further reduced. This fall in GPAT activity can be 
prevented either by preinjection with 6 OH-dopamine or by 
preperfusion with the <t adrenergic antagonist doxazosin. 
Thus, the reperfusion-induced fall in GPAT activity appears 




i. Investigation of the effects of changes in calcium 
concentration in the perfusate on TGL and GPAT activities 
during normal, ischaemic and reperfusion conditions.
ii. Investigation of the effects of anti-arrhythmic calcium 
entry blockers on the activities of TGL and GPAT after 
ischaemia and reperfusion.
iii. Investigation of the effect of the presence of fatty 
acids in the perfusate on the activities of TGL, GPAT and 
CPT and the ischaemia and reperfusion induced changes in 
enzyme activities.
iv. Investigation of the use of different concentrations of 
adrenaline and other alpha and beta agonists, possibly by 
the use of cardiac myocytes.
V. Investigation of the effects of hypoxia, compared to 
ischaemia, on the enzyme activities.
REFERENCES
195
Aas, M. (1971), Biochim. Biophys. Acta. 231 22-47.
Aas, M. and Bremer, J. (19 68), Biochim. Biophys. Acta. 164 
157-166.
Aas, M. and Daae, L.N.W. (1971), Biochim. Biophys. Acta. 239 
208-216.
Abrahamsson, T., Almgren, 0. and Carlsson, L. (1983), J.
Mol. Cell. Cardiol. _15 821-830.
Abrahamsson, T., Almgren, O. and Svesson, L. (1981), J. 
Cardiovas. Pharmacol. _3 807-817.
Acosta, D. and Wenzel, D.G. (1974), Atherosclerosis 20 
417-426.
Adler-Graschinsky, E. and Langer, S.Z. (1975), B r . J. 
Pharmacol. 53 43-50.
Agranoff, B.W. (19 62), J. Lipid Res. 3_ 190-196.
Ahlquist, R.P. (1948), Amer. J. Physiol. 153 586-600. 
Alexander, R.W., Williams, L.T. and Lefkowitz, R.J. (1975), 
Proc. Nat. Acad. Sci. U.S.A. 72 1564-1568.
Allen, D.O., Largis, E.E., Miller, E.A. and Ashmore, J. 
(1973), J. Applied. Physiol. 34 125-127.
Alousi, A.A. and Mallov, S. (19 64 ), Amer. J. Physiol. 206 
603-609.
Anderson, N.G. and Fawcett, B. (1950), Proc. Soc. Exp. Biol, 
(New York) 74 768-771.
Anfinsen, C.B., Boyle, E. and Brown, R.K. (1952), Science 
115 583-586.
Angel, A. and Roncari, D.A.K. (1967), Biochim. Biophys.
Acta. 137 464-474.
Arktories, K. and Jakobs, K.H. (1981), FEBS Lett. 130
192
235-238.
Arktories, K., Jakobs, K.H. and Schultz, G. (1979), Arch. 
Pharmacol. 308 R15.
Armstrong; A., Duncan, B., Oliver, M.F., Julian, D.G., 
Donald, K.W., Fulton, M., Lutz, W. and Morrison, S.L.
(1972), Br. Heart J. 3£ 67-80.
Arnaud, J. and Boyer, J. (1974), Biochim Biophys. Acta. 337 
165-167.
Augustin, J. and Greten, H. (1979), Atherosclerosis ^  
91-124.
Aurbach, G.D., Fedak, S.A., Woodward, C.J., Palmer, J.S., 
Hanser, D. and Troxler, F. (1974), Science 186 1223-1240. 
Bacq, Z.M. (1976), J. Physiol.(Paris) 72 371-542.
Banis, R.J. and Tove, S.B. (1974), Biochim. Biophys. Acta. 
348 210-220.
Barth, C., Sladek, M. and Decker, K. (1971), Biochim. 
Biophys. Acta. 248 23-33.
Bates, E.J. and Saggerson, E.D. (1977), FEBS Lett. 84 
229-232.
Belfrage, P., Fredikson, G., Nilsson, N.O. and Stralfors, P 
(1980), FEBS Lett. Ill 120-124.
Belfrage, P. Jergil, B., Stralfors, P. and Tornquist, H. 
(1977), FEBS Lett. T5 259-264.
Bell, R.M. and Coleman, R. (1980), Ann. Rev. Biochem. 49 
459-487.
Benfey, B.G. (1973), B r . J. Pharmacol. 48 132-138.
Berglund, L., Khoo, J.C., Jenson, D. and Steinberg, D.
, (1980), J. Biol Chem. 255 5420-5428.
Berridge, M.J. (1975), Adv. Cyclic Nucleotide. Res. £ 1-98. 
Berridge, M.J. (1980), Trends in Pharmacol. Sci. 419-424.
195
Berthelsen, S. and Pettinger, W.A. (1977), Life. Sci. 21 
595-606.
Bing, R.J. (19 65), Physiol. Rev. 45 171-213.
Bjorntorp, P. and Furman, R.H., (1962), Amer. J. Physiol.
203 323-326.
Bloch, K. and Vance, D. (1977), Ann. R e v . Biochem. 46 
263-298.
Bloor, C.M. (1978), Cardio. Pathol., Lippin. Cott. and Co., 
Philadelphia.
Borensztajn, J., Krieg, P. and Rubenstein, A.A. (1973), 
Biochem. Biophys. Res. Commun. 3 60 3-608.
Borensztajn, J. and Robinson, D.S. (1970a), J. Lipid. Res.
11 102- 110.
Borensztajn, J. and Robinson, D.S. (1970b), J. Lipid. Res.
11 111-117.
Borensztajn, J., Rone, M.S. and Sandros, T. (1975), Biochim. 
Biophys. Acta. 39 8 39 4-400.
Borensztajn, J., Samols, D.R. and Rubenstein, A.H. (1972), 
Am. J. Physiol. 223 1271-1275.
Borrebeak, B., Chrsitiansen, B.C. and Bosch, H ., van den. 
(1974 ), Ann. Rev. Biochem. _42 243-277.
Bosnajak, Z.J., Zuperku, E.J., Coon, R.L. and Kampine, J.P. 
(19 79), Proc. Soc. Exp. Biol. Med. 161 142-148.
Bracfield, W. (1973), Circulation £8_ 459-463.
Bradford, M.M. (1976) Anal. Biochem. 72 248-254.
Brandes, R ., Olley, J. and Shapiro, B. (1963), Biochem. J. 
86 244-247.
Braunwald, E. (1976), Circulation 53 suppl. 1.
Braunwald, E., Maroko, P.R. and Libby, P. (1974), Cir. Res. 
3jL (supp. Ill) 192-201.
194
Breach, R.A. and Oils, R . (1975), Int. J. Biochem. ^
329-340.
Bremer, J. (1976), Circ. Res. supp 1. 16-20.
Bremer, J. (1977), Trends in Biochem. Sciences 207-209. 
Bremer, J . , Bjerve, K.S., Borrebaek, B. and Christiansen, R. 
(1976), Mol. Cell. Biochem. 12 113-124.
Brindley, D.N., Cooling, J., Burditt, S.L., Pritchard, P.H., 
Pawson, S. and Sturton, R.G. (1979), Biochem. J. 180 
195-199.
Brophy, P.J. and Vance, O.E. (1976), Biochem. J. 160 
247-251.
Brostrom, M.H., Riemann, E.M., Walsh, D.A. and Krebs^ E.G.
(1970), Advan. Enzyme Reg. 8 191-203.
Brown, A.M. and Malliani, A. (1971), J. Physiol.(London) 212 
685-705.
Brown, W.J. and Sgoutas, D.S. (1980), Biochim. Biophys.
Acta. 617 305-317.
Brownsey R.W. and Brunt, R.V. (1977), J. Clin. Sci. Mol.
Med. ^  513-521.
Bryant, R.E., Thomas, M.A. and O'Neal, R.M. (1958), Cir.
Res. ^  699-709.
Burgess, G.M., Godfrey, P.P., McKinney, J.S., Berridge,
M.F., Irvine, R.F. and Putney, J.W. (1984), Nature, 309 
63-66.
Burns, T.W., Langley, P.E. and Robison, G.A. (1971), Annals 
of New York Acad. Sci. 185 115-128.
Burns, T.W., Langley, P.E., Terry, B.E., Byland, D.B., 
Hoffman, B.B., Thorp, M.D., Lefkowitz, R.J., Garcia-Sainz, 
J.A. and Fain, J.N. (1981), J. Clin. Invest. 67 467-479. 
Butcher, R.W., Ho, R.J., Meng, H.C. and Sutherland, E.W.
195
(1965), J. Biol. Chem. 240 4515-4523.
Campbell, C.A. and Parratt, J.R. (1981), Br. J. Pharmacol. 
2± 19 5-19 6.
Caras, J. and Shapiro, B. (1975), Biochim. Biophys. Acta.
409 201-211.
Carlsson, E., Ablad, B., Brandsorm, A. and Carlsson, B. 
(1972), Life Sci. _11 953-958.
Carlsson, E., Hedberg, A. and Mattsson, H. (1981), in 
'Catecholamine in the non-ischaemic and ischaemic 
myocardium' (eds Riemersa, R.A. and Oliver, M.F.) Elsevier 
Biomed. Press Oxford pp 19-28.
Cassel, D. and Selinger, Z. (1978), Natl. Acad. Sci. U.S.A. 
75 4155-4159.
Cavero, I. and Roach, A.G. (1980), Br. J. Pharmacol. 70 
269-276.
Challoner, D.R. and Steinberg, D. (1965), Nature 205 
602-603.
Charlier, R. (1971), Handbook Exp. Pharmacol. 2 1  442.
Chase, J.F.A., Pearson, D.J. and Tubbs, P.K. (1965), 
Biochim. Biophys. Acta. 96 162-165.
Chen, R.F. (1967), J. Biol. Chem. 242 173-181.
Cheng, C.H.K. and Saggerson, E.D. (1978), FEBS Lett. 87 
65-68.
Chohan, P. and Cryer, A. (1978), Biochem J. 172 663-666.
Chohan, P. and Cryer, A. (1979), Biochem. J. 174 319-325.
Chohan, P. and Cryer, A. (1980), Biochem. J. 176 873-879 .
Christian, D.R., Kilsheimer, G.S., Pettett, G . , Paradise, R
and Ashmore, J. (19 69), in 'Advances in Enzyme Regulation' 
Vol III (ed Weber, G . ) Pergamon Press, New York pp 71-82. 
Chung, J. and Scanu, A.M. (1977), J. Biol. Chem. 252
196
4202-4209 .
Clarke, P.R.H. and Bieber, L.L. (1980), J. Biol. Chem. 2 56 
9869-9873.
Clarke, M.G. and Patten, G.S. (1981), Nature 29 2 461-463. 
Clarke, M.G., Patten, G.S., Filsell, O.G., Reppucci, D. and 
Leopardi, S.W. (1982), Biochem. Biophys. Res. Commun. 108 
124-131.
Coleman, R. and Bell, R.M. (1976), J. Biol. Chem. 251 
4537-4543.
Coleman, R. and Hubscher, G. (1962), Biochim. Biophys. Acta 
56 479-490.
Coleman, R.A., Reed, B.C., Mackall, J.C., Student, A.K., 
Lane, M.D. and Bell, R.M. (1978), J. Biol. Chem. 253 
7256-7261.
Corbin, J.D. and Krebs, E.G. (1969), Biochem. Biophys. Res. 
Commun. 36 328-336.
Corbin, J.D., Reimann, E.M., Walsh, D.A. and Krebs, E.G.
(1970), J. Biol. Chem. 245 4849-4851.
Corr, P.B. and Gillis, R.A. (1978), Cir. Res. 4J_ 1-9.
Corr, P.B., Witowski, F.X. and Sobel, B.E. (1978), J. Clin. 
Invest. _61. 109-119.
Corr, P.B. and Witowski, F.X. (1984), J. Cardiovas. 
Pharmacol. 2  5903-5909.
Crass, M.F. (1972), Biochim. Biophys. Acta. 280 71-81. 
Crass, M.F., McCaskill, E.S. and Shipp, J.C. (1969), Amer. 
J. Physiol. 216 1569-1576.
Crass, M.F., McGaskill, E.S., Shipp, J.C. and Murphy, V.K.
(1971), Amer. J. Physiol. 220 428-435.
Crass, M.F. and Pieper, G.M. (1975), Amer. J. Physiol. 229 
885-889.
197
Crass, M.F., Shipp, J.C. and Pieper, G.M. (1975), Amer. J. 
Physiol. 228 618-627.
Crass, M.F. and Sterret, P.R. (1975), in 'Recent advances in 
studies on cardiac structure and metabolism' (Vol 10) 
University Park Press pp 251-264.
Crass, M.F., Tullis, C.S., McCaskill, E.S. and Shipp, J.C. 
(1970), Comp. Biochem. Physiol. 36 201-205.
Cruickshank, E.W.H. and Kosterlitz, H.W. (1941), J. Physiol. 
99 208-223.
Cruickshank, E.W.H. and McClure, G.S. (1936), J. Physiol. 86 
1-14 .
Culling, W ., Penny, W.J., Lewis, M.J., Middleton, K. and 
Sheridan, D.J. (1984), Cardiovas. Res. _18. 675-682. 
Cunningham, V.J. and Robinson, D.S. (19 69), Biochem. J. 112 
203-209 .
Daae, L.N.W. and Bremer, J. (1970), Biochim. Biophys. Acta. 
210 92-104 .
Dahalla, N.S., Das, P. and Sharma, G.P. (1978), J. Mol Cell. 
Cardiol. 10 363-385.
Dahalla, N.S., Zieglhoffer, A. and Harrow, J.A. (1977), Can. 
J. Physiol. Pharmacol. 55 1211-1234.
Dart, A.M., Dietz, R ., Hieronymus, K., Kubler, W ., Mayer,
E., Schomig, A. and Strasser, R. (1984a), B r . J. Pharmacol. 
^  475-478.
Dart, A.M., Schomig, A., Dietz, R . , Mayer, E. and Kubler, W. 
(1984b), Cir. Res. 55 702-706.
Datta, N.S. and Hajra, A.K. (1984), FEBS Lett. 176 264-268. 
Dawson, R.M.C. (1966), Essays in Biochemistry 2 69-116. 
Declercq, P.E., Debeer, L.J. and Mannaerts, G.P. (1982), 
Biochem. J. 202 803-806.
198
Dennis, J. and Moore, R.M. (1938), Amer. J. Physiol. 123 
443 — 447.
Denton, R.M. and Halperin, N.L. (1968), Biochem. J. 110 
27-35.
Denton, R.M. and Randle, P.J. (1965), Nature 208 488-489. 
Denton, R.M., Randle, P.J. and Martin, B.R. (1972), Biochem, 
J. yjB 161-163.
Dobson, J.G. and Mayer, S.E. (1973), Cir. Res. 32 412-420. 
Docherty, J.R. and Reichenbacher, D. (1981), Naunyn 
Schmiedeberg's Arch.
Docherty, J.R. and Starke, K. (1981), J. Cardiovas. 
Pharmacol. 2, 854-866. Pharmacol. 316 R57.
Drew, G.M. (19 79), in 'Presynaptic Receptors, Advances in 
the Biosciences (eds Langer, S.Z., Starke, K. and 
Dubocovich, M.L.) Oxford: Pergamon Press Vol 18 pp 59-65. 
Drew, G.M. and Whiting, S.B. (1979), Br. J. Pharmacol. 67 
207-215.
Dukes, I.D. and Vaughan-Williams, E.M. (1984), Br. J. 
Pharmacol. 21  419-426.
Ebert, P.A., Allgood, R.J. and Sabistan, D.C. (1968), Ann. 
Surg. 168 728-735.
Ettinger, S., Gould, L., Carmichael, J.A. and Tashjian, R.J
(1969), Amer. Heart J. T7 636-640.
Euler, V.S. and Lishajoko, F. (1961), Acta. Physiol. Scand. 
2i 193-203.
Evans, G. (1934), J. Physiol. 21 468-480.
Evans, G.L. (1977),Thesis, University of Bristol.
Evans, G.R. (1964), Can. J. Biochem. 42 955-967.
Evans, D.E., Peschka, M.T., Leigh, R.J. and Laffan, R.J. 
(1976), Eur. J. Pharmacol. 35 17-27.
195
Exton, J.H. (1981), Mol. Cell. Endocrinol. 23 233-264.
Fain, J.N. (1973), Mol. Pharmacol. _9. 59 5-604 .
Fain, J.N. (1980), In 'Biochemical actions of Hormones' (ed
Litwack, J.) Acad. Press, New York 8 pp 119-204.
Fain, J.N. and Garcia-Sainz , J.A. /
Fain, J.N. (1984), Vitamins and Hormones ^  117-160. (1983), 
'^J. Lipid. Res. 2£ 945-941.
Fallon, H.J., Barwick, J., Lamb, R.G. and Van den Bosch, H.
(1975), J. Lipid. Res. 16 107-115.
Fallon, H.J., Lamb, R.G. and Jamdar, S.C. (1977), Biochem. 
Soc. Trans. 2  37-40.
Feola, M ., Haiderer, 0. and Kennedy, J.H. (1971), J. Surg. 
Res. U  325-341.
Fielding, P.E., Shore, V.G. and Fielding, C.J. (1977), 
Biochemistry 16 1896-1900.
Fishbein, M.C., Hare, C.A., Gissen, S.A., Spardaro, J., 
Maclean,D. and Maroko, P.R. (19 80), Cardiovas. Res. L4_
41-49.
Fisher, V.J., Martino, R.A., Harris, R.S. and Kaualer, F .
(19 69), Amer. J. Physiol. 2]J_ 1127-1133 .
Fitzgerald, J.D. (1972), in 'Effect of Acute Ischaemia on 
Myocardial Function' (eds Oliver, M.F., Julian, D.G. and 
Donald, K.W.) Churchill Livingstone, Edinburgh pp 321-351. 
Forfar, J.C., Riemersma, R.A. and Oliver, M.F. (1983), J. 
Cardiovas. Pharmacol. _5. 752-759 .
Fredrickson, D.S. (1974), Horm. Metab. Res. 2  (supp 1) 2-6. 
Fredikson, G., Stralfors, P., Nilsson, N.O. and Belfrage, P. 
(1981), J. Biol. Chem. 256 6311-6320.
Fritz, I.B. (1961), Physiol. Rev. 52-129.
Garland, P.B., Yates, D.W. and Haddock, B.A. (1970),
200
Biochem. J. 119 553-564.
2+Garrison, J.C. (1983), in 'Role of Ca -dependent protein 
kinase in réponse to alpha agonists, angiotensin II and 
vasopressin' (eds Harris, R.A. and Cornell, N.W.) Elsevier, 
Amsterdam pp 591-559.
Gartner, S.L. and Vahouny, G.V. (1973) , Proc. Soc. Exp.
Biol. Med. 143 556-560.
Gaudel, Y ., Karagueuzian, H.S. and De-Leris, J. (1979), J. 
Mol. Cell. Cardiol. 11 717-732.
Gazes, P.C., Richardson, J.A. and Woods, E.F. (1959), 
Circulation. 19_ 657-661.
Gercken, G. and Doring, V. (1973 ), J. Mol. Cell. Cardiol. _3_ 
275-286.
Gevers, W. (1984), J. Mol. Cell. Cardiol. 16 3-32.
Gibbs, L.L. (1978), Physiol. Rev. 58 174-254.
Glock, G.E. and Mclean, P. (1954), Biochem. J. 5^ 171-175. 
Gordon, R.S.,Jr., Boyle, E. and Brown, R.K. (1953), Proc. 
Soc. Exp. Biol. (New York) 84 168-172.
Gould, L ., Reddy, C.V.R., Weinstein, T. and Gomprecht, R.F.
(1975), J. Clin. Pharmacol. 12 191-197.
Gould, L ., Gomprecht, R.F. and Zahir, M. (1971), B r . Heart. 
J. 22 101-104.
Greener, J.E.M. and Kanuer, T.E. (1981), Biochim. Biophys. 
Acta. 665 306-311.
Groot, P.H.E., Scholte, H.R. and Hulsman, W.C. (1976), Adv. 
Lipid. Res. 14 75-126.
Guder, W ., Weiss, L. and Wieland, O. (1969), Biochim. 
Biophys. Acta. 187 173-185.
Gupta, D.K., Young, R ., Jewitt, D.W., Guynn, R.W., Veloso, 
D. and Veech, R.L. (1972), J. Biol. Chem. 247 7325-7331.
201
Haagsman, H.P., Dehas, C.G.M., Geelen, M.J.H. and Van Golde, 
C.M.G, (1981), Biochim. Biophys. Acta 664 74-81.
Hahn, P.P. (1943), Science 98 19-21.
Hajra, A.K. (1977), Biochem. Soc. Trans. 5 34-36.
Haidar, D. (1978), Fed. Proc. 37 1494-1499.
Haidar, D., Tso, W. and Pullman, M.E. (1979), J. Biol. Chem. 
254 4502-4509.
Hamid, M.A., Lech, J.J., Barboriak, J.J. and Calvert, D.N. 
(1973), Biochem. Pharmacol. 22 2165-2170.
Hancock, A.A., Lean, A.L.de, and Lefkowitz, R.J. (1979),
Mol. Pharmacol. 16 1-9.
Harano, Y ., Kowal, J., Yamazaki, R ., Lavine, L. and Miller, 
M. (1972), Arch. Biochem. Biophys. 153 426-437.
Hartog, M. and Opie, L.H. (1969), Lancet 1 1209-1213.
Hearse, D.J. (1977), J. Mol. Cell. Cardiol. 2  605-616. 
Hedberg, A., Minneman, K.P. and Molinoff, P.B. (1980), J. 
Pharmacol. Exp. Ther. 212 503-508.
Henderson, A.H., Most, A.S. and Sonnenblick, E.H. (1969), 
Lancet 2 825-826.
Himwich, H.E., Goldfarb, W. and Nahum, L.H. (1934), Amer.J. 
Physiol. 109 403-408.
Hirche, H.J., Franz, C.H.R., Bos, R., Bissig, R . , Lang, R. 
and Schramm, M. (1980), J. Mol. Cell. Cardiol. _12 579-593. 
Hjalmarso, A. (1980), Cardiol.^  226-247.
Ho, S.J., Ho, R.J. and Meng, H.C. (1967), Amer. J. Physiol. 
212 284-290.
Hoffman, B.B. and Lefkowitz, R.J. (1980), Ann. Rev. 
Pharmacol. Toxicol. 22. 581-608.
Holmgren, S., Abrahamsson, T., Almgren, O. and Eriksson, 
B-M. (1981), Cardiovas. Res. 15 680-689.
202
Hosaka, K., Schiele, V. and Numa, S. (1977), Eur. J. 
Biochem. _76 113-118.
Howse H.D., Ferrans,V.J. and Hibbs,R.G. (1970), J. Mol. 
Cell. Cardiol. _9_ 733-748.
Hron, W.T., Jesmok, G.J., Lombardo, Y.B., Menham, L.A. and 
Lech, J.J. (1977), J. Mol. Cell. Cardiol. 9̂ 733-748.
Hron, W.T., Menham, L.A. and Lech, J.J. (1978), J. Mol. 
Cell. Cardiol. 12 764-766.
Hubscher, G. (1970), in 'Lipids' (ed Wakhill) Acad. Press, 
London, pp 279.
Hulsmann, W.C. and Stam, H. (1978), Biochem. Biophys. Res. 
Commun. 82 53-59.
Huttunen, J.K., Aquino, A.A. and Steinberg, D. (1970), 
Biochim. Biophys. Acta. 224 29 5-29 8.
Huttunen, J.K. and Steinberg, D. (1971), Biochim. Biophys. 
Acta. 239 411-427.
203
Ilebekk, A. and Lekven, J. (1974), J. Clin. Invest. 33 
153-161.
Ilebekk, A. and Mjos, O.D. (1973), Acta. Physiol. Scand. 87 
44A-45A.
Imai, S., Riley, A.L. and Berne, R.M. (1964), Circ. Res. 15 
443-450.
Iverson, L.L. (19 77), in 'Handbook of Psychopharmacology' 
(eds, Iverson, L.L., Iverson, S.D. and Snyder, S.H.) vol 3 
New York, Plenum Press pp 381-442.
Jakobs, K.H. (1979), Mol. Cell. Endocrinol. 16 147-156. 
Jakobs, K.H., Arktories, K ., Lasch, P., Saur, W. and 
Schultz, G. (1980), in 'Hormones and Cell Regulation' vol 4 
(eds Dumont, J. and Nunez, J.)
Jamdar, S.C. and Fallon, H.J. (1973), J. Lipid Res. 14 
507-516.
Jamdar, S.C., Moon, M . , Bow, S. and Fallon, H.J. (1978), J. 
Lipid Res. 19(6) 763-770.
Elsevier/North Holland, Amsterdam, pp 89-106.
Jakobs, K.H., Arktories, K. and Schultz, G. (1981), Adv. 
Cyclic Nucleotide Res. 14 173-187.
Jakobs, K.H. and Schultz, G. (1980), Trends Pharmacol. Sci. 
2  331-333.
Jarrott, B., Louis, W.H. and Summers, R.J. (1979 ), B r . J. 
Pharmacol. ^5^ 663-670.
Jason, C.J., Polokoff, M.A. and Bell, R.M. (1976), J. Biol. 
Chem. 251 1488-1492.
Jennings, R.B., Sommers, H.M., Smyth, G.A., Flack, H.A. emd 
Linn, H. (1960), Arch. Pathol. 70 68-78.
204
Jesmok, G.J., Calvert, D.N. and Lech, J.J. (1977), J. 
Pharmacol. Exp. Ther. 200 187-194.
Jesmok, G.J., Mogelnicki, S.R., Lech, J.J. and Calvert, D.N.
(1976), J. Mol. Cell. Cardiol. 8_ 283-298.
Jones, C.L. and Hajra, A.K. (19 76), Fed. Proc. Am. Soc. Exp. 
Biol. 35 1724-1736.
Jones, C.L. and Hajra, A.K. (1977), Biochem. Biophys. Res. 
Commun. 76 1138-114 3.
Joseph, S.K., Thomas, A.P., Williams, R.J., Irvine, R.P. and 
Williams, J.P. (1984), J. Biol. Chem. 2 ^  3077-3081.
Julien, D.G. and Oliver, M.F. (eds, 1968), in 'Acute 
Myocardial Infarction', Livingstone, London.
Kako, K.J. and Liu, M.S. (1974), FEBS Lett. 39_ 243-246.
Kako, K.J. and Patterson, S.D. (1975), Biochem. J. 152 
313-323.
Kako, K.J., Zarov-Behrens, G. and Peckett, S.D. (1977), Can. 
J. Biochem. 55 308-314.
Kane, K.A., McDonald, F.M. and Parratt, J.R. (1979 ), Br. J. 
Pharmacol. 66 463-464.
Kannengeiser, G.J., Lubbe, W.F. and Opie, L.H. (1975), J. 
Mol. Cell. Cardiol. 135-151.
Karapati, P., Preda, I. and Endroczi, E. (1974), Acta. 
Physiol. Acad. Sci. Hung. 45 109-114.
Karlsberg, R.D., Penkoske, P.A., Cryer, P.E., Corr, P.B. and 
Roberts, R. (1979 ), Cardiovas. Res. _13_ 523-531. 
Karwatowska-Kryna, E. and Beresewicz, A. (1983), J. Mol. 
Cell. Cardiol, 523-536.
Katz, A.M. (1977), in 'The physiology of the Heart' Raven 
Press, New York.
Kaumann, A.J. and Birnbaumer, L. (1974), J. Biol. Chem. 249
206
40-100.
Kobinger, W. and Pichler, L. (1980), Eur. J. Pharmacol. 65 
393-402.
Kobinger, W. and Pichler, L. (1982), J. Cardiovas.
Pharmacol. 4 581-585.
Kompiang, P.I., Bensdoun, A. and Yang, M-W.W. (1976), J. 
Lipid Res. 498-505.
Kopec, B. and Fritz, I.B. (1973), J. Biol. Chem. 24 8 
4069-4074.
Krasnov, N ., Neill, W.A. and Messer, J.V. (1962), J. Clin. 
Invest. 41 2075-2085.
Krause, E.G. and Wollenberger, A. (1967), Acta. Biol. Med. 
Germ. _19 331-338.
Krause, E.G., Ziegelhoffer, A., Fedelesova, M ., Styk, J., 
Kostolansky, S. Galauer, I., Blasig, I. and Wollenberger, A. 
(1978), Adv. Cardiol. 25 119-129.
Krebs, H.A. and Hensleit, K. (1932), Hoppe-Seylers Physiol. 
Chem. 210 33-36.
Kreisberg, R.A. (1966), Amer. J. Physiol. 210 385-389. 
Kruger, F.A. and Leighty, E. (1967), J. Clin. Invest. 46 
1080-1081.
Kubler, W. (1974), Basic Res. Cardiol. J59_ 105-113.
Kubler, W. and Speickerman, P.G. (1970), J. Mol. Cell. 
Cardiol. _1 351-377.
La Belle, E.F. and Hajra, A.K. (1974), J. Biol. Chem. 249 
6936-6944.
Lafontan, M. and Berlan, M. (1980), Eur. J. Pharmacol. 66 
87-93.
Lamb, R.G. and Fallon, H.J. (1970), J. Biol. Chem. 245 
3075-3083.
207
Lamb, R.G. and Fallon, H.J. (1974), Biochim. Biophys. Acta. 
348 166-178.
Lands, A.M., Arnold, A., McAnliff, J.P., Luduena, F.P. and 
Brown, T.C. (19 67), Nature 214 597-598,
Lands, A.M. and Hart, P. (1965), J. Biol. Chem. 240 
1905-1911
Langer, S.Z. (1974), Biochem. Pharmacol. 23 1793-1800. 
Langer, S.Z. (1977), Br . J. Pharmacol. ^  481-497.
Langer, S.Z. (1980), Trends Neurosci. _3. 110-112.
Langer, S.Z. (1981), Pharmacol. Rev. 3^ 337-362.
Langer, S.Z., Massingham, R. and Shepperson, N.B. (1980), 
Clin. Sci. 59 225S-228S.
Langer, S.Z. and Shepperson, N.B. (1982), Trends Pharmacol. 
Sci . _3 440-444.
Lassers, B.W., Kaijser, L. and Carlson, L.A. (1972), Eur. J. 
Clin. Invest. _2̂ 348-358.
Lassers, B.W., Wahlquist, M.L., Kaijser, L. and Carlson,
L.A. (1971), Lancet 2448-450.
Lawson, N . , Pollard, A.D., Jennings, R.J., Gurr, M.I. and 
Brindley, D.N. (1981), Biochem. J. 200 285-294.
Lea, M.A. and Weber, G. (1968), J. Biol. Chem. 243 
1096-1102.
Ledda, F. and Mantelli, L. (1984), Br. J. Pharmacol. 81 
491-497.
Lefkowitz, R.J. and Hoffman, B.B. (1980), Trends Pharmacol. 
Sci. ±  314-318.
Lefkowitz, R.J., Murkherjee, C., Coverstone, M. and Caron, 
M.G. (1974), Biochem. Biophys. Res Commun. 60 703-709. 
Leimdorfer, A. (1953), Archs. Int. Pharmacol. Ther. 94 119 
and 249 .
208
Lekven, J . , Kjekshus, J.K. and Mjos, O.D. (1973), Scan. J. 
Clin. Lab. Invest. 32 129-139.
Lekven, J., Kjekshus, J.K. and Mjos, O.D. (1974), Scand. J. 
Clin. Lab. Invest. _32 161-173.
Lekven, J., Mjos, O.D. and Kjekshus, K.J. (1973), Amer. J. 
Cardiol. 2 1  467-474.
Leiris, J-De., Opie, L.H. and Lubbe, W.F. (1975), Nature 253 
746-747.
Levitzki,A. (1981), CRC. Crit. Rev. Biochem. 1^ 81-112. 
Levitzki, A., Atlas, D. and Steer, M.L. (1974), Proc. Nat. 
Acad. Sci. U.S.A. _71 2773-2776.
Levitzki, A. and Helmriech, E.J.M. (1979), FEBS Lett. 101
213-219.
Liedtke, A.J., Nellis, S. and Neely J.R. (1978), Cir. Res.
43 652-661.
Litosch, I., Lin, S-H. and Fain, J.N. (1983), J. Biol. Chem. 
258 13727-13732
Liu, M.S. and Kako, K.J. (1974), Biochem. J. 138 11-21. 
Lloyd-Davies, K.A. and Brindley, D.N. (1975), Biochim. 
Biophys. Acta. 487 212-221.
Lorenz, R.R. and Vanhoutte, P.M. (1975), J. Physiol. 246 
479-500.
Lossow, W.J., Brown, G.W. and Chaikoff, I.L. (1956), J.
Biol. Chem. 2 ^  839-849.
Lubbe, W.F., Muller, C.A., Worthington, M . , McFadyen, E.L. 
and Opie, L.H. (1981), Cardiovas. Res. 15 690-699.
Lubbe, W.F., Podzuwiet, T., Daries, P.S. and Opie, L.H. 
(1978), J. Clin. Invest. 1260-1269.
Mahaderan, S. and Tappel, A.L. (1968), J. Biol. Chem. 248 
2849-2854.
209
Mahler, H.R. and Cordes, E.H. (1966), In 'Biological 
Chemistry', 1^^ edition. Harper and Row, New York.
Malik, K.V. (1978), Fed. Proc. 37 204-207.
Manganiello, V.C., Murad, F. and Vaughan, M. (1971), J.
Biol. Chem. 246 2195-2202.
Manning, A.S. and Hearse, D.J. (1984), J. Mol. Cell.
Cardiol. 497-518.
Manning, A.S., Keough, J.M., Hearse, D.J. and Coltart, J. 
(1980), Cardiovas. Res. 14. 619-623.
Mansour, T.E. (1963), J. Biol. Chem. 228 2285-2292.
Maroko, P.R., Kjekshus, J.K., Sobel, B.E., Watanabe, T., 
Covell, J.N., Ross, J. and Braunwald, E. (1971), Circulation 
43 67-82.
Marshall, R.J. and Parratt, J.R. (1976), B r . J. Pharmacol.
57 29 5-303.
Martin, B.R., Denton, R.M., Pask, H.T. and Randle, P.J.
(1972), Biochem. J. 129 763-773.
Mason, R.J. (1978), J. Biol. Chem. 253 3367-3370.
Mayer, S.E. (1972), J. Pharmacol. Exp. Ther. 181 116-125.
Mayer, S.E. (1974), Circ. Res. %4 and 3^ supp 1 III 129-135.
Mayer, S.E., Namm, D.H. and Rice, L. (1970), Circ. Res. 26
225-233.
Mayes, P.A. and Felts, J.M. (1967), Nature 215 716-718. 
McGarry, J.D. and Foster, D.W. (1971a), J. Biol. Chem. 246 
6247-6253.
McGarry, J.D. and Foster, D.W. (1971b), J. Biol. Chem. 246 
1149-1159.
McGarry, J.D. and Foster, D.W. (1980), Ann. Rev. Biochem. 49 
39 5-420.
McGarry, J.D., Leatherman, G.F. and Foster, D.W. (1978a), J.
210
Biol. Chem. 2 ^  4128-4136.
McGarry, J.D., Mannaerts, G.P. and Foster, D.W. (1977), J. 
Clin. Invest. ^  265 270.
McGarry, J.D., Mannaerts, G.P. cmd Foster, D.W. (1978b), 
Biochim. Biophys. Acta. 530 305-313.
McGarry, J.D., Mills, S.E., Long, L.S. and Foster, D.W.
(1983), Biochem. J. 2}A 21-28.
McGarry J.D., Stark, M.J. and Foster, D.W. (1978c), J. Biol. 
Chem. 2 ^  8291-8293.
McGrath, J.C. (1982), Biochem. Pharmacol. 21 467-484. 
McGrath, J.C. (1983), Trends Pharmacol. Sci. _1_ 14-18. 
McGrath, J.C., Lim, S.P. and Leversha, L. (1981),
Cardiovas. Res. _1A 28-34.
Michell, R.H. and Kirk, C.J. (1981), Trends Pharmacol. Sci.
_2 86-89 .
Minneman, K.P., Pittman, R.W. and Molinoff, P.B. (1981),
Ann. Rev. Neurosci. 4̂ 419-461.
Miura, Y., Inui, J. and Imamura, H. (1978), 
Naunyn-Schmiedeberg's Arch. Pharmacol. 301 201-205.
Monroy, G . , Kelker, H.G. and Pullman, M.E. (1973), J. Biol. 
Chem. 2^8 2845-2852.
Monroy, G., Rola, H. and Pullman, M.E. (1972), J. Biol.
Chem. 247 6884-6894.
Moore, G. and Parratt, J.R. (1973), Cardiovas. Res. 7 
446-457.
Morgan, H.E., Henderson, M.J., Regen, D.M. and Park, L.R. 
(1961), J. Biol. Chem. 236 253-261.
Morgan, H.E. and Parmeggiani, A. (1964), J. Biol. Chem. 247 
2440-2445.
Most, A.S., Brachfeld, N., Gorlin, R. and Wahren, J. (1969),
211
J, Clin. Invest. 2®. 1177-1188.
Most, A.S., Capone, R.J., SzydliJc, P., Bruno, C. and Devona, 
T.S. (1974), Cardiol. 59 201-213.
Muhtaseb, A1-, N. (1982), Thesis, University of Bath.
Muir, A.R. (1971), in 'The Mammalian Heart' (eds Head, J.J. 
and Lowenstein, O.E.) Oxford University Press, London.
Murad, F., Chi, Y.,Rall, T.W. and Sutherland, E.W. (1962),
J. Biol. Chem. 2^7 1233-1238.
Murthy, V.K. and Shipp, J.C. (1980), J. Mol. Cell. Cardiol. 
12 299-309
Nahorski, S.R. (1981), Trends Pharmacol. Sci. 2 95-98. 
Nayler, W.G., Fassold, E. and Yepez, C. (1980), Cardiovas. 
Res. 12 152-161.
Neely, J.R., Browman, R.H. and Morgan, H.E. (19 69), Amer. J. 
Physiol. 216 804-811.
Neely, J.R. and Morgan, H.E. (1974), Ann. Rev. Physiol. 36 
413-459.
Neely, J.R., Rovetto, M.J. and Oram, J.F. (1972a), Prog. 
Cardiovas. Diseases 21  389-399.
Neely, J.R., Rovetto, M.J. and Oram, J.F. (1972b), Prog. 
Cardiovas. Diseases 25. 289-329 .
Neely, J.R., Rovetto, M.J., Whitmer, J.T. and Morgan, H.E.
(1973), Amer. J. Physiol. 225 651-658.
Nilsson-Ehle, P., Garfinkel, A. and Schotz, M.C. (1980),
Ann. Rev. Biochem. _49 667-69 3.
Nimmo, H.G. (1979), Biochem. J. 177 283-288.
Nimmo, H.G. and Houston, B. (1978), Biochem J. 176 607-610. 
Norum, K.R. (1965), Biochim. Biophys. Acta. £8. 652-654.
Numa, S. and Yamashita, S. (1974), Curr. Topics in Cell Reg. 
A  19 7-210.
212
O'Doherty, P.J.A. (1978), in 'Handbook of Lipid Research (ed 
Kuksis, A.) New York and London Plenum press 289-339.
Okuda, H ., Yanagi, I., Sek, F.J. and Fujii, S. (1970), J. 
Biochem. ^8_ 199-203.
Oliver, M.F. (1972), Cir. 4^ 491-500.
Oliver, M.F. (1974), Adv. Cardiol. 12̂  84-93.
Oliver, M.F., Kurien, V.A. and Greenwood, T.W. (1968),
Lancet 7545 710-715.
Olson, R.E. (1962 ), Nature 29_5 597-599 .
Olson, R.E. and Hoeschen, R.J. (1967), Biochem. J. 103 
796-801.
Olsson, R.A. (1970), Circul. Res. _26 301-306.
Ontko, J.A. (1972), J. Biol. Chem. 2 ^  1788-1800.
Ontko, J.A. (1973), J. Lipid Res. 14 78-86.
Opie, L.H. (1965), J. Physiol. (London) 1 ^  529-541.
Opie, L.H. (1968), Amer. Heart J. 76 685-698.
Opie, L.H. (1969), Amer. Heart J. 77 383-410.
Opie, L.H. (1976), Circul. Res. 2® supp. 1 52-68.
Opie, L.H., Evans, J.R. and Shipp, J.C. (1963), Amer. J. 
Physiol. 205 1203-1208.
Opie, L.H., Norris, R.M., Nathan, D. and Lubbe, W.F. (1979), 
Amer. J. Cardiol. 113-148.
Opie, L.H., Norris, R.M., Thomas, M., Holland, A.J., Owen,
P. and Van Noorden, S. (1971), Lancet 1 818-822.
Opie, L.H., Owen, P. and Riemersma, R.A. (1973), Eur. J. 
Clin. Invest. 2 419-436.
Opie, L.H., Thomas, M . , Owen, P. and Shulman, G. (19 72), 
Amer. J. Cardiol. 2® 503-514.
Oram, J.F., Bennetch, S.L. and Neely, J.R. (1973), J. Biol.
213
Chem. 248 5299-5309.
Palmer, W.K., Caruso, R.A. and Oscai, L.B. (1981), Biochem. 
J. 198 159-166.
Palmer, W.K. and Kane, T.A. (1983), Biochem J. 212 379-383. 
Pande, S.V. (1971), J. Biol. Chem. 246 5384-5390.
Pande, S.V. and Blancher, M.C. (1970), Biochim. Biophys. 
Acta. 202 43-48.
Pande, S.V. and Mead, J.F. (1968), J. Biol. Chem. 243 
6180-6185.
Patelsky, J . Walligora, Z. and Szula, S. (1967), J. 
Athersclerosis Res. 7 453-459.
Pearle, D.L., Williford, D. and Gillis, R.A. (1978), Amer.
J. Cardiol. _42 960-964.
Pederson, M.E. and Schotz, M.C. (1980), J. Nutr. 110 
481-487.
Pederson, M.E., Slinde, E., Grynne, B. and Aas, M. (1975), 
Biochim. Biophys. Acta. 39 8 191-203.
Pederson, M.E., Wolf, L.E. and Schotz, M.C. (1981), Biochim. 
Biophys. Acta. 666 191-197.
Penparagkul, S. and Scheuer, J. (1970), J. Clin. Invest. 49 
1859-1868.
Pentecost, B.L. and Austen, W.O. (1966), Amer. Heart J . 72 
790-796.
Perlmutter, M. (1947), J. Biol. Chem. 171 419-429.
Pichler, L. and Koblinger, W. (1978), Eur. J. Pharmacol. 52 
287-295.
Picken, G.M. and Jarrett, B. (1975), Biochem. Pharmacol. 24 
2255-2261.
Pieper, G.M., Todd, G.L., W u , S.T., Salhany, J.M., Clayton,
F.C. and Elliot, R.S. (1980), Cardiovas. Res. 14 646-653.
Pikkukangas, A.H., Vaananen, R.A., Savrolainen, M.J. and 
Hassinen, I.E. (1982), Arch. Biochem. Biophys. 217 216-225. 
Pittman, R.C., Golanty, E. and Steinberg, D. (1972),
Biochim. Biophys Acta. 270 81-85.
Pittman, R.C., Khoo, J.C. and Steinberg, D. (1975), J. Biol. 
Chem. 2AP 450 5-4511.
Podzuweit, T., Dalby, A.J., Cherry, G.W. and Opie, L.H.
(1978), J. Mol. Cell. Cardiol. 10 81-94.
Puig, M. and Kirpekar, S.M. (1971), J. Pharmacol. Exp. Ther. 
170 134-138.
Racker, E. (1954), Adv. Enzmol. 15 141-182.
Ramadoss, C.S., Uyeda, K. and Johnston, J.N. (19 76), J.
Biol. Chem. 251 98-107.
Randle, P.J., England, P.J. and Denton, R.M. (1970), Biochem 
J. 217 677-695.
Regen, T.J., Markov, A., Oldewurtel, H.A. and Burke, W.M.
(1970), Cardiovas. Res. 2. 334-342.
Reinhart, P.H., Taylor, W.M. and Bygrave, F.L. (1984), 
Biochem. J. 233 1-13.
Rider, M.H. and Saggerson, E.D. (1983a), Biochem. J. 214
235-246.
Rider, M.H. and Saggerson, E.D. (1983b), Biochem. J. 176 
607-610.
Riemersma, R.A. and Forfar, C.J. (1982), in 'Catecholamines 
in the non-ischaemic and ischaemic myocardium' (eds 
Riemersma, R.A. and Oliver, M.F.) Elsevier, North Holland
Biomedical Press pp 139-153.
Rizack, M.A. (1961), J. Biol. Chem. 236 657-662.
Rizack, M.A. (1964), J. Biol. Chem. 239 392-395.
Robinson, D.S. (1963), Advan. Lipid. Res. 1 133-139.
215
Robinson, D.S. (1970), Compr. Biochem. 18 51-116.
Robinson, D.S. and French, J.E. (1960), Pharmacol. Rev. 12 
241-263.
Robinson, D.S. and Jennings, M.A. (1965), J. Lipid. R es. 6 
222-227.
Robinson, J. and Newsholme, E.A. (1967), Biochem. J. 104 
2C-4C.
Robinson, J. and Newsholme, E.A. (19 68), Mol. Pharmacol. 4 
522-530.
Robinson, I.N. and Zammit, V.A. (1982), Biochem. J. 206 
177-179.
Robison, G.A., Butch, R.W., Oye, I., Morgan, H.E. and 
Sutherland, E.W. (1965), Mol. Pharmacol. 1 168-177.
Rodbell, M. (1980), Nature 284 17-22.
Rognstad, R., Clark, D.G. and Katz, J. (1974), Biochem. 
Biophys. Acta. 140 249-251.
Rosen, P., Buddie, T.H. and Rienauer, H. (1981), J. Mol. 
Cell. Cardiol. 2 1  539-550.
Rosenfeld, J., Rosen, M.R. and Hoffman, B.F. (1978), Amer.
J. Cardiol. 21 1075-1082.
Rovetto, M.J., Lamberton, W.F. and Neely J.R. (1975),
Circul. Res. 2Z 742-751.
Rovetto, M.J., Whitmer, J.T. and Neely, J.R. (1973), Circul. 
Res. 2 2  699-711.
Rowe, M.J., Neilson, J.M.N. and Oliver, M.F. (1975), Lancet 
_2 295-300.
Rutenberg, H.L., Parmintuan, J.C. and Soloff, L.A. (1969), 
Lancet 2 559-564.
Saggerson, E.D. (1982), Biochem. J. 202 397-405.
Saggerson, E.D. and Carpenter, C.A. (1982), Biochem. J. 208
216
673-678..
Saggerson, E.D. and Carpenter, C.A. (1981) FEBS Lett. 129 
229-232.
Saggerson, E.D., Sooranna, S.R. and Cheng, C.H.K. (1979), 
INSERM. Colloq. ST. 223-238.
Sakai, K. and Spieckerman, P.G. (1975), Naunyn 
Schmiedeberg's Arch. Pharmacol. 291 123-130.
Schatz, J. (1965), Fed. Proc. Abstr. 24. 552-558.
Schettler, F.G. and Boyd, G.S. (eds, 1969), 
'Atherosclerosis', Elsevier, Amsterdam.
Scheuer, J. (1967), Amer. J. Cardiol. 19. 385-392.
Scheuer, J. (1972), J. Mol. Cell. Cardiol. £689-692. 
Scheuer, J. and Oison, R.E. (1967), Amer. J. Physiol. 212 
301-307.
Schlossman, D.M. and Bell, R.M. (1977), Arch. Biochem. 
Biophys. 182 732-742.
Schlossman, D.M. and Bell, R.M. (1978), J. Bacteriol. 133 
1368-1376.
Schmitt, H. (1971), Actual Pharmacol. 24 93-131.
Schomig, A., Dart, A.M., Dietz, R., Mayer, E. and Kubler, W
(1984), Circul. Res. 55 689-701.
Schotz, M.C., Twu, J-S., Pederson, M.E., Chen, C-H., 
Garfinkel, A.S. and Borenstajn, J. (1977), Biochim. Biophys 
Acta. 489 214-224.
Schultz, G., Hardman, J.G., Schultz, K., Baird, C.E. and 
Sutherland, E.W. (1973), Proc. Nat. Acad. Sci. U.S.A. 70 
3889-3893.
Schultz, G. and Jakobs, K.H. (1981), in 'Catecholamines in 
the non-ischaemic and ischaemic myocardium' (eds Riemersma, 
R.A. and Oliver, M.F.) Elsevier Biomed Press Oxford pp
217
107-117.
Schultz, G., Schultz, K, and Hardman, J.G. (1975),
Metabolism 24 429-437.
Schwartz, J.P. and Jungas, R.L. (1971), J. Lipid. Res. 12 
553-562.
Scott, J.E. (19 68), In 'Chemistry and Physiology of 
Mucopolysacharides' pp 171-187 (ed Quintarelli, G)
Sethi, V., Haider, B., Ahmed, S., Oldewurtel, H.A. and 
Regen, T.J. (1973), Cardiovas. Res. 7 740-747.
Severson, D.L. (1979), J. Mol. Cell. Cardiol. £1 569-583. 
Severson, D.L. (1979b), Can. J. Physiol. Pharmacol. 57(9) 
924-937.
Severson, D.L. and Hurley, B. (1982), J. Mol. Cell. Cardiol. 
14 467-474.
Severson, D.L., Khoo, J.C. and Steinberg, D. (1977), J.
Biol. Chem. 2 ^  1484-1489 .
Severson, D.L., Lefebure, F.T. and Sloan, S.K. (1980), J. 
Mol. Cell. Cardiol. 12 977-992.
Shahab, L.R., Hasse, M., Schiller, V.R. and Wollenberger,
A . (1969), Acta. Biol. Med. Germ. 19 9 39-9 59.
Shahab, L.R. and Wollenberger, A (1967), Acta. Biol. Med. 
Germ. £7. 541-549 .
Shahab, L.R., Wollenberger, A., Krause, E.G. and Genz, S.
(1972), in 'Effects on Acuta Ischaemia on Myocardial 
Function' (eds Oliver, M.F., Julian, D.G. and Donald, K.W.) 
Churchill Livingstone, Edinburgh pp 97-108.
Sharma, A.D., Saffitz, J.E., Lee, B.J. and Sobel, B.E.
(1983), J. Clin. Invest. 72 802-818.
Shayman, J.A., Kramer, J.B. and Corr, P.B. (1980), 
Circulation 62 supp. Ill 149.
218
Sheridan, D.J., Penkoske, P.A., Sobel, B.E. and Corr, P.B.
(1980), J. Clin. Invest. 65 161-171.
Shipp, J.C., Menahan, L.A., Crass, M.F. and Chaudhuri, S.N. 
(19 73), in 'Recent advances in studies on cardiac structure 
and metabolism' vol 3 (ed Dhalla, N.S.) Baltimore Univer. 
Park Press pp 179-204.
Shipp, J.C., Opie, L.H. and Challoner, D. (1961), Nature 189 
1018-1019.
Shipp, J.C., Thomas, J.M. and Crevasse, L. (1964), Science 
143 371-373.
Shore, B., Nichols, A.V. and Freeman, N.K. (1953), Proc.
Soc. Exp. Biol. (New York) 83 216-220.
Shousboe, I., Bartels, P.O. and Jensen, P.K. (1973), FEBS 
Lett. 15 279-283.
Shug, A.L. and Shrago, E. (1973), J. Lab. Clin. Med. 81
214-219 .
Siegmund, W ., Lepan, I. and Szekres, L. (19 79), Acta. 
Physiol. Hung. 53 209-217.
Siggers, D.C., Salter, C. and Fluck, D.C. (1971), Br. Heart 
J. ^  878-883 .
Sobel, B.E. (1974), Cir. Res. 34-5 (supp. Ill) 173-181. 
Soderling, T.R., Corbin, J.D. and Park, C.R. (1973), J.
Biol. Chem. 248 1822-1829.
Solar-Argilaga, L ., Russel, R.L. and Heimberg, M. (1978), 
Arch. Biochem. and Biophys. 190 367-372.
Sooranna, S.R. and Saggerson, E.D. (1975), Biochem. J. 150 
144-151.
Sooranna, S.R. and Saggerson, E.D. (1976) FEBS Lett. 64 
36-39 .
Sooranna, S.R. and Saggerson, E.D. (1978), FEBS Lett. 90
219
141-144.
Spies, C., Schultz,K.D. and Schultz, G. (1980), Naunyn 
Schmiedeberg's Arch. Pharmacol. 311 71-77.
Stade, W.C., Haugaard, N. and Perlmulttler, M. (1947), J. 
Biol. Chem. 171 419-429.
Stakkestad, J.A. and Bremer, J. (1983), Biochim. Biophys. 
Acta. 750 244-252.
Stam, H. and DeJong, J.W. (1977), J. Mol. Cell. Cardiol. 9 
633-650.
Starke, K. (1971), Naturwissenschaften 5£ 420-429.
Starke, K. (1972a), Naunyn Schmiedeberg's Arch. Pharmacol. 
27 4 18-45.
Starke, K. (1972b), Naunyn Schmiedeberg's Arch. Pharmacol. 
275 11-23.
Starke, K. (1977), Rev. Physiol. Biochem. Pharmacol. 77 
1-124.
Starke, K. (1981), Rev. Physiol. Biochem. Pharmacol. 88 
199-236.
Starke, K . , Borowski, E. and Endo, T. (1975), Eur. J. 
Pharmacol. 3£ 385-388.
Starke, K. and Langer, S.Z. (1979), in 'Presynaptic 
Receptors, Advances in the Biosciences' (eds Langer, S.Z., 
Starke, K. and Dubocovich, M.L.) Pergamon Press, Oxford, vol 
18 pp 1-3
Starke, K ., Montel, H. and Schumann, H.J. (1971a), Naunyn 
Schmiedebergs Arch. Pharmacol. 270 210-214.
Starke, K., Montel, H. and Wagner, J. (1971b), Naunyn 
Schmiedeberg's Arch. Pharmacol. 271 181-19 2.
Staszewska-Barczak, J. (1971), Clin. Sci. ^  419-439.
Stein, 0. and Stein, Y. (1963), Biochem. Biophys. Acta 72
220
517-530.
Steinberg, D. (1978), Mol. Biol, and Pharmacol, of Cyclic 
Nucleotides 95-108^Steinberg, D. and Huttunen, J.K. (1970),
J. Lipid Res. !£ 68-69.
Stephens, T.W., Cook, G.A. and Harris,R.A. (1983), Biochem.
J. 212 521-524 .
Stern, W. and Pullman, M.E. (1978), J. Biol. Chem. 253 
8047-8055.
Stjarne, L. (1975), in 'Handbook of Psychopharmacology (eds 
Iverson, L.L., Iverson, S.D. and Snyder, S.H.) Plenum, New 
York, vol 6 pp 179-233.
Stjarne, L. and Brundin, J. (1975), Acta. Physiol. Scand. 94 
139-141.
Stralfors, P. and Belfrage, Per. (1983), J. Biol. Chem. 258 
15146-15152.
Streb, H ., Irvine, R.F., Berridge, M.J. and Schultz, I.
(1983), Nature 306 67-69.
Summers, R.J. (1980), Br. J. Pharmacol. 71_ 57-63.
Sundin, U. and Fain, J.N. (1983), Biochem. Pharmacol. 32 
3117-3118.
Szekeres, L. (1978), Adv. Pharmac. Ther. £257-269.
Takai, Y ., Kikkawa, U., Kaibuchi, K. and Nihizuka, Y .
(1984), Adv. Cyclic Nucleotide Res.
Tanaka, T. and Starke, K. (1980), Eur. J. Pharmacol. 63 
191-194.
Tanaka, T. (1979), Eur. J. Biochem. 9J. 165-170.
Teng, M. and Kaplan, A. (1974), J. Biol. Chem. 249 
1064-1070 .
Thandroyan, F.T., Worthington, M.G., Higgenson, L. and Opie, 
L.H. (1983), J. Amer. Coll. Cardiol. 1(4) 1056-1066.
221
Thomas, M., Holland, A.J., Owen, P. and van Noorden, S.
(1971), Lancet £  (7704) 818-822.
Timmermans, P.B.M.W.M., Kwa, H.Y. and Van Zwieten, P.A.
(1979), Naunyn Schmiedeberg's Arch. Pharmacol. 310 189-193. 
Timmermans, P.B.M.W.M. and Van Zwieten, P.A. (1981), J.
Auton. Pharmacol. _£ 171-18 3.
Timmermans, P.B.M.W.M. and Van Zwieten, P.A. (1982), J. Med. 
Chem. £5 1389-1401.
Tornquist, H. and Belfrage, P. (1976), J. Biol. Chem. 251 
813-819.
Tsai, S.C. and Vaughen, M. (1974), Fed. Proc. 33 1526-1530. 
Tubbs, P.K. and Garland, P.B. (1964), Biochem. J .93 550-557. 
Twu, J.S., Garfinkel, A.S. and Schotz, M.C. (1975), 
Atherosclerosis 22 463-472.
Twu, J.S., Garfinkel, A.S. and Schotz, M.C. (1976), 
Atherosclerosis 24 119-128.
Tzur, R ., Tal, E. and Shapiro, B. (1964), Biochim. Biophys. 
Acta. £ £  18-23.
Valori, C ., Thomas, M. and Shillingford, J.P. (1967), Amer.
J. Cardiol._2ÇL 605-617 .
Van der Vusse, G.J. (1983), J. Drug Res. £  1578-1583.
Van der Vusse, G.J., Roemen, T.H.M., Prinzen, F.W., Coumans, 
W.A. and Reneman, R.S. (1982), Cir. Res. ^  538-546.
Van Toi, A. (1975), Mol. Cell. Biochem. %  19-31.
Van Toi, A. and Hulsman, W.C. (19 69), Biochim. Biophys.
Acta. 189 342-353.
Van Zwieten, P.A. and Timmermans, P.B.M.W.M. (1983), J. Mol. 
Cell. Cardiol. 15 717-733.
Vargaftig, B. and Coignet, J.L. (1969), Eur. J. Pharmacol. £
222
49-55.
Vaughan, M., Berger, J.E. and Steinberg, D. (1964), J. Biol. 
Chem. 239 401-409.
Vaughan, M. and Steinberg, D. (1963), J. Lipid. Res. 4 
193-199.
Vavrinkova, H. and Nosinger, B.(1974), Physiol. Bohemoslove 
23 187-190.
Verine, A., Guidicelli, H. and Bayer, J. (1974), Biochim. 
Biophys. Acta. 369 125-128.
Victor, T., Cook, la,C. and Lochner, A. (1984), J. Mol.
Cell. Cardiol. 16 709-721.
Videbaek, J . , Christensen, N.J. and Sterndorff, A. (1972), 
Circulation 46 846-855.
Vizi, E.S. (1979), Prog. Neurobiol. 12 181-290.
Wagner, J. and Brodde, O.E. (1978), Naunyn Schmiedeberg's 
Arch. Pharmacol. 302 239-254.
Wakade, A.R. and Furchgott, R.F. (1968), J. Pharmacol. Exp. 
Ther. 1£3 123-135.
Walsh, D.A., Perkins, J.P. and Krebs, E.G. (1968), J. Biol. 
Chem. 243 3763-3765.
Warner, T.G., Dambach, L.M., Shin, J.H. and O'Brein, J.S.
(1981), J. Biol. Chem. 2£6 2952-2957.
Watanabe, A.M., Hathway, D.R., Besch, H.R., Farmer, B.B. and 
Harris, R.A. (1977), Circul. Res. £0_ 596-602 .
Webb, S.W., Adgey, A.A.J. and Pantridge, J.F. (1972), B r . 
Med. J. ii 89-92.
Weglicki, W.B., Owens, J . , Ruth, R.C. and Sonnenblick, E.H.
(1974), Cardiovas. Res. _8 237-242.
Weishaar, R ., Sharma, J.S.M., Marayama, Y ., Fisher, R. and 
Bing, R.J. (1977), Cardiol. 62. 2-20.
225
Werner, V., Starke, K. and Schumann, H.J. (1970), Naunyn 
Schmiedeberg*s Arch. Pharmacol. 266 474-482.
Westfall, T.C. (1977), Physiol. Rev. 57 659-728.
Westfall, T.C., Peach, M.J. and Tittermany, V. (1970), Eur. 
J. Pharmacol. _5£ 67-74.
Whitmer, J.T., Idell-Wagner, J.A., Rovetto, M.J. and Neely 
J.R. (1978), J. Biol. Chem. 253 4305-4309.
Wieland, O. and Matschinsky, F. (1962), Life Sci. 2 49-54. 
Wieshaar, R ., Sharma, J.S.M., Maryama, Y ., Fisher, R. and 
Bing, R.J. (1977), Cardiol. £2 2-20.
Wikberg, J.E.S. (1979), Acta. Physiol. Scand. supp. 468 
1-99.
Wildenthal, K., Morgan, H.E. and Opie, L.H. (1976), Cir.
Res. ^  supp 1.
Wilgram, G.F. and Kennedy, E. (1963), J. Biol. Chem. 238 
2615-2619.
Williams, R.S. and Lefkowitz, R.J. (1978), Circul. Res. 43 
721-727.
Williamson, J.R. (1964), J. Biol. Chem. 23£ 2721-2729. 
Williamson, J.R., Ford, C., Illingworth, J. et al (1976), 
Circul. Res. 3£ supp 1 39-51.
Williebrands, A.F. (1964), Biochim. Biophys. Acta. 84 
607-610 .
Williebrands, A.F., Ter Welle, H.F. and Tasserson, S.J.A.
(1973), J. Mol. Cell. Cardiol. _5 259-275.
Willis, E.D. (1961), In 'Enzymes of Lipid Metabolism' (ed 
Desneulle, P.) Pergamon Press, London.
Wise, L.A. and Jungas, R.L. (1978), J. Biol. Chem. 253 
2524-2627.
Witters, L.A., Moriarity, D. and Martin, D.B. (1979), J.
224
Biol. Chem. 254 6644-6649.
Wollenberger, A. and Krause, E. (19 68), Amer. J. Cardiol. 22 
349-359 .
Wollenberger, A., Krause, E.G. and Heier, G. (1969 ),
Biochem. Biophys. Res. Commun. 3_6 664-670.
Wollenberger, A., Krause, E.G. and Shahab, L. (1967), in 
'International Symposium on coronary circulation and 
energetics of the myocardium' (ed Karger, S.), Basel.
Wood, J.M., Sordahl, L.A., Lewis, R.M. and Schwartz, A.
(1973), Cardiovas. Res. 32 340-347.
Woodside, W.F., and Heimberg, M. (1972), Israel J. Med. Sci. 
_8_ 309-316.
Wright, E.E. and Simpson, E.R. (1981), J. Lipid Res. £2 
1265-1270.
Yamada, K. and Okuyama, H. (1978), Arch. Biochem. Biophys. 
190 409-420.
Yamaguchi, N. , de Champlain, J. and Nadeau, R.A. (1977), 
Circul. Res. 41 108-117.
Zarov-Behrens, G. and Kako, K.J. (1976), Biochim. Biophys. 
Acta. 441 1-13.
